MINISTRY OF HEALTH OF UKRAINE
ZAPORIZHZHYA STATE MEDICAL AND PHARMACEUTICAL UNIVERSITY
DEPARTMENT OF INTERNAL MEDICINE 1

O. V. Nazarenko, Ya. V. Zemliany

RESPIRATORY DISEASES
DIAGNOSIS AND TREATMENT

EDUCATIONAL MANUAL
for Master's degree students
specialty Medicine

Zaporizhzhia
2025

UDC 616.2(075.8)

N32

Recommended for publication by Central Methodical Council of Zaporizhzhia State Medical and Pharmaceutical University (Protocol of 2025)

Reviewers:

S. Ya. Dotsenko – DM, Professor, Head of the Internal Medicine №3 Department, Zaporizhzhia State Medical and Pharmaceutical University;

L. V. Lukashenko – DM, Professor, Head of the Propedeutic of internal medicine, radiation diagnostic and radiation therapy department, Zaporizhzhia State Medical and Pharmaceutical University.

Authors:

O. V. Nazarenko - PhD, Associate Professor of Department of Internal Diseases No. 1, Zaporizhzhia State Medical and Pharmaceutical University;

Ya. V. Zemliany - PhD, Associate Professor of Department of Internal Diseases No. 1, Zaporizhzhia State Medical and Pharmaceutical University.

N32

Nazarenko O. V.

Respiratory diseases. Diagnosis and treatment: for master's degree students, specialty Medicine/ O. V. Nazarenko, Ya. V. Zemliany. – Zaporizhzhia: ZSMPhU, 2025. – 168 p.

The educational manual contains materials on the main methods of clinical, laboratory, and instrumental diagnostics, as well as the principles of treatment for the most common diseases of the respiratory system. The textbook is intended for students of medical higher education institutions in preparation for practical classes in the course "Internal Medicine" for the specialty Medicine.

UDC 616.2(075.8)

CONTENTS

PREFACE

The educational manual contains data on the etiology, pathogenesis, clinical manifestations, modern diagnostic methods, and treatment algorithms for the most common respiratory diseases.

The manual provides materials for the academic discipline "Internal Medicine", Section 1, Content Section 3: "Fundamentals of Diagnosis, Treatment, and Prevention of Major Respiratory Diseases." According to the curriculum, 49 hours (1.63 ECTS credits) are allocated for studying this section, which corresponds to 25% of the approved syllabus for the "Internal Medicine" course. This course is designed for 4th-year students within the "Medicine" educational-professional program at the second (master's) level of higher education in Ukraine, within the field of knowledge I " Healthcare and social security", for the specialties 222 "Medicine", leading to the professional qualification of "Doctor". The necessity of creating this manual is driven by the update of knowledge regarding the diagnosis and treatment of major respiratory system diseases.

The manual presents the latest classification and treatment approaches for bronchial asthma. The treatment of chronic obstructive pulmonary disease (COPD) is outlined in accordance with the updated GOLD 2025 recommendations. The standards for the diagnosis and treatment of community-acquired pneumonia and respiratory failure are supplemented with information on managing patients with COVID-19.

A key principle in the current clinical guidelines for managing patients with chronic respiratory pathology is an individualized approach and the economic feasibility of treatment strategies.

LIST OF ABBREVIATIONS

ARDS	Acute respiratory distress syndrome
ARF	Acute respiratory failure
BA	Bronchial asthma
BE	Bronchiectasis
BP	Blood pressure
ICS	Inhaled corticosteroids
CAD	Coronary artery disease
CAP	Community-acquired pneumonia
CRP	C reactive protein
COPD	Chronic obstructive pulmonary disease
CT	Computed tomography
ECG	Electrocardiogram
ESR	Erythrocyte sedimentation rate
FEV1	Forced expiratory volume in 1 second
FiO2	Inspiratory fraction of oxygen
FVC	Forced vital capacity
HAP	Hospital-acquired pneumonia
HR	Heart rate
IDLD	Infectious destructive lung diseases
IV	Intravenously
LABA	Long-acting β2-agonist
LAMA	Long-acting muscarinic antagonist
LDH	Lactate dehydrogenase
mMRC	Modified Medical Research Council
MRI -	Magnetic resonance imaging
MV	Mechanical ventilation
NPPV	Non-Invasive Positive Pressure Ventilation
NSAIDs	Non-steroidal anti-inflammatory drugs
pMDI	Pressurized metered-dose inhalers

PaO2	Arterial partial pressure of oxygen
PCR	Polymerase chain reaction
PEFR	Peak expiratory flow rate
PH	Pulmonary hypertension
PSI	Pneumonia severity index
RR	Respiratory rate
SABA	Short-acting β2-agonist
SAMA	Short -acting muscarinic antagonist
SpO2	Oxygen saturation
Va/Q	Ventilation-perfusion ratio
WHO	World Health Organization

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Relevance of the topic. Chronic obstructive pulmonary disease (COPD) remains one of the three leading causes of death worldwide, with 90% of these deaths occurring in low- and middle-income countries. Air pollution is the leading cause of COPD worldwide, accounting for ~50% of the risk of COPD in low- and middle-income countries. Experts estimate that the increase in smoking prevalence in low- and middle-income countries, combined with the aging of populations in high-income countries, will result in more than 5.4 million deaths annually from COPD and related conditions by 2060 [13].

In Ukraine, the prevalence of COPD is about 3 thousand cases per 100 thousand population, and its share in the structure of overall mortality is 4%. According to experts, considering the statistics of smoking in Ukraine, the real prevalence of the disease may reach 15-30%. COPD is most often first detected in patients aged 55-65 years. Frequent exacerbations of the disease lead to the development of complications and a significant decrease in the quality of life of patients. COPD is a preventable disease, since its causes are well known. First of all, these are long-term smoking and industrial and household air pollutants.

The constant increase in morbidity and mortality, frequent patient visits for medical care due to exacerbations of COPD, and high economic costs determine the relevance of studying this pathology by students.

COPD is a heterogeneous lung disease characterized by chronic respiratory symptoms (dyspnea, cough, sputum production) caused by pathology of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema), causing persistent, often progressive airflow obstruction [13].

Exacerbations and comorbid conditions are an integral part of COPD and contribute significantly to the clinical picture and prognosis. The chronic airway obstruction characteristic of COPD is due to a combination of small airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), the relative contribution of each component being different in different patients.

Pulmonary emphysema is a persistent dilation of the airways distal to the terminal bronchioles, accompanied by a decrease in the gas exchange surface of the lungs. The cause of the condition is the destruction of the alveolar walls, not associated with fibrosis.

The term "emphysema" describes one of the many structural changes inherent in COPD [9].

It is an independent disease that can precede the development of bronchial obstruction or aggravate existing inflammation, causing persistent airway obstruction.
The term "chronic bronchitis" characterizes a patient with a productive (with sputum production) cough for at least 3 months for two consecutive years and is a common but variable condition in patients with COPD. Chronic bronchitis is more common in younger men, who have a long history of smoking and occupational hazards, severe airway obstruction, and live in rural areas [9].

Etiology of COPD

COPD is the result of an interaction between genes and the environment that occurs throughout a person's life and can lead to lung damage and/or disruption of their normal development and aging process.

Exogenous risk factors for COPD

- long-term smoking of tobacco (smoking index 10-20 pack-years) or other smoking substances;
- passive smoking;
- industrial and household factors (organic and inorganic dust, chemicals (pesticides), gases and combustion products of bio-organic fuels);
- polluted air (solid toxic particles, ozone, nitrogen and sulfur oxides, heavy metals and other greenhouse gases);
- frequent infections in childhood;
- low socio-economic status.

Endogenous risk factors for COPD:

- genetically determined hereditary deficiency of α-1-antitrypsin (mutations in the SERPINA1 gene);
- age (over 40 years);

- bronchial hyperreactivity (concomitant bronchial asthma);
- lung developmental abnormalities, accelerated aging processes.

Patients at high risk of developing COPD:

- age over 40 years, with the presence of risk factors;
- children who have often had severe respiratory infections;
- children born to a mother with a complicated pregnancy, childbirth, or AIDS;
- hereditary α-1-antitrypsin deficiency;
- patients who have smoked for many years (smoking index 10–20 pack-years), passive smokers.
- persons whose working conditions are associated with hazardous production conditions and household harmful emissions;
- low socio-economic status (malnutrition, overcrowding, frequent hypothermia);
- patients, primarily smokers, with tuberculosis, HIV infection;
- signs of bronchial hyperreactivity (concomitant bronchial asthma, especially in smokers);
- incomplete lung development in newborns, congenital lung defects [13].

The 2025 GOLD guidelines proposed to classify COPD according to the predominant mechanism of its development (Table 1). This was due to the fact that the pathogenetic mechanisms of only one underlying cause of COPD (cigarette smoking) were mainly studied, without sufficient attention to other heterogeneous processes that influence the final clinical picture. Therefore, types of COPD not related to smoking were identified in order to improve the treatment of these patients.

Table 1. Etiological types of COPD [GOLD 2025]

Etiology of COPD	Description
Genetically determined COPD (COPD G)	• Alpha-1 antitrypsin deficiency • Other genetic variants with lesser effect in combination
COPD due to developmental abnormality of the lung (COPD-D)	Postnatal events, premature birth, low birth weight, etc..

Environmental COPD Cigarette smoking (COPD-C) Impact of household and industrial pollutants (COPD-P)	• Tobacco smoke exposure (also in utero through passive smoking) • Vaping or e-cigarette use • Cannabis • Exposure to household pollutants, air pollution, smoke from forest fires, occupational hazards
Infectious COPD (COPD-I)	Childhood infections, tuberculosis-associated COPD, HIV-associated COPD
COPD+Asthma (COPD-A)	Especially childhood asthma
COPD of unknown cause (COPD-U)	

Pathogenesis of COPD

• Chronic inflammation of the airways, parenchyma and pulmonary vessels

• Oxidative stress

• Imbalance of the proteinase-antiproteinase system

• High concentration of inflammatory mediators, structural changes in the airways

• Expiratory airflow limitation due to reversible and irreversible components.

• Pulmonary hyperinflation [9]

Irreversible components of bronchial obstruction:

- fibrosis and narrowing of the airway lumen;
- loss of elastic recoil of the lungs due to alveolar destruction;
- loss of alveolar support of the lumen of the small airways.

Reversible components of bronchoobstruction:

• accumulation of inflammatory cells, mucus, and plasma exudate in the bronchi;

• impaired contractile properties of respiratory muscles;

• dynamic hyperinflation (increased lung capacity) during exercise [13].

Pulmonary hyperinflation ("air trap") develops due to air retention in the alveoli during expiration due to loss of elastic recoil of the lungs (static pulmonary hyperinflation) or as a result of insufficient expiratory time in conditions of pronounced

restriction of expiratory airflow (dynamic pulmonary hyperinflation). Narrowing of the lumen and a decrease in the number of terminal bronchioles precede the development of emphysematous destruction of the alveoli in both centroacinar and panacinar emphysema [15].

Severe COPD is characterized by ***impaired gas exchange*** and the development of hypoxemia and hypercapnia. The main pathogenetic mechanism of hypoxemia is a violation of the ventilation-perfusion ratio Va/Q (Va - alveolar ventilation, Q-cardiac output). Areas of the lungs with low Va/Q are associated with the development of hypoxemia, and areas with increased Va/Q increase the physiological dead space, as a result of which the total ventilation of the lungs increases to maintain a normal level of partial pressure of carbon dioxide in arterial blood (PaCO2) [9].

Mucus hypersecretion in patients with COPD is caused by mucosal metaplasia with an increase in the number of goblet cells and the size of submucosal glands in response to chronic irritation of the airways by noxious substances, manifested by chronic productive cough.

Pulmonary hypertension develops in the late stages of COPD due to hypoxia-induced spasm of small pulmonary arteries, which ultimately leads to structural changes (intima hyperplasia and hypertrophy/hyperplasia of the smooth muscle layer). The vessels show an inflammatory response similar to that in the airways and epithelial dysfunction. The loss of the capillary bed in emphysema also contributes to an increase in pressure in the pulmonary arterial system [15].

Circulating inflammatory mediators in COPD contribute to muscle loss and cachexia, provoke the development or worsen the course of heart failure, osteoporosis, anemia, and depression in patients.

COPD Clinic

• Chronic cough, both productive and unproductive (initially episodic, later continuing throughout the day)

• Chronic sputum production - intermittent, with periods of exacerbation and remission

• Wheezing on inspiration and/or expiration, feeling of tightness in the chest

• Progressive shortness of breath, which increases with physical exertion and bothers the patient throughout the day [13]

• Feeling of tightness in the chest after physical exertion

The presence of these symptoms in a patient over 40 years of age with risk factors (smoking, exposure to industrial pollutants and fuel combustion products) indicates a high probability of a diagnosis of COPD.

Physical signs of COPD may only be evident as the disease progresses:

• Diffuse cyanosis

• Barrel-shaped chest, widening of the xiphosternal angle

• Involvement of accessory muscles in breathing, retraction of the lower ribs during inspiration

• Box percussion sound over the lungs

• Reduction of the zone of relative cardiac dullness during percussion

• Increased respiratory rate (>20/min)

• Shallow breathing with prolonged expiration, expiration through pursed lips

• Auscultation of the lungs - weakening of respiratory sounds, wheezing, crackles on inspiration

• Heart sounds are better heard in the xiphoid process.

According to the characteristics of the clinical course of the disease, A. Dornhorst, B. Burrows et al. identified two phenotypes of COPD: bronchitic and emphysematous type.

Bronchitic type of COPD (Fig. 1) is more often observed in heavy smokers. The main complaints of patients are prolonged cough with sputum, with objective examination there are symptoms of bronchial obstruction (wheezing, dry rales). As the disease progresses, the clinical picture begins to be dominated by manifestations of pulmonary cor pulmonale - diffuse cyanosis, weight gain, edema, ascites [15].

Fig. 1. Bronchitic type of COPD [1].

Patients with emphysematous type of COPD (Fig. 2) are usually asthenic, with exhaustion, loss of weight and muscle mass, and anorexia [15].



[1] https://basicmedicalkey.com/obstructive-pulmonary-disorders

Fig. 2. Emphysematous type of COPD.[2]

The cough in patients is not intense, with a small amount of sputum. The chest later acquires a barrel-shaped shape, there is a flattening of the domes of the diaphragm, retraction of the lower ribs in the inhalation phase. The dominant symptom is progressive shortness of breath. Due to the characteristic loud exhalation, the lips are closed everywhere (to slow down exhalation and improve lung emptying), patients are described as "pink puffers".

Laboratory investigations

• **Complete blood count.** Patients with COPD may have anemia, and some patients with chronic respiratory failure develop compensatory erythrocytosis (polycythemia). The period of exacerbation of COPD is often accompanied by leukocytosis, an increase in the ESR level.

• **Biochemical blood tests** (bilirubin, transaminases, urea, creatinine, electrolytes, glucose, albumin).

• **Level of inflammatory biomarkers in serum** during exacerbation of COPD (C-reactive protein, procalcitonin).

• **Arterial blood gases** (PaO2, PaCO2, pH, bicarbonates, lactate). Performed when SpO2 decreases <92%. It is one of the criteria for the severity of COPD exacerbation.

• **Microbiological examination of sputum** (bacteriological, virological analysis).

• **Determination of α1-antitrypsin deficiency in serum.** It is recommended for patients younger than 45 years of age, with no history of smoking, rapid disease progression, or a family history of emphysema.

Instrumental examinations

1. **Spirometry** (Fig. 3) is performed during remission of the disease on the background of adequate bronchodilator therapy. Spirometric measurements are evaluated by comparing the results with appropriate values, corresponding to age, height, sex and race. Indicators are evaluated after inhalation of a bronchodilator (10-15 minutes after taking 400 μg of salbutamol or another short-acting beta 2-agonist

[2] https://basicmedicalkey.com/obstructive-pulmonary-disorders

(SABA); 30-45 minutes after taking 160 μg of a short-acting anticholinergic or their combination) [14].



Fig. 3. Spirometry indicators in COPD[3]

The following indicators are measured:

- forced vital capacity of the lung (FVC);
- forced expiratory volume in the first second (FEV1);
- the ratio FEV1/FVC (Tiffeneau index) is calculated

The main diagnostic criterion for COPD is the ratio FEV1/FVC less than 0.7 after taking a bronchodilator. [13].

2. X-ray examination of the chest cavity. In COPD, signs of pulmonary hyperinflation are detected (increased area of the lung fields, increased transparency, low standing and flattening of the dome of the diaphragm, enlarged retrosternal air space), sometimes emphysematous bullae are detected.

3. Computed Tomography (CT) scan of the chest. Performed in patients with COPD in the presence of comorbidities, planning surgery with a decrease in lung volume, and to determine the extent of emphysema.

4. Body plethysmography. Allows you to determine lung volumes and lung diffusion capacity. COPD is characterized by an increase in residual lung volume and an increase

[3] https://emedicine.medscape.com/

in total lung capacity (static hyperinflation). Determination of lung diffusion capacity reveals functional disorders in emphysema in patients with COPD and is recommended for patients with shortness of breath that does not correspond to the degree of bronchial obstruction according to spirometry.

5. Pulse oximetry - determination of blood oxygen saturation (SpO2).

6. Exercise tests (6-minute walk, treadmill test, cycle ergometry) are performed to diagnose comorbidities (CAD). Exercise tolerance is also a sensitive prognostic factor in patients with COPD [14].

COPD classification

The division of patients with COPD into clinical groups is carried out considering exclusively the clinical manifestations of the disease (their perception by the patient) and the frequency of exacerbations.

Spirometry is used for:

• diagnosis of COPD (FEV1/FVC <0.7);

• to monitor the progression of COPD, assess the effectiveness of treatment.

Airway obstruction based on the results of post-bronchodilation FEV1 determination is divided into four categories of airflow limitation severity.

Table 2. Classification of severity of bronchial obstruction in COPD (GOLD, 2025)

Group	Severity	*FEV1%*
GOLD 1	light	≥80
GOLD 2	moderate	≥50<80
GOLD 3	severe	≥30<50
GOLD 4	very severe	<30

The clinical classification of COPD is based on a comprehensive assessment of the patient and allows for the assessment of the patient's prognosis (risk of exacerbations, hospitalization, death).

Table 3. Modified Medical Research Council Dyspnea Severity Rating Scale

Score	Description of symptoms
0	Shortness of breath occurs only with very intense physical exertion

1	Shortness of breath occurs when climbing stairs quickly or walking uphill
2	Shortness of breath makes me walk more slowly than people my age walk, or I have to stop when walking at my own pace on level ground
3	Shortness of breath makes me stop when walking about 100 m or after a few minutes of walking on level ground
4	Shortness of breath makes it impossible to leave my house or occurs when getting dressed and undressed

The division of COPD patients into 3 clinical groups considers the severity of clinical symptoms - the assessment is carried out using the mMRC dyspnoea Scale (Table 3) and the CAT questionnaire (Table 4).

A level of dyspnea on the mMRC dyspnoea scale ≥2 or a CAT result ≥10 points indicate a high level of symptoms [13].

Table 4. COPD severity assessment test (COPD Assessment Test (CAT)), http://www/catestonline.org

I don't cough at all	0	1	2	3	4	5	I cough constantly
I have absolutely no phlegm (mucus) in my chest	0	1	2	3	4	5	My chest is completely filled with phlegm (mucus)
I have absolutely no chest tightness	0	1	2	3	4	5	My chest feels very tight
I don't feel short of breath when I walk downhill or up one flight of stairs	0	1	2	3	4	5	When I walk downhill or up one flight of stairs, I feel very short of breath
I do all my household chores without any restrictions	0	1	2	3	4	5	I am very limited in doing household chores

I feel confident when I leave the house, despite my lung disease	0	1	2	3	4	5	I feel uneasy when I leave the house because of my lung disease
I sleep soundly	0	1	2	3	4	5	I am not sleeping well because of my lung disease
I have a lot of energy	0	1	2	3	4	5	I have no energy at all

The total score of the CAT test is defined as the sum of the scores of the answers to 8 questions. A total score of ≥10 indicates the severity of COPD symptoms [13].

Table 5. Clinical classification of COPD (clinical groups), (GOLD, 2025)

Group	Risk of exacerbation	Number of COPD exacerbations and hospitalizations in the past year	MMDR scale,
A (few symptoms, few exacerbations	low	0 or 1 no hospitalization	CAT test
B (many symptoms, few exacerbations)			mmDR 0-1, CAT <10
E	Risk of exacerbation		

Example of COPD diagnosis formulation.

1. A 56-year-old COPD patient. FEV1 24% of predicted, CAT - 16 points. There were no exacerbations or hospitalizations for COPD during the year.

2. A 62-year-old COPD patient. FEV1 28% of predicted, CAT - 18 points. He was hospitalized three times for COPD during the last year.

1. Clinical diagnosis: COPD, group B, GOLD 4.

2. Clinical diagnosis: COPD, group E, GOLD 4.

Differential diagnosis

Typical symptoms of COPD (dyspnea, productive cough) may be manifestations of other diseases (Table 6).

Table 6. Differential diagnosis of COPD

Diagnosis	Clinical features
COPD	Symptoms progress slowly History of smoking or other risk factors
Bronchial asthma	Onset: early age (often in childhood) Family history of asthma Variability of bronchial obstruction Symptoms vary over the week Symptoms worsen at night/early morning Allergies, rhinitis, and/or eczema
Heart failure	X-ray of the OGK - cardiomegaly, pulmonary congestion Spirometry - changes in respiratory function of a restrictive, not obstructive type
Bronchiectasis	Excretion of purulent sputum in large quantities Usually associated with bacterial infection CT of the OGK - bronchial dilation, bronchial wall thinning
Tuberculosis	Onset: at any age X-ray of the OGK - infiltrative, focal changes Microbiological confirmation High prevalence of tuberculosis in this locality
Bronchiolitis obliterans	Onset — young age (childhood)

	Observed after lung or bone marrow transplantation On CT during inhalation — areas of low density Most patients — men and non-smokers
Diffuse panbronchiolitis	Often associated chronic sinusitis Radiography and CT of the OGK — diffuse small centrilobular nodular opacities and signs of pulmonary hyperinflation

The most difficult is the differential diagnosis of asthma and COPD. The key difference is the incomplete reversibility of obstruction in COPD with constant dyspnea compared to the reversible obstruction (only during attacks) in asthma, which causes variability in symptoms, but in some patients the distinction between these diseases is impossible.

COPD exacerbation

An exacerbation is associated with increased inflammation in the airways and is defined as an acute worsening of respiratory symptoms in a patient with COPD that requires the appointment of additional therapy.

According to Decramer M. et al. the most common (78%) cause of COPD exacerbations is respiratory tract infections, mainly bacteria, but also rhinoviruses and adenoviruses).

Symptoms of COPD exacerbation

COPD exacerbation is an acute event characterized by the appearance or worsening of typical symptoms of the disease within 2 weeks, may be accompanied by tachypnea and/or tachycardia, and is often associated with infection, pollution, or other airway injury.

Patient complaints during COPD exacerbation

- New/increased shortness of breath
- New/increased cough

• Increased sputum production and purulent sputum

• Fever

• New/increased wheezing

Classification of COPD exacerbations

By frequency:

• rare - no more than 1 episode per year

• frequent - 2 or more exacerbations per year

By severity:

• mild exacerbation - for treatment, salbutamol, ipratromium is enough

• moderate exacerbation - antibiotics and/or oral corticosteroids are added to short-acting bronchodilators

• severe exacerbation (patients are treated in a hospital):

- without acute respiratory failure

- with acute respiratory failure

The latest revision of the GOLD guidelines proposes a classification of exacerbation severity based on the assessment of the patient's clinical condition, considering laboratory data (Fig. 4). If the patient has 3 out of 5 criteria, the severity of the exacerbation is assessed as moderate. At the prehospital stage, it is recommended to assess the severity of dyspnea using a visual scale, asking the patient to rate the severity of dyspnea from 0 to 10 (zero means no dyspnea, and 10 points is the most severe dyspnea the patient has ever experienced) [14].

Severity	Variable thresholds to determine severity
Mild (default)	• Dyspnea VAS < 5 • RR < 24 breaths/min • HR < 95 bpm • Resting SaO_2 ≥ 92% breathing ambient air (or patient's usual oxygen prescription) AND change ≤ 3% (when known) • CRP < 10 mg/L (if obtained)
Moderate (meets at least three of five*)	• Dyspnea VAS ≥ 5 • RR ≥ 24 breaths/min • HR ≥ 95 bpm • Resting SaO_2 < 92% breathing ambient air (or patient's usual oxygen prescription) AND/OR change > 3% (when known) • CRP ≥ 10 mg/L *If obtained, ABG may show hypoxemia (PaO_2 ≤ 60 mmHg) and/or hypercapnia ($PaCO_2$ > 45 mmHg) but no acidosis
Severe	• Dyspnea, RR, HR, SaO_2 and CRP same as moderate • ABG show new onset/worsening hypercapnia and acidosis ($PaCO_2$ > 45 mmHg and pH <7.35)

Fig. 5. Classification of the severity of COPD exacerbations. [4]

Indications for hospitalization for COPD exacerbation

- Severe condition of the patient (sudden increase in dyspnea at rest, tachypnea, decreased SpO2<88%, impaired consciousness, lethargy)
- Development of acute respiratory distress syndrome
- Appearance of new clinical symptoms in the patient (cyanosis, peripheral edema, ascites)
- Ineffectiveness of initial drug therapy
- Severe concomitant diseases (heart failure, arrhythmias, diabetes mellitus, etc.)
- Impossibility of treatment at home

Signs of moderate acute respiratory failure

- RR >24/minute; participation in breathing of accessory respiratory muscles
- Consciousness is clear

[4] https://patsjournal.org/global-initiative-for-chronic-obstructive-lung-disease-2023-report-gold-executive-summary/

- Hypoxemia decreases on the background of oxygen therapy through a Venturi mask > 35% FiO2
- Hypercapnia (increased PaCO2) at the previous level or within 50-60 mm Hg.

Signs of severe acute respiratory failure

- RR >24/min, accessory respiratory muscle involvement
- Mental status changes
- Hypoxemia not improving with Venturi oxygen therapy or requiring FiO2 >40%
- Hypercapnia >60 mmHg or acidosis (pH ≤7.25).

Patients with severe acute respiratory failure require immediate admission to the intensive care unit.

Complications of COPD

Pulmonary hypertension (PH) is an increase in pulmonary artery pressure exceeding 25 mm Hg. PH in patients with COPD develops as a result of vasoconstriction against the background of chronic hypoxia, as well as structural changes associated with inflammatory processes in the respiratory tract [9]. Progressive PH leads to the development of cor pulmonale.

Cor pulmonale is a violation of the structure and function of the right ventricle as a result of diseases of the respiratory system, except in cases where lung pathology develops against the background of a disease affecting the left heart [15].

The main pathogenetic factor in the formation of pulmonary cor pulmonale is pulmonary hypertension.

Clinical symptoms of cor pulmonale

- edema of the lower extremities, ascites
- swelling of the neck veins, hepatomegaly
- increased pulsation (heart impulse) in the zone of absolute dullness of the heart (as a result of right ventricular hypertrophy)
- increased second tone on the pulmonary artery

ECG signs of right ventricular failure

- The position of the heart is vertical or semi-vertical, deviation of the electrical axis of the heart to the right (angle > 90^{o}).

• Formation of "P-pulmonale" - an increase in the amplitude and shape (high, pointed, symmetrical) of the P wave in II, III standard, aVF leads up to 2.5 mm. In leads V1, V2, the amplitude of the right atrial component (positive phase) of the P wave increases due to right atrial hypertrophy (Fig. 5).

• Right ventricular hypertrophy.



Fig. 5. Right atrial hypertrophy, P-pulmonale in COPD.

ECG signs of right ventricular hypertrophy:

1) R-type - an increase in the amplitude of the R wave in the right thoracic leads (RV1≥7 mm), the R/S ratio in V1 ≥1; an increase in the amplitude of the S wave in the left thoracic leads to 5 mm or more, RV1+SV5=10.5 mm; the amplitude of the S wave in leads V1-V2 ≤2 mm; oblique displacement below the isoline of the ST segment, which turns into a negative asymmetric T wave in leads V1-V2.

2) S-type - deep S waves in standard and all thoracic leads, the QRS complex is characterized by the rS graph, the transition zone is shifted to the left. SV1 - minimal, S V5 - maximal

3) rSR'-type - signs of blockade of the right bundle branch.

Echocardiographic signs of right ventricular failure

- Right ventricular hypertrophy and dilation
- Right atrial dilation (Fig. 6)

- Increased pulmonary artery systolic pressure



Fig. 6. Echocardiography - dilation of the right ventricle and right atrium in COPD.

The most accurate methods for diagnosing right ventricular failure in patients with COPD are cardiac MRI and radionuclide ventriculography.

COPD TREATMENT

Principles of COPD treatment:

- reduction of clinical symptoms and improvement of quality of life;
- slowing of disease progression;
- prevention and treatment of complications and exacerbations.

Non-drug therapy

- Smoking cessation is a key factor
- Pulmonary rehabilitation (physical training, teaching the patient the principles of self-management of the disease, increasing adherence to therapy)
- Training in inhalation techniques
- Influenza and pneumococcal vaccination
- COVID-19 vaccination according to national recommendations
- Oxygen therapy
- Non-invasive ventilation

COPD patients with severe hypoxemia are prescribed long-term oxygen therapy (at least 15 hours per day), which is monitored using pulse oximetry or blood gas analysis.

Indications for long-term oxygen therapy in patients with COPD:

• PaO 2 ≤55 mm Hg or SpO2 ≤88% at rest.

• Chronic cor pulmonale, coronary artery disease, polycythemia - PaO2 ≤60 mm Hg or SpO2 ≤89% at rest.

Optimal is to maintain PaO2 within 60−65 mm Hg. and SaO2 within 90−95% [16]. Long-term oxygen therapy at home is carried out using autonomous and portable oxygen sources. The method is quite expensive, but in severe patients with COPD it is the only way to prolong life.

In patients with severe chronic hypercapnia (PaCO2 ≥53 mm Hg) and frequent hospitalizations, long-term noninvasive ventilation of the lungs can reduce mortality and prevent rehospitalizations [14].

Annual influenza vaccination reduces the severity of clinical symptoms and mortality in patients with COPD and is therefore recommended for all patients. Pneumococcal vaccine is recommended for COPD patients older than 65 years, as well as for patients with significant comorbidities (heart failure) [13].

Drug treatment

Medications are mostly used in the form of inhalers (metered dose inhalers, breath-activated inhalers, dry powder inhalers, spacers). Many drugs are also used in the form of nebulizer solutions.

Groups of drugs for the treatment of COPD

Bronchodilators are the mainstay of COPD treatment, and are mainly administered by inhalation. Bronchodilators increase FEV1 by altering bronchial smooth muscle tone and are used to prevent and reduce symptoms on a daily or as needed basis [14].

• ***Short-acting β2-agonists*** (salbutamol, fenoterol, levalbuterol, terbutaline). The therapeutic effect lasts for 4-6 hours.

• ***Long-acting β2-agonists*** last for 12 hours (salmeterol, formoterol, arformoterol) and 24 hours (indacaterol, olodaterol). The main side effects of β2-agonists are sinus tachycardia and arrhythmia.

• ***Anticholinergics: short-acting*** (ipratropium and oxitropium bromide) last for 6-8 hours; long-acting with an effect for 12 hours (aclidinium bromide, glycopyrrolate) and 24 hours (tiotropium, umeclidinium, glycopyrronium bromide, revefenacin). Side effects - dry mouth.

For the treatment of COPD, combination drugs that include anticholinergics and long-acting β2-agonists are recommended:

- indacaterol / glycopyrronium
- vilanterol / umeclidinium
- olodaterol / tiotropium
- formoterol / aclidinium bromide
- formoterol / glycopyrrolate

Methylxanthines (theophylline) have a small bronchodilator effect when administered orally. Side effects include dose-dependent toxicity, epileptic seizures, arrhythmias, headache, insomnia, and heartburn. Because of this, their use is limited, and the only advantage is their low price.

Combination bronchodilator therapy is associated with more effective bronchodilation and a reduced risk of side effects. Common combinations include combinations of short- and long-acting β2-agonists with anticholinergics (salbutamol/ipratropium, fenoterol/aclidinium, formoterol/glycopyrronium, olodaterol/tiotropium, indacaterol/glycopyrronium, fenoterol/ipratropium) [13].

Inhaled corticosteroids (ICS)

Used for basic therapy of COPD only in combination with bronchodilators - beclomethasone, fluticasone, budesonide. The combination of ICS and long-acting β2-agonists is currently recommended for COPD patients with concomitant bronchial asthma, in other cases ICS are used immediately as part of a triple combination: anticholinergic + β2-agonist + ICS (fluticasone/vilanterol/umeclidinium, beclomethasone/formoterol/glycopyrronium, budesonide/glycopyrrolate/formoterol) [14].

ICS therapy is most effective in patients with eosinophilia (eosinophil level >300/μl). Side effects of ICS - oral candidiasis, hoarseness, increased risk of pneumonia.

Phosphodiesterase-4 inhibitors

The drugs reduce inflammation by inhibiting the enzyme phosphodiesterase-4 and increasing intracellular levels of cyclic AMP. Roflumilast is administered orally at 500 mcg once daily. Side effects include nausea, decreased appetite, abdominal pain, diarrhea, insomnia, and headache.

Mucolytics and antioxidants (N-acetylcysteine, carbocysteine, erdosteine). Regular intake of mucolytics, primarily erdosteine, may be recommended for COPD patients with frequent exacerbations if they are not receiving ICS [13].

Pharmacological treatment of patients with COPD (Table 7) is aimed at reducing symptoms, frequency and severity of exacerbations, improving health status and exercise tolerance.

Table 7. Initial COPD therapy

COPD Clinical Group	Drugs
A	β2-agonists or short- or long-acting anticholinergics
B	Long-acting anticholinergics in combination with long-acting β2-agonists
E	Long-acting anticholinergics in combination with long-acting β2-agonists with the addition of ICS (if blood eosinophils >300/μl, concomitant bronchial asthma)

Follow-up pharmacological treatment of COPD depends on (Fig. 7):

• clinical symptoms (dyspnea, limitation of physical activity)

•frequency and severity of annual exacerbations



Fig. 7. Follow-up pharmacological treatment of COPD.

[5]Notes: * - combination in one inhaler is more convenient and effective than using multiple devices; ** - discontinue ICS in case of pneumonia or other adverse events. If eosinophil level is 300 per μL or higher, discontinuation of ICS may lead to exacerbation of COPD.

Surgical treatment of COPD

Patients with bullous emphysema undergo bullectomy. Patients with upper lobe emphysema and low exercise tolerance undergo lung volume reduction surgery after pulmonary rehabilitation, which involves removing part of the lung to reduce hyperinflation and improve the pumping function of the respiratory muscles [13].

Treatment of COPD exacerbations

Depending on the severity of COPD exacerbation, patients are treated on an outpatient or inpatient basis.

Oxygen therapy is a key component of inpatient treatment of COPD exacerbations. It is administered using nasal cannulas, Venturi masks (high-flow oxygen therapy) to maintain SpO2 levels between 88–92%. Non-Invasive Positive Pressure Ventilation

[5] https://patsjournal.org/global-initiative-for-chronic-obstructive-lung-disease-2023-report-gold-executive-summary/

(NPPV) is used in patients with severe COPD exacerbations and severe ARF [14]. NPPV is a method of ventilatory support without endotracheal access. It is administered through a face mask that covers the nose or nose and mouth. Unlike conventional oxygenation via a face mask or nasal cannulas, NPPV reduces the risk of expiratory closure of small airways and the development of atelectasis.

Indications for emergency ventilation

• RR> 24/min, participation in breathing of accessory respiratory muscles, paradoxical movement of the abdominal wall, retraction of intercostal spaces)

• Respiratory acidosis ($PaCO_2$> 45 mm Hg, arterial blood pH <7.35)

• Hypoxemia persists despite oxygen therapy

Indications for intensive care and invasive mechanical ventilation

• Severe dyspnea, progressing on therapy (oxygen, bronchodilators)

• Impaired consciousness (stupor, sopor, coma)

• Severe hypoxemia (PaO_2 < 40 mm Hg) and/or severe acidosis (arterial blood pH < 7.25) on oxygen therapy or invasive mechanical ventilation

• Decreased blood pressure (need for vasopressors)

Drug therapy for COPD exacerbations:

• Bronchodilator therapy - short-acting β2-agonists/anticholinergics by inhalation (in weakened patients, nebulizers are preferable). After stabilization of the condition, long-acting bronchodilators are added

• Anti-inflammatory therapy (systemic corticosteroids) - prednisolone IV or per os at a dose of 30-40 mg per day for 5 days [13]. ICS (budesonide) can also be prescribed, preferably via a nebulizer.

• ***The use of methylxanthines is not recommended (high percentage of side effects)!***

Antibacterial therapy for COPD exacerbation

Antibiotics are prescribed according to indications (increased shortness of breath, increased sputum volume, its purulent nature; development of severe acute respiratory distress syndrome with the need for invasive mechanical ventilation) for 5-7 days orally

or intravenously. The choice of antibiotic depends on the patient's age and the severity of the disease (Table 8).

Table 8. Choice of antibacterial therapy for COPD exacerbation.

Type of exacerbation	Uncomplicated exacerbation	Complicated exacerbation without risk of Pseudomonas aeruginosa infection	Complicated exacerbation with risk of Pseudomonas aeruginosa infection
Group of patients	Age ≤65 years, FEV1 ≥50%, <4 exacerbations/year, no comorbidities	Age > 65 years, FEV1 <50 ≥30%, >4 exacerbations/year, comorbidities	FEV1 <30%, frequent courses of antibiotics and/or corticosteroids, bronchiectasis, need for mechanical ventilation
Probable pathogens	H. influenza, M. catarrhalis, S. pneumoniae, C. pneumoniae, viruses	H. influenzae, M. catarrhalis, S. pneumoniae, C. pneumoniae, viruses, Enterobacterales	H. influenzae, M. catarrhalis, S. pneumoniae, C. pneumoniae, viruses, P. aeruginosa, A. baumanii, multidrug-resistant Enterobacteriaceae
First-line antibiotics	Amoxicillin, Azithromycin, clarithromycin, doxycycline	Amoxicillin/clavulanate, cefditoren, respiratory fluoroquinolones (levofloxacin, moxifloxacin)	Fluoroquinolones (ciprofloxacin), cephalosporins (ceftazidime), carbamapenems with activity against P. aeruginosa

Treatment of cor pulmonale. In patients with COPD and edema associated with cor pulmonale, treatment with loop diuretics (furosemide, torasemide) is effective. In severely ill patients, long-term oxygen therapy should be considered [13].

Test tasks for self-assessment

1. Using the Tiffeneau index, you can assess the patient's:

A. bronchial patency

B. functional residual lung capacity

C. inspiratory reserve volume

D. tidal volume

E. forced vital capacity

2. A 68-year-old man complains of severe shortness of breath when walking 50-100 m. He has been smoking for more than 40 years. Objectively: temperature - 36.5, respiratory rate - 26/min, heart rate - 104/min, blood pressure - 100/70 mm Hg. Diffuse cyanosis, swelling of the lower legs. Over the lungs - weakened vesicular breathing, scattered dry rales. Heart tones are weakened, at the apex - systolic murmur. Liver +4 cm. ECG: P “pulmonale”. What pathology is most likely the cause of the patient's deterioration?

A. Bronchial asthma

B. Aortic heart defect

C. Chronic obstructive pulmonary disease

D. Ischemic heart disease

E. Pulmonary artery thromboembolism

3. According to the results of spirography, the Tiffeneau index was 78%. Assess the patient's respiratory function.

A. Violation of bronchial patency

B. Decreased vital capacity

C. Decreased residual lung volume

D. Normal

E. Decreased expiratory reserve volume

4. A 43-year-old man complains of shortness of breath when walking quickly, morning cough with a small amount of mucous sputum. He has smoked for 20 years, 2 packs a

day, drinks 1 liter of beer every Sunday. On examination, there are isolated dry wheezing above the lungs. FVC 82%, FEV1-80%. Which of the following treatment recommendations would you give to the patient?

A. Refusal to drink alcohol

B. Refusal to smoke

C. Oral theophylline

D. Inhaled budesonide

E. Oral roflumilast

5. The presence of a patient with labored breathing with prolonged exhalation and dry wheezing are signs of the syndrome:

A. bronchial obstruction

B. infiltration of lung tissue

C. pleural effusion

D. increased lung airiness

E. pulmonary dissemination

6. Choose a long-acting bronchodilator for COPD.

A. Budesonide, fluticasone

B. Salbutamol, fenoterol

C. Salmeterol, indacaterol

D. Roflumilast, montelukast

E. Montelukast, zafirlukast

7. A 50-year-old woman with COPD, group B, GOLD 2. Give the patient basic treatment.

A. Prednisolone + Theophylline orally

B. Tiotropium + Olodaterol inhaled

C. Tiotropium + Salbutamol inhaled

D. Budesonide + Tiotropium inhaled

E. Theophylline + Salmeterol inhaled

8. A 72-year-old man complains of shortness of breath with difficulty exhaling at rest, cough with a small amount of mucopurulent sputum. He has been suffering from COPD for many years. Objectively: temperature - 36.7, respiratory rate - 25/min, heart rate -

96/min, blood pressure - 140/80 mm Hg. The skin is moist, diffuse cyanosis. The accessory muscles take part in the act of breathing. The chest is enlarged in the anteroposterior dimension, the intercostal spaces are widened. There is a box sound over the lungs. On auscultation, breathing is weakened, scattered dry rales. What spirographic changes are most likely in the patient?

A. Normal FVC, decreased FEV1

B. Decreased FVC, increased FEV1

C. Decreased FVC, normal FEV1

D. Decreased FVC and FEV1

E. Increased FVC, decreased FEV1.

9. A 69-year-old man complains of shortness of breath with difficulty exhaling, cough with yellow sputum. He has been smoking for more than 40 years. Objectively: t - 37.3; RR - 24/min, HR - 88/min, BP - 130/70 mm Hg. Breathing is vesicular, weak, wheezing, single moist rales in the lower parts of the lungs. What is the preliminary diagnosis?

A. Bronchial asthma

B. Community-acquired bilateral pneumonia

C. COPD

D. Bronchiectasis

E. Lung cancer

10. A 57-year-old patient complains of shortness of breath with slight physical exertion, cough with mucous sputum. Objectively: diffuse cyanosis. Barrel-shaped chest. In the lungs, vesicular breathing is weakened with prolonged exhalation, dry wheezing. BP – 140/80 mm Hg. Pulse – 92/min, rhythmic. Spirometry: FEV1 – 65%, FEV1/FVC –0.5. Determine the type of respiratory failure (RF) in the patient:

A. Mixed type of RF with a predominance of obstruction

B. Restrictive type of RF

C. Obstructive type of RF

D. Mixed type of RF with a predominance of restriction

E. No respiratory failure

Standard answers: 1 - A, 2 - C, 3 -D, 4 -B, 5 - A, 6 - C, 7 - B, 8 - D, 9 - C, 10 - A.

BRONCHIAL ASTHMA

Relevance of the topic. Bronchial asthma (BA) is the most prevalent chronic non-communicable disease impacting about 300 million individuals globally. Severe forms of the disease impose a significant burden not only on individuals but also on healthcare systems and society as a whole. The most severe consequences of asthma include a reduced quality of life, loss of work capacity, and premature death [1].

Asthma is becoming more prevalent in countries with a high socio-demographic index, while asthma-related mortality rates are highest in low- and lower-middle-income countries. These countries have a high percentage of asthma-related deaths, which, according to WHO, is associated with inadequate diagnosis and treatment.

Currently, the most authoritative international guideline for managing asthma patients is the **Global Strategy for Asthma Management and Prevention** issued by **GINA (Global Initiative for Asthma)**. This document includes a dedicated section on asthma management in low- and middle-income countries, as these regions face the greatest challenges in terms of disease burden and mortality—many of which are preventable.

GINA asserts that the fundamental principles and goals of asthma treatment are the same across all countries. However, in resource-limited settings, several obstacles hinder achieving these goals, including insufficient availability or accessibility of inhaled medications and a healthcare system that prioritizes emergency care over planned treatment.

Ukraine is classified as a lower-middle-income country. According to the Center for Medical Statistics of the Ministry of Health, in 2017, there were 212,883 patients with asthma in Ukraine, including 37,427 children. In April 2017, the “Affordable Medicines” reimbursement program was launched, allowing asthma patients to receive medications either free of charge or with a small co-payment.

The aforementioned data highlight the importance and relevance of studying the etiology, pathogenesis, key clinical manifestations, and diagnostic approaches to bronchial asthma. This knowledge will contribute to the timely identification of patients,

enabling the prescription of appropriate treatment and the prevention of life-threatening complications in individuals with asthma.

Bronchial asthma is a heterogeneous disease usually characterized by chronic airway inflammation with bronchial hyperreactivity. It is characterized by respiratory symptoms (wheezing, coughing, shortness of breath, chest tightness) against the background of variable bronchial obstruction.

Clinical phenotypes of asthma

Allergic asthma: the most easily recognised phenotype, in which asthma usually begins in childhood, is associated with the presence of other allergic diseases (eczema, allergic rhinitis, food or drug allergies) in the patient or relatives. This phenotype is characterised by eosinophilic airway inflammation. Patients with allergic asthma usually respond well to therapy with inhaled corticosteroids (ICS) [1].

Non-allergic asthma: occurs in adults and is not associated with allergy. The cellular profile of the sputum of these patients may be neutrophilic, eosinophilic or contain only a few inflammatory cells (paucigranulocytic). Patients with non-allergic asthma often demonstrate a lesser short-term response to ICS therapy.

Cough variant asthma and cough predominant asthma: some children and adults have only cough as symptom of asthma, and evidence of variable airflow limitation may be absent apart from during bronchial provocation testing. Some patients subsequently also develop wheezing and bronchodilator responsiveness. ICS-containing treatment is usually effective.

Adult-onset (late-onset) asthma: some patients, especially women, present with asthma for the first time in adulthood. These patients are more likely to have no allergies and are usually relatively refractory to steroid therapy or require higher doses of inhaled corticosteroids. A special form of this variant of asthma is occupational asthma (caused by exposure to harmful factors at work).

Asthma with persistent airflow limitation: some patients with long-standing asthma develop airflow limitation that is persistent or incompletely reversible. This is thought to be due to airway wall remodeling.

Asthma with obesity: some obese patients with asthma have prominent respiratory symptoms and a different pattern of airway inflammation, with little eosinophilic inflammation.

Risk factors for asthma

- *Genetics*. Asthma follows a complex hereditary pattern. Multiple genes are involved in its pathogenesis, varying across different ethnic groups.
- *Sex*. Male sex is a risk factor for asthma up to the age of 14. However, in adulthood, women have a higher prevalence of the disease.
- *Obesity*. Asthma is more common in women with abdominal obesity.
- *Depression*. A systematic review and meta-analysis of several prospective studies found that depression increases the risk of developing asthma in adulthood by 43%.
- *Occupational factor*s. 15% of asthma cases in working-age individuals are caused by occupational exposures.

*Infections***.** Respiratory syncytial virus, human rhinoviruses, and parainfluenza viruses can trigger asthma-like symptoms in children.

Smoking. Children of mothers who smoked during pregnancy have a 4 times increased risk of asthma. Passive smoking also increases the risk of lower respiratory tract diseases in childhood. In patients with asthma, smoking accelerates the deterioration of lung function, worsens the response to inhaled and systemic corticosteroids, and reduces the possibility of achieving adequate control of asthma.

Diet. Infants fed formula containing whole cow's milk or soy proteins are more likely to develop wheezing in early childhood than those who are breastfed. Increased consumption of processed foods and reduced intake of antioxidants (from fruits and vegetables) are associated with a higher risk of asthma and atopic diseases. A higher ratio of omega-6 polyunsaturated fatty acids (found in margarine and vegetable oils) and a lower intake of omega-3 polyunsaturated fatty acids (from fatty fish) have also been linked to an increased prevalence of asthma.

Pathophysiology of asthma

A hallmark feature of bronchial asthma is chronic inflammation of the airways, which persists even during asymptomatic periods. The effects of this inflammation are most

pronounced in the medium-sized bronchi. A characteristic inflammatory pattern is observed not only in asthma but also in other allergic diseases.

In addition to the inflammatory response, airway wall remodeling occurs in asthma, leading to:

- Subepithelial fibrosis
- Hypertrophy and hyperplasia of airway smooth muscles
- Increased vascularity within the airway walls
- Increased goblet cell numbers in the epithelium
- Mucus hyperproduction

Some of these changes may contribute to irreversible airflow limitation.

Another key feature is airway hyperreactivity —a functional abnormality where airway narrowing occurs in response to stimuli that are harmless to healthy individuals. This leads to variable airflow limitation and intermittent symptoms, which are partially reversible with treatment.

Mechanisms of nighttime asthma symptoms

The exact mechanisms leading to nocturnal asthma symptoms remain unclear. However, it is suggested that circadian rhythms of circulating hormones (such as epinephrine, cortisol, and melatonin) and nervous system regulation (via cholinergic tone) play a role. Increased nighttime inflammation in asthma may reflect a decrease in endogenous anti-inflammatory mechanisms.

In some patients with severe, long-standing asthma, progressive airway obstruction develops, which is not completely reversible despite the available therapeutic options. This may be a result of structural changes in the airways due to chronic inflammation and remodeling.

The higher prevalence of asthma in individuals with obesity is influenced by: mechanical changes, development of a proinflammatory state with increased production of proinflammatory cytokines and chemokines, higher oxidative stress, higher frequency of comorbidities, common etiological factors, dietary and environmental factors.

Exercise-induced asthma. Increased ventilation during exercise causes an increase in the osmolarity of the airway lining, which in turn irritates the surface of mast cells. This triggers the release of mediators, such as leukotriene D4, resulting in bronchospasm.

Aspirin-induced asthma. This well-defined phenotype is associated with cyclooxygenase-1 inhibitor intolerance and increased release of cysteinyl-leukotrienes in response to increased expression of leukotriene C4 synthetase in mast cells and eosinophils. The term ‘aspirin asthma’ is used for the clinical variant of the disease if one of the triggers of asthma is non-steroidal anti-inflammatory drugs (NSAIDs), including acetylsalicylic acid.

The term “aspirin asthma” is used for the clinical variant of the disease when NSAIDs (including acetylsalicylic acid) act as asthma triggers. It is characterized by the classic triad:

1. Polypoid rhinosinusitis
2. NSAID intolerance
3. NSAID-induced choking attacks (severe dyspnea episodes)

Classification

The asthma symptom-based classification is used in newly diagnosed patients who are not yet receiving ICS-containing treatment (Table 9).

In patients receiving continuous therapy, the concept of asthma control is used to determine the results of treatment (Table 10)

The modern definition of asthma severity is based on a retrospective assessment after at least 2–3 months of asthma treatment and is grounded in the concept of "difficulty to treat asthma."

It is important to distinguish true severe asthma from uncontrolled asthma due to modifiable factors (incorrect inhaler technique, poor treatment adherence).

Asthma severity may change over months and years and can be assessed in a patient after several months of stable therapy.

Table 9. Asthma symptom-based classification

Components of severity	**Intermittent asthma БА**	**Persistent asthma**		
		Mild	**Moderate**	**Severe**
Day symptoms	≤ 2 days/week	> 2 days/week, not daily	Daily; daily SABA rescue inhaler use for symptoms	Throughout the day; frequent SABA rescue inhaler use for symptoms
Night awakening	≤ 2 times/month	3–4 times/month	> 1 time/week but not nightly	Often 7 times/week
Interference with normal activity	None	Minor limitation	Some limitation, restricted physical activity and sleep disturbances	Extreme limitation
Lung function	FEV1 or PEFR ≥80% predicted FEV1/FVC>85%	FEV1 or PEFR ≥80% predicted FEV1/FVC>80%	FEV1 or PEFR 60–80% predicted FEV1/FVC 75–80%	FEV1 or PEFR ≤60% predicted FEV1/FVC <75%
PEFR variability	<20%.	20—30%	>30%.	>30%.

Table 10. GINA assessment of asthma control

Symptom control	***Level of asthma symptom control (in the past 4 weeks)***		
	Well-controlled	***Partly-controlled asthma***	***Uncontrolled***
Daytime symptoms for more than a few minutes, more than once a week?	None of these	1-2 of these	3-4 of these
Activity limitation (runs, tires easily during walks)			
SABA reliever medication needed more than once a week?			
Any night waking or night coughing due to asthma?			

Mild asthma – successfully controlled with Step 1 or 2 treatment, such as as-needed ICS/formoterol or low-dose ICS plus as-needed SABA.

Moderate (intermediate) asthma – controlled with Step 3–4 treatment (e.g., low or medium doses of ICS/LABA).

Severe asthma – requires Step 5 treatment (high doses of ICS/LABA) to achieve control or remains uncontrolled despite appropriate therapy.

In clinical practice, the term "mild asthma" is often used to describe infrequent or mild symptoms, leading patients to mistakenly believe they are not at risk and do not require treatment [1]. Therefore, GINA recommends avoiding the term "mild asthma" in clinical practice or reminding patients that even those with infrequent symptoms can still experience severe exacerbations.

Diagnosis of Bronchial Asthma

The diagnosis of asthma (fig.8) is based on patient complaints, medical history, results of functional respiratory tests, specific allergological examination, and exclusion of other diseases.



Fig 8. Diagnosis of asthma [6]

[6] https://gpraj.com/respiratory/2019/7/28/diagnosis-of-asthma[6]

Respiratory symptoms include wheezing, shortness of breath, chest tightness, cough, and variability in bronchial obstruction.

Clinical presentation of asthma

- Presence of more than one symptom (wheezing, breathing difficulty, cough, chest tightness), especially in adults.
- Symptoms often worsen at night or in the early morning. They vary over time and in intensity (***variability***).
- Asthma symptoms are triggered by factors such as viral infections, physical exertion, allergen exposure, weather changes (temperature and/or humidity fluctuations), strong emotions, laughter, air pollutants (ozone, nitrogen oxides, acid aerosols, particulate matter, vehicle exhaust, tobacco smoke, strong perfume odors, etc.).

Physical examination in asthma

- Lung auscultation: wheezing, which intensifies during forced exhalation, or diffuse dry wheezing against the background of weakened breath sounds; prolonged exhalation.
- Chest percussion: a hyperresonant ("boxy") percussion sound may be detected.

During exacerbation patients may exhibit the use of accessory respiratory muscles, tachycardia, and cyanosis.

Instrumental diagnostic methods

Assessment of pulmonary function

Spirometry. forced expiratory volume in 1 sec (FEV_1) and forced vital capacity (FVC) are measured during a maximal, rapid (forced) exhalation into a spirometer. A decrease in FEV_1 can occur in many lung diseases, so the FEV_1/FVC ratio should also be considered. The formula for calculating predicted values of FEV_1 and FVC includes age, sex, height, and racial background.

Peak Flow Rate Measurement. Assesses peak expiratory flow (PEF). Typically, PEF is measured immediately after waking up in the morning (when it is usually lowest) and again in the afternoon or evening (when it is generally highest). In clinical practice, airflow variability in bronchial obstruction is assessed by changes in FEV_1 or PEF.

Bronchial obstruction variability. Measured using PEF twice daily over two weeks. Excessive variability is defined as an average daily PEF variation of >10% in adults.

Bronchodilator Reversibility. A rapid improvement in FEV_1 (or PEF) within minutes after inhalation of a short-acting bronchodilator. A positive response is defined as an FEV_1 increase of >12% and >200 mL (more reliable if >15% and >400 mL). Values are assessed 10–15 minutes after inhaling 200–400 mcg of salbutamol (albuterol). The results are more reliable if the patient has not previously used β_2-agonists.

Improvement in lung function after 4 weeks of ICS treatment is also of diagnostic value: an increase in FEV1 by >12% and >200 ml (or FEV1 by >20%) from baseline.

Bronchial provocation testing

Bronchial obstruction may be absent during the initial assessment in some patients, but documented bronchial obstruction variability is a key aspect of asthma diagnosis. One diagnostic approach involves bronchoprovocation tests to assess airway hyperresponsiveness.

The most commonly used tests include:

- Methacholine challenge test
- Exercise challenge test
- Hyperventilation test
- -Histamine or mannitol challenge test

These tests have an average sensitivity in the diagnosis of asthma and limited specificity. In particular, airway hyperresponsiveness to methacholine can also occur in allergic rhinitis, cystic fibrosis, bronchopulmonary dysplasia, and COPD, meaning a positive test is not always a definitive indicator of asthma.

Exercise challenge test. Positive if FEV_1 decreases by >10% and >200 mL from baseline.

Methacholine bronchoprovocation test (adults only). Positive if FEV_1 decreases by ≥20% with standard doses or by ≥15% with standard hyperventilation, hypertonic saline, or mannitol challenge.

Imaging

Imaging studies are not routinely used in the diagnosis of asthma, but may be useful to investigate the possibility of comorbid conditions or alternative diagnoses.

Chest X-ray. Performed to differentiate asthma from other respiratory diseases (emphysema).

Computed tomography of the lungs can identify conditions such as bronchiectasis, emphysema, lung nodules, airway wall thickening and lung distension, and may assess airway distensibility.

Laboratory Tests

Complete blood count. May show elevated eosinophil count (eosinophilia).

Sputum analysis. Assesses signs of airway inflammation, detecting eosinophils or neutrophils in spontaneous or saline-induced sputum. Not a specific diagnostic method for asthma but is associated with an increased risk of exacerbation when corticosteroid therapy is reduced or discontinued.

Allergy testing

The presence of atopy increases the probability that a patient with respiratory symptoms has allergic asthma, but this is not specific for asthma nor is it present in all asthma phenotypes.

Allergy history – assessing personal or family history of allergic rhinitis, atopic dermatitis, food, or drug allergies.

Skin prick testing with common environmental allergens.

Measurement of specific IgE level in serum.

Asthma exacerbations

Exacerbations represent an acute or sub-acute worsening in symptoms (shortness of breath, cough, wheezing, or chest tightness) and lung function from the patient's usual status, or in some cases, a patient may present for the first time during an exacerbation.

The terms 'episodes', 'attacks' and 'acute severe asthma' are also often used, but they have variable meanings.

Objective signs of the severity of asthma exacerbation are: tachypnoea and tachycardia; difficulty talking (ability to talk in sentences, phrases or only words) and walking; patient's position and oxygen saturation (SpO_2) on room air (table 11).

Common exacerbation triggers

✓ Viral respiratory infections (rhinovirus, influenza, adenovirus, pertussis, respiratory syncytial virus)

✓ Allergen exposure (grass pollen and other pollens, soybean dust, fungal spores, food allergens)

✓ Outdoor air pollution

✓ Seasonal changes

✓ Poor adherence with ICS

Table 11. Criteria for categorizing the severity of asthma exacerbations

Severity	Symptoms
Mild/Moderate	✓ Patient is calm/ may be agitated ✓ Talks in sentences/phrases ✓ Can lie down/prefers sitting ✓ RR normal ✓ The accessory respiratory muscles are not involved in breath ✓ HR 100-120 bpm ✓ SpO2 90-95% ✓ - PEF – 50% and more predicted or percent personal best
Severe	✓ Patient is agitated ✓ Talks in words ✓ Sits upright, forced sitting position, leaning forward with the torso and supporting themselves with their hands. ✓ RR >30/min ✓ The accessory respiratory muscles involved in breath ✓ HR >120 bpm ✓ SpO2 < 90% ✓ - PEF ≤ 50% predicted or percent personal best
Respiratory arrest imminent (Status asthmaticus)	✓ Patient is drowsy or confused, does not talk ✓ Risk of respiratory failure ✓ Respiratory muscle fatigue (paradoxical movements of the chest and abdominal wall) ✓ Diffuse cyanosis

	✓ "Silent chest" ✓ Bradycardia ✓ The PEF cannot be assessed ✓ SpO2 < 90% and less

Severe asthma exacerbation risk factors

- Excessive use of short-acting β2-agonists (>1 inhaler (200 doses) per month)
- Inadequate ICS therapy: not used, low adherence to therapy, incorrect inhalation technique
- Low FEV1, especially if <60% predicted
- High variability of bronchial obstruction
- Significant psychological and socioeconomic problems
- Smoking; allergen exposure in case of sensitisation
- Comorbidities: obesity, rhinosinusitis, food allergy
- Eosinophilia in sputum or blood
- Pregnancy
- ≥ 1 severe exacerbation in the last year

Differential diagnosis

Differential diagnosis of asthma is made with such diseases as laryngospasm, pneumothorax, pulmonary edema, pneumonia, exacerbation of COPD (Table 12), pulmonary embolism (PE), hyperventilation syndrome, panic attacks, upper airway obstruction by a foreign body or bronchial tumor.

Table 12. Differential diagnosis of asthma and COPD

Symptoms	Asthma	COPD
Respiratory symptoms episodes, wheezing	Present	Present
Allergy history	Allergic rhinitis, atopic dermatitis, food, or drug allergies; A family history of asthma	Absent

Cough	Dry, at night, physical activity	With/without sputum During day
Signs of bronchial obstruction	Disappear quickly with bronchodilators	Irreversible bronchial obstruction that gradually progresses
Smoker or former smoker	Possible	Almost always
Breathlessness (dyspnea)	Varies	Persistent and progressive
Clinical manifestation after 40 years	Sometimes	Usually

Clinical assessment of asthma

Every patient with asthma should be assessed for disease control (symptom control and risk of exacerbation), treatment-related problems (inhalation technique, adherence to the prescribed therapy regimen), and any comorbidities that may worsen symptoms and quality of life (Tables 13, 14).

Table 13. Asthma Control Questionnaire – ACQ

On average, during the past week, how often were you woken by your asthma during the night?	0 =Never 1=Hardly ever 2=A few times 3=Several times 4=Many times 5=A great many times 6=Unable to sleep because of asthma
On average, during the past week, how bad were your asthma symptoms when you woke up in the morning?	0=No symptoms 1=Very mild symptoms 2=Mild symptoms 3= Moderate symptoms 4= Quite severe symptoms 5= Severe symptoms

	6= Very severe symptoms
In general, during the past week, how limited were you in your activities because of your asthma?	0= Not limited at all 1= Very slightly limited 2=Slightly limited 3=Moderately limited 4= Very limited 5= Extremely limited 6= Totally limited
In general, during the past week, how much shortness of breath did you experience because of your asthma?	0= None 1= A very little 2= A little 3= A moderate amount 4= Quite a lot 5= A great deal 6= A very great deal
In general, during the past week, how much of the time did you wheeze?	0= Not at all 1= Hardly any of the time 2= A little of the time 3= A moderate amount of the time 4= A lot of the time 5= Most of the time 6= All the time
On average, during the past week, how many puffs of short-acting bronchodilator have you used each day?	0= None 1= 1–2 puffs most days 2= 3–4 puffs most days 3= 5-8 puffs most days 4= 9-12 puffs most days 5= 13-15 puffs most days 6=More than 16 puffs most days

To be completed by a member of the clinic staff (Record actual values on the dotted lines and score the FEV1 % in the next column)	FEV1 prebronchodilator: 0 > 95% predicted FEV1 1 95–90% 2 89–80% 3 79–70% 4 69–60% 5 59–50% 6 < 50% predicted

ACQ ≤0.75 indicated a high probability that asthma was well controlled; 0.75–1.5 as a 'grey zone'; and ≥1.5 a high probability that asthma was poorly controlled. The minimum clinically important difference for all three versions of ACQ is 0.5 [1].

***Table 14*. Asthma Control Test – ACT**

In the past 4 weeks, how much of the time did your asthma keep you from getting SCORE as much done at work, school or at home?	1= All of the time 2= Most of the time 3= Some of the time 4= A little of the time 5= None of the time
During the past 4 weeks, how often have you had shortness of breath?	1= More than once a day 2= Once a day 3= 3 to 6 times a week 4= Once or twice a week 5=Not at all
During the past 4 weeks, how often did your asthma symptoms (wheezing, coughing, shortness of breath, chest tightness or pain) wake you up at night or earlier than usual in the morning?	1= 4 or more nights a week 2= 2 to 3 nights a week 3= Once a week 4= Once or twice 5= Not at all

During the past 4 weeks, how often have you used your rescue inhaler or nebuliser medication (such as albuterol)?	1 3 or more times per day 2= 1 or 2 times per day 3= 2 or 3 times per week 4= Once a week or less 5= Not at all
How would you rate your asthma control during the past 4 weeks?	1= Not controlled at all 2= Poorly controlled 3= Somewhat controlled 4= Well controlled 5= Completely controlled

Scores of 20–25 are classified as 'well-controlled'; 16–19 as 'not well-controlled'; and 5–15 as very poorly controlled asthma. The ACT has four symptom/ reliever questions plus patient self-assessed control. The minimum clinically important difference is 3 points.

Treatment

There are two approaches to achieving control of asthma with basic therapy.

The first approach is to achieve rapid control of symptoms through intensive treatment (short course prednisolone or high dose inhaled corticosteroids in addition to therapy that is appropriate for the patient's severity according to the stepwise approach) and then reduce the intensity of treatment.

The second approach (step therapy) is to start treatment appropriate to the severity of asthma and increase therapy if control is not achieved or is unstable. Usually, improvement can be achieved within a month. However, it is necessary to check whether the patient adheres to the prescribed treatment and avoids asthma triggers. If asthma control is stable, the intensity of therapy can be reduced after at least 3 months [10].

As a result of each of these approaches, the patient should take the minimum amount of medication necessary to maintain asthma control. The effectiveness and safety of treatment should be checked every 3-6 months if asthma is under control.

Medications for the treatment of bronchial asthma

Controller medications used for regular maintenance therapy.

- ***Inhaled corticosteroids*** (beclomethasone, fluticasone, budesonide, mometasone) are anti-inflammatory drugs for the treatment of persistent asthma. ICS differ in strength and bioavailability, so there is considerable individual variability in response to different ICS, possibly due to the heterogeneity of inflammation in the airways.
- ***Systemic corticosteroids*** (prednisolone, methylprednisolone) are used for maintenance therapy only in severe asthma with severe eosinophilia in short courses of 5-10 days. If possible, it is recommended to reduce their dose or stop taking them altogether by switching to high-dose ICS.
- ***Long-acting beta-2-agonists*** (formoterol, salmeterol, indacaterol, olodaterol) - used only in combination with ICS, monotherapy has a negative effect on the cardiovascular system.
- ***Leukotriene modifiers*** (montelukast, pranlukast, zafirlukast, zileuton) - can help reduce the dose of ICS in patients with moderate/severe asthma.
- ***Anti-IgE*** (omalizumab) - treatment of severe allergic asthma in patients with elevated levels of specific IgE.
- ***Anti-IL-5*** (mepolizumab), Anti-IL-5R (reslizumab, benralizumab), Anti-IL-4R (dupilumab) - interleukin receptor antagonists are indicated as an additional treatment for patients with severe asthma with severe eosinophilia (≥300 μL).
- ***Tezepelumab*** (humanised monoclonal antibody to anti-thymic stromal lymphopoietin (anti-TSLP)) is a new additional treatment for patients with severe asthma. The drug is prescribed in a dose of 210 mg subcutaneously every 4 weeks.

Before considering immunobiological therapy in patients with severe asthma (‘difficult to treat’), it is recommended to investigate the causes of eosinophilia that may not be related to asthma: to examine for parasites, including strongyloidiasis [10].

- ***Long-acting cholinolytics*** (tiotropium bromide, glycopyrronium bromide) - can be prescribed to patients with severe asthma in addition to the combination of ICS/LABA (‘triple’ combination).
- ***Azithromycin*** - can be used in addition to control therapy in patients with severe asthma, but the role of long-term macrolide use in asthma is still being investigated.

- ***Sublingual immunotherapy with allergens*** - can be used in addition to controlling treatment in patients with mild allergic asthma.

- Extended-release theophylline is not included in the list of GINA-recommended medicines for the treatment of asthma due to side effects and insufficient efficacy.

- The use of cromones (nedocromil sodium, cromoglycate sodium) has been discontinued worldwide. Drugs in this group have a good safety profile but low efficacy, and delivery devices containing the active ingredient require painstaking daily washing to avoid contamination [10].

Emergency medications for asthma exacerbation

Emergency medications are prescribed to relieve asthma symptoms and treat exacerbations:

- Short-acting inhaled β_2-agonists: salbutamol, fenoterol, terbutaline. To improve asthma control, the use of SABAs "as needed" should be supplemented with inhaled corticosteroids.
- Short-acting inhaled anticholinergics.
- Systemic corticosteroids.

Reliever medications

These include (Table 15) ICS/Formoterol, ICS/SABA, and SABA. If a patient is prescribed ICS/Formoterol, the recommended dose is:

Adults & Adolescents: 200/6 mcg (160/4.5 mcg)

Children (6-11 years): 100/6 mcg (80/4.6 mcg).

One inhalation as needed, with a repeat dose after a few minutes if necessary.

Maximum daily doses: Budesonide/Formoterol: 12 doses (adults), 8 doses (children), Beclometasone/Formoterol: 8 doses (adults).

If symptoms worsen rapidly or there is no response to increased ICS/Formoterol doses within 2-3 days, medical assistance should be sought (see Fig. 9).

For adults on maintenance therapy with ICS or ICS/SABA as needed, in case of exacerbations it is recommended to take 2 inhalations of budesonide/salbutamol (100/100 mcg) as needed. A maximum number of 6 as-needed doses can be taken in a day. If the

condition deteriorates rapidly or repeated doses of ICS/SABA are required for 1-2 days, medical consultation is necessary.

For patients using SABA for symptom relief, repeated inhalations provide only temporary relief until the underlying cause of the exacerbation is addressed or intensified ICS therapy begins. SABA alone is less effective in preventing exacerbation progression compared to low-dose ICS/Formoterol or ICS/SABA.

The need for repeated SABA doses for more than 1-2 days indicates the necessity to reassess and likely intensify ICS-based therapy.

Table 15. Categories of asthma medications

Category	Definition	Notes
Maintenance treatment	Daily or on a regularly scheduled basis asthma treatment	Medications intended to be used continuously - ICS + beta-2-agonists, leukotriene modifiers
Controller medications	Medication targeting both domains of asthma control (symptom control and future risk)	"ICS-containing treatment" and "Maintenance treatment" have been substituted as appropriate where the intended meaning was unclear
Reliever medications	Asthma inhaler taken as needed, for quick relief of asthma symptoms	"Rescue inhalers" - SABAs (e.g., salbutamol, terbutaline, ICS-salbutamol), ICS-formoterol, ICS-SABA
Anti-inflammatory reliever (AIR)	Reliever inhaler that contains both a low-dose ICS and a rapid-acting bronchodilator AIRs can be used as needed before exercise or allergen exposure to prevent symptoms	Budesonide-formoterol, beclometasone-formoterol, ICS-salbutamol combinations

Maintenance-and-reliever therapy (MART)	Treatment regimen in which the patient uses an ICS-formoterol inhaler every day (maintenance dose), and also uses the same medication as needed for relief of asthma symptoms (reliever doses) MART is also sometimes called SMART (single-inhaler maintenance-and-reliever therapy	Only ICS-formoterol inhalers (budesonide-formoterol, beclometasone-formoterol)

Reviewing response and adjusting treatment

The condition of asthma patients should be regularly reassessed to monitor symptoms and risk factors for exacerbations. For most controller medications, improvement begins within a few days of treatment initiation, but a full response may become evident after 3–4 months of therapy [1]. In severe cases or in patients who have consistently received insufficient treatment, the response may be more delayed (Fig. 9).

Step-Up in asthma treatment:

- Step-up (at least after 2–3 months): some patients may not achieve a full response to initial therapy.
- Short-term step-up (for 1–2 weeks): a short-term (1–2 weeks) increase in the dose of inhaled corticosteroids may be recommended, for example, during viral infections or seasonal allergen exposure.

Step-Down – if asthma is well controlled.

If good control is achieved and maintained for 3 months, treatment can often be reduced without loss of control.



Figure 9. Asthma treatment steps.[7]

[7] https://ginasthma.org/2024-report/

Treatment of asthma exacerbation

Initial therapy includes repeated use of SABA (tab. 16), early administration of systemic corticosteroids, and controlled oxygen therapy. The goal is to rapidly relieve airway obstruction and hypoxemia, treat inflammation, and prevent relapse.

Initial therapy

- Increase the SABA dose to 4–10 puffs every 20 minutes during the first hour (fig. 10). After the first hour, adjust the dose based on exacerbation severity:
  - Mild to moderate cases:4–10 puffs every 3–4 hours;
  - Severe cases:6–10 puffs every 1–2 hours or more frequently, depending on the patient's individual response.

It is recommended to use pressurized metered-dose inhalers (pMDI) with a spacer or, if available, nebulized bronchodilator solutions [1].

In case of incomplete response (PEF not increasing to 60–80% of predicted or personal best) continue inhaled β2-agonists (6–10 puffs every 1–2 hours); add systemic corticosteroids – 40–50 mg of prednisolone per os (equivalent doses of other corticosteroids) for at least 24 hours; add inhaled anticholinergics or use combination therapy (SABA + LAMA). If available, administer controlled oxygen therapy to maintain oxygen saturation at 93–95% [10].

If therapy is ineffective and the patient’s condition worsens, hospitalization is required (fig. 11).

Severe exacerbations are life-threatening and require inpatient treatment. Initial therapy includes:

- Oxygen therapy (nasal cannula or Venturi mask);
- SABA administration (preferably via nebulizer, initially as continuous therapy, then as needed for hospitalized patients);
- Systemic corticosteroids.

Reassessment after one hour. If the exacerbation is classified as moderate to severe: oxygen therapy, inhaled SABA + LAMA every hour; systemic corticosteroids (oral) for 1–3 hours until clinical improvement is observed.

Table 16. Management of patients with poor asthma control.

Medication	Short-term change (1–2 weeks) for worsening asthma
Increase usual reliever	
Low-dose ICS-formoterol	Increasing frequency of as-needed low-dose ICS-formoterol
SABA	Increasing frequency of SABA use for pMDI, add spacer
Combination ICS-SABA	Increasing frequency of as-needed ICS-SABA
Increase usual maintenance treatment	
Maintenance-and-reliever ICS-formoterol	Continue usual maintenance dose of ICS-formoterol and increase ICS-formoterol reliever doses as needed
Maintenance ICS with SABA as reliever	Consider quadrupling ICS dose
Maintenance ICS-formoterol with SABA as reliever	Consider quadrupling maintenance ICS-formoterol
Maintenance ICS plus other LABA with SABA as reliever	Step up to higher dose formulation of ICS plus other LABA. In adults, consider adding a separate ICS inhaler to quadruple ICS dose
Add oral corticosteroids; review before ceasing	
Prednisone, prednisolone	For severe exacerbations (PEF or FEV1 <60% personal best or predicted), or patient not responding to treatment over 48 hours. Once started, morning dosing is preferable. Adults: prednisolone 40–50 mg/day, usually for 5–7 days.



Figure 10. Management of asthma exacerbations in primary care[8]

[8] https://ginasthma.org/2024-report/



Figure 11. Management of severe asthma exacerbations in emergency department[9]

[9] https://ginasthma.org/2024-report/

Test tasks for self-assessment

1. A 43-year-old patient has an asthma attack during the flowering period of poplar trees. The patient has been ill for 3 years. Previously, asthma attacks were triggered by inhaling perfumes. Exhalation is difficult, and dry wheezing is heard in the lungs. The lung sound has a tympanic tone. Radiologically: enhancement and enrichment of the lung pattern, increased transparency of the upper lobes. FEV1 is reduced. The blood shows eosinophilia at 16/%. Charcot-Leyden crystals and Curschmann's spirals are found in sputum, and eosinophils are present at 10 per field of view. What condition is responsible for the asthma attack?

A. Allergic bronchial asthma

B. Acute bronchitis

C. Asthma, unspecified

D. COPD

E. Pneumonia

2. A 47-year-old patient complains of an attack of dyspnea and cough that has persisted for 2 days. The patient has been ill for 15 years. The use of salbutamol has not brought relief. On examination: the patient’s condition is severe. Diffuse cyanosis is present. Wheezing is audible at a distance. Tympanic sound is heard over the lungs, breathing is weakened, and a large number of dry rales are heard. The pulse rate is 120 per minute, blood pressure is 130/80 mmHg. Heart sounds are muffled. What is the diagnosis?

A. Bronchiectasis, exacerbation

B. Pneumonia

C. COPD, exacerbation

D. Partially controlled bronchial asthma

E. Bronchial asthma, severe exacerbation

3. A 42-year-old man, with more than 20 years of bronchial asthma, seeks medical help due to an increase in asthma attacks up to 10 times per day. On examination –forced

sitting position, the auxiliary muscles are involved in the act of breathing. Which group of medications should be prescribed first?

A. Mucolytics

B. Systemic corticosteroids

C. Inhaled short-acting β2-adrenergic agonists

D. Methylxanthines

E. Leukotriene antagonists

4. A patient with bronchial asthma is on basic therapy with beclomethasone at a daily dose of 500 μg but continues to need a short-acting β2-agonist 2-3 times per day, with daily variations in peak flow rate of 30%. What is your next step in management?

A. Continue the therapy unchanged

B. Increase the dose of beclomethasone

C. Prescribe theophylline

D. Add formoterol

E. Add azithromycin

5. A patient with asthma experiences shortness of breath at rest. The patient is sitting, leaning forward, and speaks in single words. The respiratory rate is 30 per minute. The auxiliary muscles are involved in the act of breathing. Wheezing is heard over the entire lung surface. Pulse rate is 120 per minute. After 4 inhalations of salbutamol, the peak flow rate is 45% of the predicted value. SpO2 is 80%. Assess the severity of the asthma exacerbation:

A. Mild

B. Moderate

C. Severe

D. Life-threatening

6. According to peak expiratory flow (PEF) monitoring, bronchial asthma is characterized by:

A. PEF consistently remains at low values (<50% of the predicted)

B. PEF is consistently above 80% of the predicted, with low PEF variability

C. PEF does not change after the use of inhaled β2-agonists

D. PEF does not change after the use of inhaled corticosteroids

E. High PEF variability is observed (difference between morning and evening PEF >10%)

7. A patient with asthma experiences episodes of breathing difficulty 3-4 times a week during the daytime, which are relieved by inhaling salbutamol. There are no nighttime awakenings due to asthma. There are no activity limitations. Determine the level of asthma control:

A. Well-controlled

B. Partially controlled

C. Uncontrolled

D. Exacerbation

E. Remission

8. A 36-year-old woman has been suffering from pollinosis for 7 years. For the last 2 years, during august-september (the ragweed flowering season), she has experienced 2-3 episodes of dyspnea, which are relieved by a single dose of salbutamol. Objectively: temperature – 36.5°C, respiratory rate – 18/min, heart rate – 78/min, blood pressure – 115/70 mmHg. Vesicular breathing over the lungs. Heart sounds are clear, rhythm is regular. Which medication would most effectively prevent asthma attacks in this patient?

A. Inhaled fenoterol

B. Inhaled ipratropium bromide

C. Inhaled beclometasone

D. Oral montelukast

E. Oral extended-release theophylline

9. After experiencing psycho-emotional stress, a 24-year-old patient frequently develops conditions accompanied by wheezing, expiratory dyspnea, and frequent nighttime

symptoms that limit physical activity. PEF is 55%, variability is 35%. What is the preliminary diagnosis?

A. Severe persistent bronchial asthma

B. Moderate persistent bronchial asthma

C. Intermittent bronchial asthma

D. Mild persistent bronchial asthma

E. COPD

10. A 25-year-old woman suddenly felt unwell in a pharmacy. She is standing, leaning against a windowsill. Objectively – short inhalation, prolonged exhalation, respiratory rate – 25/min, heart rate – 100/min, blood pressure – 100/70 mmHg. Percussion over the lungs reveals a hyperresonant sound. Auscultation reveals dry, wheezing sounds, more pronounced during exhalation; accentuated second heart sound over the pulmonary artery. What is the preliminary diagnosis?

A. Pulmonary embolism

B. COPD exacerbation

C. Pulmonary edema

D. Acute laryngotracheitis

E. Bronchial asthma attack

Standard answers: 1 - A, 2 - E, 3 - B, 4 - D, 5 - C, 6 - E, 7 - B, 8 - C, 9 - A, 10 - E.

PNEUMONIA

Relevance of the topic. Pneumonia remains an important medical and social problem in the 21st century. This is due, first of all, to its significant prevalence, fairly high rates of disability and mortality, as well as significant economic losses due to this disease. According to WHO, in 2022, lower respiratory tract infections will rank fourth in the world among the causes of death of modern humans, with community-acquired pneumonia (CAP) posing a serious threat to the lives of patients. Every year, about 5.6 million cases of CAP are observed in the world, of which 1.1 million require hospitalization. The mortality rate from CAP in outpatient settings is from 1 to 5%. Mortality in hospitalized patients is about 12%, and in patients requiring intensive care, it reaches 40% [11].

In 2017, the incidence of acute respiratory infections in the adult population in Ukraine was 384 per 100,000, and the mortality rate was 11.7 per 100,000. The lowest mortality rate from acute respiratory infections (1–3%) is recorded in young and middle-aged people without comorbidities. In older people with comorbidities (cardiovascular disease, COPD, malignant neoplasms, alcoholism, diabetes, kidney and liver disease, obesity, etc.), as well as in patients with severe acute respiratory infections, this figure reaches 15–30%. Pneumonia associated with coronavirus infection Covid-19 (a new type of pneumonia) in Ukraine was first diagnosed on March 3, 2020 in Chernivtsi. According to the Ministry of Health of Ukraine, as of January 2024, 5,557,995 cases of COVID-19 were registered in Ukraine, of which 112,418 people died.

Pneumonia is an acute infectious disease, mainly of bacterial etiology, characterized by focal lesions of the respiratory tract and the presence of intraalveolar exudation.

The classification of pneumonia, which most fully reflects the features of its course and allows the patient to be prescribed etiotropic therapy, should certainly be based on the etiological principle. It is on this principle that the classification of pneumonia, which is given in the ICD-10, is based.

However, in practice, etiological diagnosis of pneumonia in 50–70% of patients is complicated due to the insufficient informativeness and significant duration of traditional

microbiological studies. Therefore, many countries use a classification that takes into account the conditions of disease onset, the characteristics of lung tissue infection, and the state of the patient's immune reactivity. This allows for a fairly high probability of predicting the possible causative agent of the disease [15].

The division of pneumonia into community-acquired (acquired outside a medical facility) and hospital-acquired (nosocomial, acquired in a medical facility) is of greatest practical importance.

Community-acquired pneumonia

Definition and classification

Community-acquired pneumonia is defined as an acute illness that develops in the community (outside a hospital or later than 4 weeks after discharge from a hospital, or diagnosed within the first 48 hours of hospitalization) and is accompanied by symptoms of lower respiratory tract infection (fever; cough; sputum production, possibly purulent; chest pain; shortness of breath) and radiological signs of new focal infiltrative changes in the lungs in the absence of an obvious diagnostic alternative [11].

Community-acquired pneumonia is divided into the following types:

1) community-acquired pneumonia in patients with no apparent immune disorders;
2) community-acquired pneumonia in patients with apparent immune disorders:
    a) acquired immunodeficiency syndrome (HIV/AIDS),
    b) other diseases/pathological conditions;
3) aspiration pneumonia.

In addition, depending on the severity of the disease, pneumonia is classified as mild, moderate, and severe; severity is assessed clinically and using criteria given in the PORT, CRB-65, and SMART-COP scales [11].

Classification. ICD 10

J10.0. Influenza (broncho)pneumonia, other identified influenza virus

J11.0 Influenza (broncho)pneumonia, unspecified

J12 Viral pneumonia, not elsewhere classified

J12.0 Adenovirus pneumonia

J12.1 Respiratory syncytial virus pneumonia

J12.2 Parainfluenza pneumonia

J12.8 Other viral pneumonias

J13 Pneumococcal pneumonia

J14 Pneumonia due to Haemophilus influenzae

J15 Bacterial pneumonia, not elsewhere classified

J15.0 Pneumonia due to Klebsiella pneumonia

J15.1 Pneumonia due to Pseudomonas

J15.2 Pneumonia due to staphylococcus

J15.3 Pneumonia due to group B streptococcus

J15.4 Pneumonia due to other streptococci

J15.5 Pneumonia due to Escherichia coli

J15.6 Pneumonia due to other aerobic gram-negative bacteria

J15.7 Pneumonia due to mycoplasmas

J15.8 Other bacterial pneumonias

J17 Pneumonia in diseases classified elsewhere (bacterial, viral, parasitic, mycotic)

J18 Pneumonia due to unspecified pathogen

1. Community-acquired pneumonia (synonyms: community-acquired, home-acquired, outpatient), acquired outside a medical facility.

2. Hospital-acquired pneumonia (synonyms: nosocomial, hospital-acquired) occurs 48 hours or more after a patient is hospitalized for another disease or within 4 weeks after discharge.

3. Aspiration pneumonia is an acute chemical injury to the lungs (chemical pneumonitis) caused by aspiration of acidic gastric contents (not less than 25 ml with a pH less than 2.5). It is characterized by the development of a two-phase bronchopulmonary reaction: 1) the occurrence of bronchial obstruction and 2) the development of inflammation and acute damage to lung tissue.

4. Pneumonia in individuals with severe immune defects – congenital immunodeficiency, HIV infection, previous chemotherapy, radiotherapy, long-term immunosuppressive therapy including corticosteroids, leukemias, aplastic anemias [15].

In addition, the diagnosis indicates:

- localization of pneumonia (left, right, upper, middle, lower lobe, total, segmental);
- severity of pneumonia (mild, severe).

Assessing the severity of pneumonia

The PORT scale, developed based on the results of the Pneumonia Patient Outcomes Research Team, uses criteria that allow calculating the pneumonia severity index (PSI), predicting the risk of fatal outcome, and forming recommendations regarding the place of treatment and priority areas of empirical antibacterial therapy. In patients under 50 years of age, in the absence of concomitant diseases and dangerous functional disorders, the risk of fatal outcome is very low (risk class I). In patients over 50 years of age (risk class II-V), data on age, gender, the presence of concomitant diseases, dangerous functional disorders, as well as the results of laboratory and radiological studies are evaluated using points [16].

Based on the results of the total score, the risk class is determined:

• Risk class I - 0 points, mortality 0.1%, treatment - outpatient;

• Risk class II - sum of points ≤ 70, mortality 0.6%, treatment - outpatient;

• III risk class - sum of points 71–90, mortality 2.8%, outpatient treatment (inpatient up to 4 days);

• IV risk class - sum of points 91–130, mortality 8.2%, inpatient treatment.

V risk class sum of points > 130, mortality 29.2%, inpatient treatment (intensive care unit)

The CURB-65 scale provides for the assessment of 5 parameters: impaired consciousness, increased urea nitrogen level > 7 mmol/l, respiratory rate, systolic and diastolic blood pressure, patient's age. Each indicator is assessed at 1 point.

By the sum of the points:

• score – group I, mortality 1.5% (outpatient treatment);

• points – group II, mortality 9.2% (short-term hospitalization or outpatient treatment under supervision);

• and more points – group III, mortality 22% (urgent hospitalization).

The CRB-65 scale differs from the previous one in the absence of a laboratory parameter – urea nitrogen.

The SMART-COP scale provides for a point assessment of clinical, laboratory, physical and radiological signs with the determination of the probable need for intensive treatment methods. A modified version of the SMRT-COP scale can be used in outpatient practice and emergency departments, as it does not require the determination of albumin levels, PaO2, and arterial blood pH [11]. According to the recommendations of the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA), “minor” and “major” criteria for severe pneumonia are distinguished.

"Big" criteria

1. Severe respiratory failure (RF) requiring mechanical ventilation (MV)

2. Septic shock (need for vasopressors).

"Small" criteria"

1 RR ≥ 30/min 2. PaO2/FiO2 ≤ 250 (e.g., SpO2 less than 90%, according to pulse oximetry or PaO2 below 60 mm Hg when breathing air)

2. Multilobar or bilateral infiltration, decay cavities, pleural effusion, rapid progression of focal-infiltrative changes in the lungs: increase in the size of the infiltration by more than 50% within the next 2 days

3. Impaired consciousness

4 Uremia (residual urea nitrogen ≥ 20 mg/dl)

5. Leukopenia (< 4 x 10^9/l)

6. Thrombocytopenia (< 100 x 10^12/l)

7. Hypothermia

8. Hypotension requiring intensive infusion therapy (systolic blood pressure below 90 mm Hg, diastolic blood pressure below 60 mm Hg).

Severe pneumonia is indicated by the presence of at least one “major” or three “minor” criteria in patients, each of which significantly increases the risk of death. In such cases, urgent hospitalization of patients in the intensive care unit is recommended.

Disease course (acute, prolonged).

Possible risk factors for a prolonged course of the disease may be:

• age over 50 years; alcoholism; the presence of concomitant disabling diseases of internal organs (COPD, congestive heart failure, renal failure, malignant tumor, diabetes mellitus, etc.);

• severe course of pneumonia; multi-partite prevalence of pneumonic infiltration; virulent pathogens of pneumonia (L. Pneumophila, S. Aureus, gram-negative enterobacteria);

• smoking;

• clinical ineffectiveness of the prescribed therapy (leukocytosis and fever persist);

• secondary bacteremia;

• acquired antibiotic resistance of the pathogen.

In the presence of risk factors for a prolonged course of CAP, if clinical improvement is observed, it is advisable to conduct a control X-ray examination of the chest cavity after 4 weeks. If there are no signs of clinical improvement and/or the patient has risk factors for a prolonged course of CAP, then, of course, immediate additional examination of the patient is indicated –CT of chest cavity, bronchoscopy, etc.

Etiology

Pathogens of community-acquired pneumonia:

- typical (in 40-70% of cases pneumococcus, hemophilic bacillus, staphylococcus, Klebsiella (Friedlander's bacillus)
- atypical (legionella, mycoplasma, chlamydia - intracellular pathogens).

Most of the CAP is caused by S. pneumoniae (28%); 2nd place is occupied by M. pneumoniae (11.4%) and C. pneumoniae (11.4%). Less often, the causative agent of the disease is L. pneumophila (4.4%) and H. influenzae (4.1%). At the same time, in 37% of cases, the pathogen cannot be identified [11].

The main pathogens of community-acquired pneumonia are Pseudomonas aeruginosa, Escherichia coli, Klebsiella (Friedlander's bacillus), Proteus, Enterobacter, Staphylococcus aureus.

Aspiration pneumonia is almost always caused by anaerobic or gram-negative microflora.

In immunocompromised patients, pneumonia is caused by various microorganisms: fungi, bacteria, viruses, but most often by pneumocystis or cytomegalovirus [17].

Pathogenesis

In the pathogenesis of pneumonia, the infectious agent that penetrates the lungs plays a key role. There are three ways in which microflora penetrates the respiratory tract of the lungs:

- bronchogenic (main)
- inhalation (together with the air we breathe)
- aspiration (from the nasopharynx or oropharynx)
- hematogenous (sepsis, infectious diseases)
- lymphogenous (penetrating injuries to the chest, from neighboring affected organs)

In addition to infection, the development of pneumonia is facilitated by a decrease in the local bronchopulmonary defense system.

Clinical presentation

Pneumonia is characterized by the following main syndromes:

intoxication – general weakness, fatigue, headaches, muscle pain, decreased appetite, increased sweating, in severe cases delirium;

syndrome of general inflammatory changes – fever, chills, feeling of heat; changes in acute phase blood parameters: leukocytosis, neutrophilic shift to the left (band cells > 6%), increased ESR, increased levels of fibrinogen, sialic acids, β2 and γ-globulins, the appearance of C-reactive protein (CRP);

syndrome of inflammatory changes in lung tissue – cough, sputum, shortness of breath, chest pain, increased voice tremor, dull or dull percussion sound over the area of the affected lobe of the lung, weakened and/or hard bronchial breathing, the appearance of pathological respiratory sounds (crepitation, moist small-bubble sonorous rales).

Features of the clinical course of pneumonia depending on the pathogen.

Pneumococcal pneumonia. Pneumococcus (Streptococcus pneumoniae) is the most common pathogen of community-acquired pneumonia. Pneumococci of types I-III

cause typical partial pneumonia (croupous pleuropneumonia), pneumococci of other strains cause the development of focal pneumonia. Characteristic are acute onset, t˚ - 39˚-40˚, the appearance of "rusty" sputum, herpes labialis, nasalis, redness of the cheek on the affected side, pronounced pleural pain in the chest, lagging of half of the chest during the act of breathing, clinical and radiological signs of partial damage, parapneumonic pleurisy often occurs [11, 15].

 [10]

Fig. 12. Pneumococcal right-sided pneumonia in the middle lobe.

Staphylococcal pneumonia (Staphylococcus aureus). It accounts for about 5% of pneumonias, often develops against the background of influenza and is complicated by abscessation (Fig. 13), pyopneumothorax.

[10] https://emedicine.medscape.com/article/225811-workup

 [11]

Fig. 13. Staphylococcus aureus associated pneumonia. Lower right-sided pneumonia with abscessation. Upper left-sided pneumonia. Left-sided exudative pleurisy.

The clinical presentation is characterized by an acute onset, significant intoxication, severe course, and fever. Radiologically, against the background of infiltration, multiple areas of necrosis are observed, with the possible development of a solitary abscess.

Mycoplasma pneumonia (Mycoplasma Pneumoniae). It accounts for about 10% of all cases of pneumonia. The clinic can be either typical (fever, productive cough), or manifested by nonspecific symptoms - general weakness, fatigue, malaise, myalgia. Histological features of pneumonia caused by M. pneumoniae are acute bronchiolitis with edematous-ulcerative lesions of the bronchial walls and peribronchial and perivascular interstitial infiltrates containing lymphocytes, plasma cells and macrophages [15].

[11] https://www.ncbi.nlm.nih.gov/books/NBK553877/figure/ch7.Fig2/



Fig. 14. Right lower lobe Mycoplasma pneumonia [12]

Segmental bronchopneumonia most often develops (Fig. 14), and radiologically both typical alveolar infiltration and interstitial infiltration - the “ground glass” symptom - can be detected.

Legionella pneumophila. It accounts for about 5% of all pneumonias. The most common source of infection is humidification systems and tap water. Infection occurs by inhalation of infected aerosol or by microaspiration of water.

Risk factors for legionellosis are working near water and sewage facilities, living near water bodies, contact with air conditioners, immunodeficiency states, diabetes mellitus.

Characterized by acute onset, fever up to 39-40 °C, cough, headache and muscle pain. Half of the patients have a severe course of the disease (ARF, impaired consciousness).

[12] https://ajronline.org/doi/10.2214/ajr.174.1.1740037

There are also signs of extrapulmonary lesions - diarrhea, liver enlargement, jaundice, increased transaminase levels, hyponatremia, proteinuria and hematuria. In general, a blood test shows lymphopenia, sharply increased ESR (60 - 80 mm / h). Infiltration of the lung parenchyma is most often unilateral, and pleurisy and lung abscess may develop.

Pneumonia caused by Klebsiella pneumoniae (Friedlander's bacillus) usually occurs in patients with chronic alcoholism, diabetes, cirrhosis of the liver, after major surgeries, and against the background of immunosuppression. Acute onset, severe intoxication, and severe course of pneumonia are characteristic.

The clinical feature of Klebsiella pneumonia is dark brown or redcurrant jelly-like sputum with an unpleasant odor ("burnt meat"). Lung abscess and empyema are common. The location of pneumonia is usually upper lobe (Fig. 15).

 [13]

Fig. 15. Right upper lobe pneumonia (Klebsiella pneumoniae).

[13] https://radiopaedia.org/cases/klebsiella-pneumonia-causing-a-bulging-fissure

Viral pneumonia

Influenza pneumonia. In influenza, according to the mechanism of development, severity of the course and consequences, primary influenza pneumonia is distinguished, which develops on the 2nd–3rd day of the disease, and secondary viral-bacterial pneumonia, which develops at the end of the first - beginning of the second week from the onset of the disease. Primary pneumonia occurs as a result of the pathological effect of the virus on the epithelium of the respiratory tract. The most pronounced tropism to the lower respiratory tract is shown by strains of the influenza A virus (H1N1) - they affect the epithelium of almost the entire respiratory system, up to the bronchioles with the development of acute respiratory distress syndrome (ARDS). The clinical picture is dominated by fever, headache, pain in the eyeballs, muscles. One of the features is a pronounced discrepancy between clinical, radiological data and blood oxygen saturation. Thus, with insignificant physical data in the form of respiratory depression and intermittent wheezing, signs of total or subtotal pneumonia are detected on radiographs against the background of a decrease in saturation of less than 90%. The results of treatment are significantly influenced by the timeliness of hospitalization of patients (the first 2 days of the disease) and the possibility of using non-invasive methods of respiratory support [11].

Secondary influenza-bacterial pneumonia is associated with the addition of bacterial superinfection (S. pneumoniae, S. pyogenes, S. aureus, H. influenzae, M. Catarrhalis, Klebsiella spp.). Patients on mechanical ventilation are at risk of ventilator-associated pneumonia. It is characterized by the appearance of a second wave of fever, increased cough, the appearance of purulent sputum, the change of leukopenia to leukocytosis (usually moderate) and/or the appearance of neutrophilosis.

The most dangerous is staphylococcal pneumonia, which develops 2–3 days after the debut of the first symptoms of the disease and is accompanied by bilateral pulmonary infiltration with the appearance of hemorrhagic sputum, the development of severe hypoxemia, high neutrophilic leukocytosis.

Coronavirus infection (SARS-CoV-2, COVID 19). The virus uses angiotensin-converting enzyme II receptors of alveolar type II cells, which synthesize surfactant, to enter target cells, which can lead to ARDS.

Clinical signs of COVID-19

Most people experience fever, cough, fatigue, anorexia, shortness of breath, and myalgias. Some patients experience sore throat, nasal congestion, headache, diarrhea, nausea, vomiting, loss of smell (anosmia) or loss of taste (ageusia) before respiratory symptoms appear.

Symptoms of COVID-19-associated pneumonia in a patient with normal temperature:

• dry cough;
• increased fatigue;
• feeling of heaviness in the chest;
• pale skin;
• shortness of breath with minor physical exertion.

The clinical course of severe coronavirus pneumonia is characterized by intoxication syndrome and progressive respiratory failure. Other complications described in patients with COVID-19 include septic shock, pulmonary embolism, acute coronary syndrome, acute cerebrovascular accident, and delirium.

Laboratory changes: increased C-reactive protein levels above 50 U, progressive absolute lymphopenia, increased ferritin and interleukin 6 levels [].

Criteria for severe coronavirus infection:

- RR ≥30/min
- SpO2 ≤92%;
- PaO2/FiO2 ratio <300.
- Lung infiltrates >50% of the lung field and their progression within 24-48 hours.

Morphological changes in COVID-19-associated pneumonia are characterized by diffuse alveolar damage to the lung tissue. Radiological manifestations are initially defined as a “ground glass” symptom. With disease progression and bacterial superinfection, typical alveolar consolidation is observed (Fig. 16).

а) б)



Fig. 16. COVID-19-associated pneumonia: a) bilateral lung lesions in the middle and lower fields ("ground glass"); b) 10th day of the disease - consolidation in the left lower lobe, spread of peripheral changes ("ground glass") in the middle, lower lobe on the right and lower lobe on the left.[14]

Pneumocystis pneumonia (Pneumocystis jirovecii) - Caused by an opportunistic pathogen, which is carried by almost all people. It is classified as a fungus, but with certain biological features of protozoa. Before the widespread use of pneumocystis pneumonia prophylaxis and antiretroviral therapy, it was observed in 70-80% of patients with AIDS. When treated, pneumocystis pneumonia is associated with a 20-40% mortality rate in patients with severe immunosuppression. Today, it is mainly observed in patients with undiagnosed HIV infection, without ongoing therapy, and with severe immunosuppression (CD4 cell count < 100 cells/mm3).

Clinical manifestations include fever, nonproductive cough, chest discomfort, shortness of breath, tachycardia. A common concomitant infection is oral candidiasis. Chest X-ray reveals diffuse, bilateral, symmetrical basal infiltrates that expand from the roots to the periphery in the shape of a butterfly (Fig. 17).

[14] https://kiai.com.ua/ua/archive/2022/6%28143%29/pages-5-12/radiologichni-harakteristiki-difuznogo-alveolyarnogo-urazhennya-pnevmoniyi-zumovlenogo-covid-



Fig. 17. Pneumocystis pneumonia [15]

Clinical groups of patients with community-acquired pneumonia

Group I – patients with a mild course of acute respiratory infections, who do not require hospitalization, without concomitant pathology and have not taken antibacterial drugs during the last three months. The most common pathogens of acute respiratory infections in such patients are S. pneumoniae, M. pneumoniae, C. pneumoniae, H. influenzae (usually in smokers) and respiratory viruses.

Group II – patients with a mild course of acute respiratory infections, who do not require hospitalization, with the presence of concomitant pathology and/or have taken antibacterial drugs during the last three months. The pathogens of acute respiratory infections in these patients are S. pneumoniae (including antibiotic-resistant strains), H. influenzae, S. aureus, respiratory viruses. The possibility of the presence of gram-negative infection should also be considered: the Enterobacteriales family (E. coli, Klebsiella spp.), especially in the elderly.

[15] https://radiopaedia.org/cases/pneumocystis-carinii-pneumonia-1

Group III - patients with moderately severe acute respiratory infections requiring hospitalization in a therapeutic or pulmonological department. In patients of this group, the development of acute respiratory infections may be caused by S. pneumoniae, H. influenzae, atypical pathogens, gram-negative enterobacteria, respiratory viruses. In 10–40% of patients in group III, a “mixed” infection is often detected.

Group IV - patients with severe acute respiratory infections requiring hospitalization in an intensive care unit. The spectrum of microbial flora in such patients includes S. pneumoniae, Legionella spp., H. influenzae, gram-negative enterobacteria, Pseudomonas spp., S. aureus and M. pneumoniae (rarely).

Formulating the diagnosis:

1. Left lower-lobe hospital-acquired pneumonia, severe course, severe ARF.
2. Right upper lobe community-acquired pneumonia, moderate severity, clinical group III, mild ARF.

Approaches to diagnosis

1. Chest X-ray in two views.

The main radiological sign of community-acquired pneumonia is a local decrease in the airiness of the lung tissue (infiltration) due to the accumulation of inflammatory exudate in the respiratory tract.

There are 2 types of lung tissue infiltration:

- **Alveolar type (consolidation)** – occurs when the alveoli, alveolar sacs, alveolar ducts, and respiratory bronchioles are filled with inflammatory exudate, which leads to loss of airiness in the affected area. It is more common in cases of infection with bacterial pathogens, especially pneumococcus.
- **Interstitial type ("ground glass")** is observed when the interalveolar spaces are filled with inflammatory exudate. It is characterized by a low-density shadow of the consolidated area. Such pneumonic changes may not be detected on conventional radiography. The 'ground-glass opacity' sign is more accurately identified on high-resolution chest CT - with visualization of bronchial walls and elements of the vascular pattern within the area of infiltration. It is more commonly observed in viral pneumonias.

2. Chest CT scan.

Indications

1. The absence of changes in the lung fields on chest radiographs, or the presence of indirect changes (such as alteration of the pulmonary pattern), in a patient with clear clinical signs of pneumonia.

2. The presence of changes atypical for pneumonia according to the data of the chest X-ray in the patient with suspected pneumonia (based on clinical signs).

3. Recurrent pneumonia, in which infiltrative changes occur in the same lobe (segment) as in the previous episode of the disease.

4. Pneumonia with a prolonged course, in which infiltrative changes in the lung tissue persist for more than one month [11].

3. Lung Ultrasound.

4. Bronchoscopy. In severe pneumonia and suspected pulmonary tuberculosis, bronchogenic carcinoma, aspiration of foreign bodies into the bronchi.

Laboratory findings

Complete blood count. Leukocytosis >10-12*10^9/l indicates a high probability of bacterial infection. Leukopenia <4*10^9/l or leukocytosis >25*10^9/l are unfavorable prognostic signs.

Biochemistry. Liver and kidney function tests, glycemia have some prognostic value. An increase in the level of CRP is associated with severe inflammation and helps determine the tactics of antibiotic therapy. At the level of CRP <20 mg/l, NICE experts consider the appointment of antibiotics inappropriate and mandatory at the level of CRP >100 mg/l. An increase in the concentration of procalcitonin indicates a bacterial etiology of CAP and the need for the use of antibiotics, and its level ≥2 ng/ml correlates with a severe course of the disease [11].

Arterial blood gases - determination of PaO2, PaCO2, pH, bicarbonates, lactate (assessment of the severity of RF).

Coagulation tests - determination of prothrombin time, international normalized ratio, activated partial thrombin time is indicated in severe pneumonia.

Microbiological (bacteriological and virological) research

Bacteriology of sputum. It is performed before the start of antibiotic therapy. Detection in smears of a significant number of gram-negative or gram-positive microorganisms with typical morphology (gram-positive lanceolate diplococci - S. pneumoniae; clusters of gram-positive cocci in the form of clusters - S. aureus, gram-negative coccobacilli - H. influenzae) may be useful in prescribing empirical antibacterial therapy.

Sputum culture + determination of the sensitivity of microflora to antibiotics (material obtained during bronchoalveolar lavage, bronchoscopy has high diagnostic value).

PCR (polymerase chain reaction). Confirmation of infection with M. Pneumoniae, C. pneumoniae, influenza A (H1N1) virus, SARS-CoV-2.

The diagnosis of CAP is definite if the patient has radiologically confirmed focal infiltration of the lung tissue and at least two of the following clinical signs [9]:

• acute onset of the disease with body temperature above 38 °C;

• cough with sputum production;

• physical signs (dull or dull percussion sound, weakened and/or hard bronchial breathing, focus of sonorous small-bubble rales and/or crepitations);

• leukocytosis (more than 10x10^9 /l) and/or rod nuclear shift (more than 10%).

In the absence of, or inability to obtain, radiological confirmation of focal infiltration in the lungs, the diagnosis of CAP remains uncertain or indeterminate. In this case, the diagnosis is made based on epidemiological history, the patient's complaints, and relevant physical examination findings [17].

The presence of CAP is unlikely in patients with fever, complaints of cough, shortness of breath, sputum production, and/or chest pain in the absence of physical signs and the inability to perform a chest X-ray.

Differential diagnosis

- pulmonary tuberculosis
- lung cancer
- lung metastases
- pulmonary infarction
- acute bronchitis

- exudative pleurisy
- fibrosing alveolitis

Complications

Pulmonary:

- parapneumonic pleurisy
- pleural empyema
- lung abscess and gangrene
- bronchoobstructive syndrome
- respiratory failure
- ARDS

Extrapulmonary:

- acute cor pulmonale
- septic shock
- sepsis
- myocarditis, meningoencephalitis
- disseminated intravascular coagulation syndrome

Hospital-acquired pneumonia (nosocomial) (HAP) is a disease characterized by the appearance on the chest X-ray of new focal-infiltrative changes in the lungs 48 hours or more after hospitalization in combination with clinical symptoms confirming their infectious nature (a new wave of fever, purulent sputum or purulent discharge from the tracheobronchial tree, leukocytosis, etc.), with the exclusion of infections that were in the incubation period at the time of the patient's admission to the hospital.

Classification

The criterion for classifying HAP is the term of the disease, the presence or absence of risk factors for its development.

Early HAP - occurs within the first 5 days from the moment of hospitalization and is caused by pathogens that were present in the patient before admission to the hospital, - S.pneumoniae, H.influenzae, methicillin-sensitive S.aureus (MSSA) and other representatives of the normal microflora of the oropharyngeal cavity.

Late HAP - develops after 6 days of hospitalization and is caused by hospital microflora with a higher risk of the presence of highly virulent and multidrug-resistant pathogens, such as P. aeruginosa, Acinetobacter spp., representatives of the Enterobacteriaceae family, methicillin-resistant S. aureus (MRSA).

Ventilator-associated pneumonia (VAP) - pneumonia that occurred 48 hours after the start of mechanical ventilation in the absence of signs of pulmonary infection at the time of intubation.

Risk factors for developing HAP

Patient-related factors: delayed initiation of feeding, prolonged (≥3 days) stay in the intensive care unit, comatose states, acute and chronic diseases (metabolic acidosis, diabetes mellitus, COPD, alcoholism, chronic kidney disease) (U.S. Food and Drug Administration, 2019).

1. Factors related to infection prevention: inadequate hand hygiene of medical personnel and incorrect work with respiratory support devices (humidification, filters, sanitation systems) (Di Pasquale M et al., 2016).

2. Factors arising from certain manipulations: prolonged sedation, prolonged surgical time, inadequate antibacterial therapy and prolonged use of corticosteroids (Huang Y et al., 2018).

Diagnosis of HAP

Clinical symptoms – fever (increased body temperature above >38°C), productive cough with purulent sputum, shortness of breath (increased RR).

Physical examination – appearance of a focus of crepitus, moist railes, raspy/bronchial purulent breathing.

Laboratory signs –leukocytosis (> 12*10^9/l) with a shift to the left or leukopenia (<4.0 *10^9/l) in peripheral blood.

PaO2/FiO2 - less than 240.

Chest X-ray – new focal-infiltrative changes in the lungs.

Bacteriology of sputum – more than 25 polymorphonuclear leukocytes in the field of view.

Treatment

Antibacterial therapy of Community-acquired pneumonia.

Antibiotics for the treatment of patients with CAP are prescribed empirically depending on the clinical group of CAP. First-line therapy (drugs of choice and alternative drugs) and second-line therapy are distinguished. After establishing the diagnosis of CAP, treatment is started with drugs of choice, and if their appointment is impossible (absence, intolerance or use during the last 3 months for any reason) - with alternative drugs.

Assessment of the effectiveness of antibacterial therapy must be carried out 48–72 hours after the start of treatment. The main criteria for effectiveness during this period are a decrease in the manifestations of intoxication and a decrease in the patient's body temperature, the absence of RF [11].

In case of ineffectiveness of initial therapy, second-line antibiotics are prescribed. In patients with CAP of Group I, an adequate clinical effect can be achieved with oral administration of a single antibiotic (Table 17).

Due to the rapid and significant increase in S. pneumoniae resistance to macrolides in Ukraine, their use as first-line therapy is not advisable. Macrolides should only be considered as alternative agents. If amoxicillin proves ineffective within 48–72 hours from the start of treatment, a macrolide (azithromycin, clarithromycin) or doxycycline should be prescribed. If an alternative agent was initially used, it should be replaced with a third- or fourth-generation fluoroquinolone (levofloxacin, moxifloxacin, gemifloxacin, gatifloxacin).

Table 17. Outpatient treatment of community-acquired pneumonia

Group of patients	Possible pathogen	Drug of choice	Alternative drug
Group I	S. pneumoniae, M. pneumoniae, C. pneumoniae, H. influenzae, respiratory viruses	Amoxicillin orally	Macrolide or doxycycline per os

Group II	S. pneumoniae, H. influenzae, M. pneumoniae, C. pneumoniae, S. aureus, M. catarrhalis, Enterobacterales family, respiratory viruses	Amoxicillin/clavulanic acid per os	Fluoroquinolones III–IV generation or cefditoren per os

In patients with CAP of Group II (Table 17), the drug of choice is protected aminopenicillins (amoxicillin/clavulanic acid, ampicillin/sulbactam). As alternative agents, cephalosporin III generation (cefditoren) or fluoroquinolones III–IV generation can be prescribed. In case of ineffectiveness after 48–72 hours from the start of treatment, fluoroquinolones III–IV generation should be used.

In patients with mild pneumonia, the average duration of antibiotic treatment is 5–7 days, with drug withdrawal after normalization of body temperature and absence of symptoms of the disease for 3–4 days. In patients with mycoplasma or chlamydial CAP, the duration of antibacterial therapy is 10–14 days [17].

In Legionella pneumonia, a combination of macrolide with rifampicin is effective, and alternative therapy is fluoroquinolones of the III–IV generation.

Hospitalized patients with CAP of Group III (Table 18) are prescribed combined antibiotic therapy with parenteral administration, preferably protected aminopenicillins or cephalosporins of the III generation (cefotaxime, ceftriaxone) in combination with a macrolide. In the absence of absorption disorders in the digestive tract, the macrolide is prescribed orally.

Table 18. Inpatient treatment of community-acquired pneumonia

Group of patients	Possible pathogen	Drug of choice	Alternative drug

Group III	S. pneumoniae, H. influenzae, atypical pathogens, Gram-negative enterobacteria, respiratory viruses	Protected aminopenicillins IM, IV + macrolide orally or third generation cephalosporin parenteral + macrolide orally	Fluoroquinolone III–IV generation IV or carbapenem (inactive against Pseudomonas aeruginosa - ertapenem) + macrolide per os, or cephalosporin V generation (ceftaroline) + macrolide per os
The patient without risk factors for P. aeruginosa infection.			
Group IV	S. pneumoniae, Legionella spp., H. influenzae, S. aureus, M. pneumoniae, Gram-negative enterobacteria, Pseudomonas spp., respiratory viruses, polymicrobial associations	IV protected aminopenicillin + macrolide or third generation cephalosporin + macrolide, or ertapenem + macrolide, or fifth generation cephalosporin (ceftaroline) + macrolide	IV fluoroquinolone III-IV generation (monotherapy) or in combination with β-lactams According to indications - protected cephalosporins (cefoperazone/sulbactam, ceftriaxone/sulbactam, ceftriaxone/tazobactam, cefotaxime/sulbactam)
The patient with risk for P. aeruginosa infection			
		IV cephalosporin III–IV generation (with anti-pseudomonal activity) + aminoglycoside or	IV carbapenem (imipenem, meropenem, doripenem) + aminoglycoside

		ciprofloxacin (levofloxacin)	or ciprofloxacin (levofloxacin)

In patients with moderate CAP, the duration of treatment is 7–10 days. Antibiotic therapy for severe pneumonia lasts 10–14 days usually.

When the patient's condition stabilizes, it is advisable to use stepwise antibiotic therapy - switching from parenteral to oral forms of antibacterial agents.

Antibacterial therapy of HAP

In patients with early HAP, the likely pathogens are S. pneumoniae, H. influenzae, S. aureus (MSSA), gram-negative bacteria of the intestinal group with usual sensitivity to antibiotics: E. coli, K. pneumoniae, Enterobacter spp. Proteus spp., S. marcescens. For treatment, third-generation cephalosporins (ceftriaxone, cefotaxime, ceftazidime, cefixime, cefoperazone, cefpodoxime) are used in combination with macrolides (azithromycin, clarithromycin). An alternative is respiratory fluoroquinolones (levofloxacin, moxifloxacin) as monotherapy or in combination with third-generation cephalosporins.

In patients with late HAP, the most common pathogens are gram-negative bacteria (P. aeruginosa, K. pneumoniae, Acinetobacter spp. L.pneumophila) and gram-positive cocci resistant to methicillin - S. Aureus (MRSA). Treatment includes cephalosporins with antipseudomonal activity (cefepime, ceftazidime) or carbapenems (imipenem, meropenem), protected by b-lactams (cefoperazone/sulbactam, piperacillin/tazobactam) in combination with fluoroquinolones with antipseudomonal activity or aminoglycosides (amikacin, gentamicin, tobramycin), linezolid, or vancomycin (in the presence of MRSA risk factors, high incidence of nosocomial infections in the hospital) [16].

The average duration of antibiotic therapy in patients with HAP is 14 - 21 days.

The main method of correcting hypoxemia in patients with moderate and severe acute respiratory distress syndrome is oxygen therapy.

In the development of septic shock, crystalloid solutions are used for resuscitation, vasopressors.

In the presence of thick sputum that is difficult to expectorate and bronchial obstruction in a patient with pneumonia, the use of mucolytics (acetylcysteine,

carbocisteine, inhalations of a 3% sodium chloride solution) and bronchodilators in nebulizer form (salbutamol, ventolin) is indicated.

NSAIDs (diclofenac, ibuprofen) are indicated for significant hyperthermia.

Corticosteroids are prescribed according to indications to patients with pneumonia and septic shock. Side effects include immunosuppression, hyperglycemia, and an increased risk of gastrointestinal bleeding [3].

Treatment of influenza pneumonia

Etiotropic therapy: neuraminidase inhibitors of influenza A and B viruses (oseltamivir, zanamivir. Most effective in the first 48 hours after the onset of the disease. In the case of the development of severe pneumonia, ARDS, respiratory support is provided in the modes of artificial and assisted lung ventilation, extracorporeal membrane oxygenation [5].

Treatment of pneumonia associated with COVID-19

During the COVID-19 pandemic, most pneumonias were viral. Bacterial coinfection is observed in approximately 10% of patients with COVID-19 [3]. Routine use of antibiotics can reduce their availability, lead to Clostridioides difficile infection and antimicrobial resistance.

Antiviral agents for COVID-19 are recommended for outpatients and hospitalized patients with a high risk of developing severe disease and complications (persons older than 65 years, decompensated diabetes mellitus, severe chronic pathology of the respiratory and cardiovascular systems, immunosuppressive conditions, renal failure) [17].

Remdesivir is prescribed in the first 7 days. Loading dose IV 200 mg/day once, then 100 mg/day IV for 4 days.

Nirmatrelvir-ritonavir - in the first 5 days. 300 mg of nirmatrelvir + 100 mg of ritonavir twice a day for 5 days.

Molnupiravir - in the first 5 days. 800 mg every 12 hours for 5 days.

Dexamethasone (possible combination with remdesivir) is indicated for patients with COVID-19 who require oxygen therapy, but without the use of devices (high flow, non-

invasive ventilation, mechanical ventilation) - 6 mg IV or per os 1 time per day for 10 days.

Tocilizumab is prescribed for hospitalized patients who require high flow oxygen or non-invasive ventilation, in the first 3 days: 8 mg/kg of actual body weight (up to 800 mg) IV once.

Prophylaxis

Pneumonia prevention is aimed at implementing general sanitary and hygienic measures (work regime, combating air pollution, dust exposure, hypothermia, ventilation of premises, isolation of patients) and vaccination (pneumococcal and influenza vaccines).

Target groups for vaccination:

- persons over 50 years of age;
- persons living in nursing homes;
- patients with chronic bronchopulmonary and cardiovascular diseases;
- patients who have undergone inpatient treatment due to diabetes mellitus, kidney pathology, hemoglobinopathy, immunodeficiency state (HIV infection);
- women in the II and III trimesters of pregnancy.

Personal prevention includes hardening of the body, proper nutrition, physical activity, sanitation of foci of infection, timely treatment of acute respiratory infections.

Test tasks for self-assessment

1. A 35-year-old woman was hospitalized with complaints of a fever of 39.5°C, shortness of breath, right-sided chest pain, and a cough with dark red sputum. The patient abuses alcohol, having drunk 0.5 liters of vodka 2 days ago. A chest X-ray revealed areas of infiltration in the upper and middle lobes of the right lung. Which of the following is the most likely cause of the disease?

A. Klebsiella pneumoniae

B. Legionella pneumophila

C. Pneumocystis jirovecii.

D. Mycobacterium tuberculosis

E. Streptococcus pneumoniae

2. A 32-year-old man, HIV-positive (CD4 cells < 200/μl), was hospitalized with complaints of fever, dry cough, shortness of breath, night sweats, and joint pain. Objectively: t 38.9 ° C, SpO2 87%. Weakened vesicular breathing in the lower parts of the lungs on both sides, wheezing. Chest X-ray: diffuse bilateral basal infiltrates. Which of the following is the most likely cause of the disease?

A. Aspergillus fumigatus

B. COVID-19

C. Staphylococcus aureus

D. Pneumocystis jirovecii.

E. Mycobacterium tuberculosis

3. Which antibiotic is best to prescribe to an 18-year-old patient with pneumonia, based on the epidemiological situation and a mycoplasma etiology?

A. Doxycycline

B. Azithromycin

C. Meropenem

D. Ceftriaxone

E. Amoxicillin

4. Which group of antibiotics is best to prescribe to a 25-year-old patient who developed pneumonia after hypothermia and is determined to be pneumococcal according to clinical and bacteriological studies?

A. Tetracyclines

D. Fluoroquinolones

C. Penicillins

D. Carbapenems

E. Aminoglycosides

5. A 22-year-old patient works in an air-conditioned room. He fell ill acutely: body temperature - 39oC, shortness of breath, dry cough, chest pain on the right when

coughing, myalgia, arthralgia. Objectively: moist rales on the right, pleural friction rub. Chest radiography: infiltration of the lower lobe of the right lung. Complete blood count: leukocytes - 14*10^9/l, band cells - 12%, segmented neutrophils - 80%, lymphocytes - 8%, ESR - 42 mm/h. What is the probable etiological factor of pneumonia?

A. Pneumococcus

B. Legionella

C. Mycoplasma

D. Staphylococcus

E. Chlamydia

6. The gold standard for etiological diagnosis of pneumonia is:

A. Chest X-ray

B. A sputum Gram stain

C. Complete blood count

D. A sputum culture

E. Computed tomography

7. A 45-year-old man complains of a fever of 39.2 °C, productive cough, shortness of breath, general weakness. Respiratory rate - 30/min. Dullness of percussion sound under the right scapula, with auscultation revealing crackles against the background of bronchial breathing. Blood test: leukocytes - 15 x 10^9/l, ESR - 45 mm/h. What is the preliminary diagnosis?

A. Community-acquired right lower lobe pneumonia

B. Focal right-sided pneumonia

C. Tuberculosis of the right lung

D. Exacerbation of chronic bronchitis

E. Exudative pleurisy

8. Which of the following diagnostic criteria is the most informative and specific for establishing the diagnosis of pneumonia:

A. Dull percussion sound

B. Loud moist fine crackles

C. Crepitation

D. High leukocytosis, ESR on the background of cough and intoxication syndrome

E. Chest X ray shows intra-alveolar infiltration

9. The likely pathogen that caused the development of lobar community-acquired pleuropneumonia in a 31-year-old female patient, which debuted with a body temperature up to 39.9°C and pronounced toxic syndrome, is:

A. Str. pneumoniae

B. Haemophilus influence

C. Mycoplasma pneumoniae

D. Mor. Cattaralis

E. Staphylococcus aureus

10. In hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA), the drug of choice is:

A. Linezolid

B. Oxacillin

C. Amoxicillin/clavulanate

D. Levofloxacin

E. Tetracycline

Standard answers: 1 - A, 2 - D, 3 - B, 4 - C, 5 - B, 6 - D, 7 - A, 8 - E, 9 - A, 10 - A.

PLEURISY

Relevance of the topic. Pleural diseases are very common in medical practice and reflect a wide range of pathological conditions affecting the lungs, chest wall, and systemic diseases, which is why pleurisy is one of the most common respiratory diseases after bronchitis and pneumonia. Pleurisy complicates the course of about 4% of all diseases and occurs in 10% of surgical patients [12].

Pleurisy is inflammation of the pleura with the formation of a fibrinous plaque on its surface (dry pleurisy) or effusion in its cavity (inflammatory or non-inflammatory). It is always secondary, is a syndrome or complication of many diseases, but at a certain period it can come to the fore in the clinical picture, masking the underlying disease [15].

Pleural effusion is not an independent disease, but is a pathological condition that complicates the course of certain processes in the lungs and, much less often, in the chest wall, mediastinum, diaphragm and subphrenic space, or a manifestation of general (systemic) diseases, including those that proceed without obvious damage to the tissues in contact with the pleura. Despite the secondary nature of almost all inflammatory and reactive processes in the pleura, the latter are distinguished by their peculiar clinical manifestations, which often determine the peculiarities of the course and severity of the underlying disease and often require special treatment measures.

In most cases, pleurisy is recorded under the headings of the underlying diseases, which they complicate and are often masked by other manifestations of the latter and are not diagnosed at all.

Normally, the pleural space contains approximately 1 ml of fluid (J. Rubins).

Pleural effusion is the accumulation of at least 10–20 ml of fluid (I. Abdulhamid). An effusion occurs when more fluid enters the pleural space than is removed from it.

Pathophysiological mechanisms of pleural effusion

- Increased interstitial fluid levels in the lungs due to increased pressure in the pulmonary capillaries (heart failure) or their permeability (pneumonia)
- Decreased intrapleural pressure (atelectasis)
- Decreased oncotic pressure of blood plasma (hypoalbuminemia)

- Increased permeability of the pleural membrane and obstruction of lymphatic drainage (malignant diseases or pleural infections)
- Defects of the diaphragm (hepatic hydrothorax); rupture of the thoracic duct (chylothorax).

In adults, the most common etiology of pleural effusion is heart failure, cancer, pneumonia, tuberculosis and pulmonary embolism, while in children - pneumonia [7]. Pleurisy is divided into 3 groups by etiology: infectious, non-infectious and idiopathic.

The most common is the lymphogenous route of infection of the pleura, less often hematogenous, which leads to the appearance of inflammatory exudate. With effective lymphatic drainage, liquid exudate does not accumulate in the pleural cavity, but fibrin may precipitate on the surface of inflamed areas of the pleura, which leads to the development of acute fibrinous (dry) pleurisy. The precipitation of fibrin against the background of the accumulation of liquid exudate leads to the development of an adhesive process in the pleural cavity, which further disrupts the normal functioning of the lungs.

Pleural effusion

Normally, pleural fluid has the following characteristics: a clear ultrafiltrate of blood plasma with a pH of 7.60–7.64, a protein content of less than 2% (10–20 g/l), less than 1000 leukocytes/mm^3, a sugar content similar to blood plasma, a lactate dehydrogenase level less than 50% of the plasma level, and sodium, potassium, and calcium levels similar to interstitial fluid.

Based on biochemical analysis, pleural effusion is divided into exudate (total protein >30 g/l) and transudate (total protein <30 g/l), which usually reflects the pathophysiological mechanism of its formation.

Transudate is formed as a result of an imbalance between hydrostatic and oncotic pressure, caused by a limited number of well-known clinical syndromes, such as heart failure and cirrhosis. Less common etiologies include nephrotic syndrome, atelectasis, peritoneal dialysis, constrictive pericarditis, superior vena cava obstruction, and urinothorax. Transudate effusions often resolve with treatment of the underlying disease (diuretics for heart failure).

Exudate, on the contrary, is caused by the influence of local factors on the accumulation of pleural fluid. Establishing its etiology is often a diagnostic dilemma. Most cases of exudative pleural effusion are caused by pneumonia, malignant diseases and tuberculosis.

To distinguish exudate from transudate, the criteria of R.W. Light (1997) [15] are used. A fluid is an exudate if one or more of the following criteria are present:

1) the ratio of protein content in pleural fluid to its content in blood serum is more than 0.5;

2) the ratio of the level of lactate dehydrogenase (LDH) in pleural fluid to its level in blood serum is more than 0.6;

3) the level of LDH in pleural fluid exceeds 2/3 of the upper limit of normal LDH level in blood serum.

Additional diagnostic criteria:

1. The relative density of transudate ranges from 1.002 to 1.015, and of exudate - above 1.018.

2. Rivalta's test is negative for transudate, positive for exudate.

3. In transudate, the glucose level in the pleural fluid is more than 3.3 mmol/l; glucose levels less than 3.3 mmol/l are found in pleural exudates with empyema, rheumatic diseases, systemic lupus erythematosus, tuberculosis, malignant tumors or ruptures of the esophagus. The lowest glucose concentration is found in rheumatoid effusions and empyema.

4. The pH of the fluid is more than 7.3 is characteristic of transudate. In infectious genesis of pleurisy, a decrease in pH below 7.3 is noted.

Pleural fluid pH less than 7.2 with normal blood pH is observed in empyema, rheumatic diseases, systemic lupus erythematosus, tuberculosis, malignant tumors or esophageal ruptures. In effusions of infectious etiology, a decrease in pH less than 7.2 is an indication for drainage of the pleural cavity [4].

Causes of transudate

1. Changes associated with circulatory disorders:

- Congestive heart failure

- Pulmonary embolism (without infarction pneumonia)

2. Dysproteinemic effusions

- Nephrotic syndrome (glomerulonephritis, renal amyloidosis)
- Cirrhosis
- Myxedema

3. Changes associated with impaired lymphatic drainage

- Sarcoidosis of the lungs

ICD-10: J 90.0 Pleural effusion

Examination of patients with exudate

The first step in the evaluation of patients with pleural effusion is to determine whether the effusion is a transudate or an exudate. In patients with pleural exudate after the first thoracentesis, the following tests should be performed on the fluid obtained: quantitative and qualitative composition of blood cells, glucose level, adenosine deaminase and cytology (tab. 19, 20).

Table 19. Standard tests for pleural contents

Test	Index	**Possible diagnosis**	**Notes**
Adenosine deaminase	> 40 units/l (667 nkat/l)	Tuberculosis (> 90%), empyema (60%), complicated parapneumonic effusion (30%), malignant disease (5%), rheumatoid arthritis	
Cytological examination	Presence of atypical cells	Malignant disease	Actively dividing mesotheliocytes may resemble adenocarcinoma
Glucose	< 3.3 mmol/L	Complicated parapneumonic effusion or empyema,	A pleural effusion with low glucose content usually also

		tuberculosis (20%), malignant disease (<10%), rheumatoid arthritis	has a low pH and high LDH levels
LDH	More than 2/3 of the upper limit of normal serum LDH level	Any disease that can cause exudate	Very high levels of LDH in pleural effusion (>1000 units/L) are usually found in patients with complicated parapneumonic pleural effusion and in approximately 40% of patients with tuberculous pleurisy
LDH in pleural fluid/ LDH in serum	> 0,6	Any disease that can cause exudate	Most patients who meet the criteria for exudate based on LDH levels but not protein content have parapneumonic effusion or malignancy.
Ratio of pleural fluid protein level to serum protein level	> 0,5	Any disease that can cause exudate	Pleural fluid protein levels > 30 g/L are common in exudates, but if the diagnosis of exudate is based solely on this indicator, diagnostic errors can occur in more than 10% of cases of exudate and 15% of transudates
Red blood cell count	> 100 x 10^6/л	Malignancy, trauma, parapneumonic effusion, pulmonary embolism	Pleural fluid hematocrit levels <1% are clinically irrelevant

Leukocyte count with formula	> 10 x 10^9/л	Empyema, other exudates	In purulent effusions, leukocytosis is usually much lower than expected, since its turbidity is mainly due to the presence of dead cells or other breakdown products
Eosinophil count	> 10%	Not diagnostic	The most common etiology is the presence of air or blood in the pleural space. In one third of patients, the etiology of eosinophilic pleural effusion cannot be established
Lymphocyte count	> 50%	Malignant disease, tuberculosis, pulmonary embolism, coronary artery bypass grafting	Lymphocytosis > 90% of pleural fluid indicates tuberculosis or lymphoma
Neutrophil count	> 50%	Parapneumonic effusion, pulmonary embolism, abdominal disease	Pleural fluid neutrophilia is found in approximately 7% of cases of acute tuberculous pleurisy and 20% of cases of malignant pleural effusion

Table 20. Additional tests for pleural effusion analysis

Test	Indicator	Possible diagnosis	Notes
Amylase	Above the upper limit of normal	Malignant disease (< 20%), pancreatic pathology, esophageal rupture	The test is indicated in suspected esophageal rupture and pancreatic pathology. In malignant disease and esophageal rupture, amylase

			is derived from the salivary glands
Cholesterol	> 1.16–1.55 mmol/L	Any disease that can cause exudate	The test is indicated in suspected chylothorax or pseudochylothorax. If the diagnosis of an exudate is based solely on this indicator, a diagnostic error may occur in 10% of cases of exudates and 20% of cases of transudates
Spore culture	Positive	Infection	This test should be performed in all cases of parapneumonic pleural effusion, since a positive result on culture or Gram stain is an indication for pleural drainage
Pleural fluid hematocrit to blood hematocrit ratio	≥ 0,5	Hemothorax	The test is indicated for bloody pleural effusion. Most often, hemothorax occurs as a result of blunt or penetrating trauma to the chest
Interferon	Different cut-off values	Tuberculosis	The test is indicated for suspected tuberculosis when it is impossible to perform a test for the level of adenosine deaminase or its result is non-diagnostic

Natriuretic peptide	>1500 pg/ml	Heart failure	The test is indicated for suspected heart failure and the obtained effusion meets the criteria for exudate
pH	< 7,20	Complicated parapneumonic effusion or empyema, malignancy (<10%), tuberculosis (<10%), esophageal rupture	The test should be performed in all cases of nonpurulent exudate with suspected infection. If the pleural fluid pH is low, tube drainage should be performed only in the presence of parapneumonic pleural effusion
PCR	Positive result	Infection	The test is indicated if infection is suspected. The sensitivity of PCR for the detection of Mycobacterium tuberculosis in pleural fluid is 40–80%, usually lower in patients with negative tuberculosis culture results
Triglycerides	> 1,24 mmol/l	Chylothorax	The test is indicated when the pleural fluid obtained is cloudy or milky. Chylothorax occurs due to lymphoma or trauma. Pseudochylothorax may be due to tuberculosis or rheumatoid arthritis.

The hemorrhagic nature of pleural effusion is observed in pleural carcinomatosis, other tumors, pulmonary infarction, pleural tuberculosis.

Differentiation of pleural effusions is important, since transudates do not require further diagnostic measures, but only treatment of the underlying disease. When pleural exudate is detected, additional diagnostics are often required.

If infection is suspected, the pH level should be determined and cultured for sterility.

Classification of pleurisy:

By etiology:

- Infectious (bacterial - pneumococcus, staphylococcus, gram-positive flora, etc., viral, rickettsia, mycoplasma, fungal, protozoan, parasitic pathogens, tuberculosis (20% of all pleurisy), syphilis, brucellosis, typhus and typhus, tularemia.
- Non-infectious (tumor, thromboembolism of the branches of the pulmonary artery with infarction-pneumonia, diffuse connective tissue diseases, rheumatism, Dressler's syndrome, diseases of the digestive tract (pancreatitis, liver abscess, esophageal perforation), consequences of mechanical trauma, burns, radiation therapy, drug allergy, asbestosis, etc.)
- Idiopathic

By the nature of the pathological process:

- Dry (fibrinous)
- Exudative (sweaty) pleurisy
- Pleural empyema

By the nature of the exudate:

- Serous
- Serous-fibrinous
- Fibrinous
- Purulent
- Putrefactive
- Hemorrhagic
- Eosinophilic
- Cholesterol
- Chylous

- Mixed

By the way:

- Acute
- Subacute
- Chronic

By prevalence:

- Diffuse
- Encapsulated pleuritis (apical, paracostal, diaphragmatic, basal, paramediastinal, interlobar)

Formulating the diagnosis:

1. Left-sided exudative tuberculous pleurisy, serous-fibrinous.

2. Community-acquired right lower lobe severe pneumonia. Right-sided pneumococcal serous-fibrinous pleurisy. ARF II stage.

3. CAD: post-infarction cardiosclerosis. Congestive heart failure with reduced ejection fraction, stage D. Bilateral hydrothorax.

Clinic

Acute fibrinous (dry) pleurisy is manifested by general weakness, pain in the side, which increases with coughing, deep breathing, and movements. The body temperature rises to subfebrile levels. The pain intensifies when tilting to the healthy side - Shepelman's symptom. The affected side of the chest lags during breathing. Patients adopt a forced position on the affected side- Rubinstein's symptom. Pleural friction vibration in the area of inflammation is palpated. There are no changes in percussion tone and vocal fremitus.

There is a pleural friction rub, resembling the sound of snow squeaking underfoot. The pleural friction rub has the same intensity on both inhalation and exhalation, an intermittent nature, it does not change after coughing, and intensifies when pressure is applied to the stethoscope. Apical pleurisy is characterized by rigidity of the pectoralis major (Pottenger-Vorobyov sign) and trapezius (Sternberg sign) muscles. In diaphragmatic pleurisy, the pain is localized in the hypochondrium,

radiates to the shoulder, and is accompanied by hiccups, vomiting, and rigidity of the muscles of the anterior abdominal wall [15].

In exudative pleuritis, the most common symptom is shortness of breath, the severity of which depends on the volume of the effusion and the rate of fluid accumulation. The patient assumes a forced semi-sitting position, cyanosis of the lips may be observed, along with distension of the jugular veins, lag of the affected side during the act of breathing, and widening of the intercostal spaces.

The pain is disturbing at the onset and at the end of the disease, and disappears with the accumulation of fluid. Reflex cough is associated with inflammation of the parietal pleura. In addition, when the lung is compressed by fluid, the bronchial walls collapse, which causes a cough reflex. With an effusion of more than 400 ml, the Sokolov-Damoiseau-Ellis line can be determined [15]. With effusions of 1 liter or more, the mediastinal organs are shifted to the healthy side. Percussion determines "stone dullness", auscultation - weakening of breathing and often - a zone of bronchial breathing above the level of the fluid.

Table 21. Causes of pleural effusion

Pathological changes	**Possible cause of pleural effusion**
History	
Abdominal surgery	Postoperative pleural effusion, subphrenic abscess, pulmonary embolism
Alcohol abuse or pancreatic disease	Pancreatic effusion
Creation of artificial (iatrogenic) pneumothorax for therapeutic purposes	Tuberculous empyema, lymphoma-associated pyothorax, collapsed lung
Asbestos exposure	Mesothelioma, benign asbestos pleural effusion
Cancer	Malignant disease

Heart surgery or myocardial injury	Pleural effusion due to coronary artery bypass grafting or Dressler syndrome
Chronic hemodialysis	Heart failure, uremic pleurisy
Cirrhosis	Hepatic hydrothorax, spontaneous bacterial empyema
Childbirth	Postpartum pleural effusion
Endoscopic examination or dilation of the ureter	Pleural effusion due to ureteral perforation
HIV infection	Pneumonia, tuberculosis, primary lymphoma with effusion, Kaposi's sarcoma
Medication	Drug-induced pleural injury
Distant pleural inflammation	Collapsed lung
Rheumatoid arthritis	Rheumatoid pleurisy, pseudochylothorax
Gonadotropin-induced superovulation	Pleural effusion due to ovarian hyperstimulation syndrome
Systemic lupus erythematosus	Lupus pleurisy, pneumonia, pulmonary embolism
Trauma	Hemothorax, chylothorax, duropleural fistula
Physical examination data	
Ascites	Hepatic hydrothorax, ovarian cancer, Meigs syndrome
Dyspnea with exertion, orthopnea, peripheral edema, increased jugular venous pressure	Heart failure, constrictive pericarditis

Pericardial friction rub	Pericarditis
Unilateral lower extremity edema	Pulmonary embolism
Yellow nails, lymphedema	Pleural effusion due to yellow nail syndrome
Common symptoms	
Fever	Pneumonia, empyema, tuberculosis
Hemoptysis	Lung cancer, pulmonary embolism, tuberculosis
Weight loss	Malignant disease, tuberculosis, anaerobic bacterial pneumonia

Parapneumonic effusions and empyema

Approximately 40% of patients with bacterial pneumonia develop concomitant pleural effusion, in 15% of the effusions are reinfected and empyema develops. Empyema also occurs with surgical interventions (20%), trauma (5%), esophageal perforation (5%), subdiaphragmatic infections (1%) [12].

The following stages are distinguished in the course of parapneumonic pleurisy:

1. Exudation - increased capillary permeability, rapid accumulation of sterile fluid in the pleural cavity (pH, glucose and LDH levels are normal, the number of neutrophils is not increased)

2. Fibrous-purulent - bacteria from the inflammatory focus penetrate the pleural fluid, the level of glucose and pH decreases in it, LDH and the number of neutrophils increase

3. Organization - the appearance of pleural moorings.

Clinically, the patient's condition improves slowly, with persistent or recurrent fever, weight loss and malaise, persistent polymorphonuclear leukocytosis and elevated C-reactive protein. Patients are concerned about cough (often with sputum production), shortness of breath, chest pain when breathing.

The development of pleural empyema is characterized by a sharp deterioration in the patient's condition. Concerned about chest pain, hectic fever, chills, shortness of breath. The patient takes a position on the affected side. In the blood: hypochromic anemia, leukocytosis with a shift to the left, accelerated ESR. In the urine: proteinuria, cylindruria. Pleural fluid - purulent exudate, the neutrophils count more than 15,000/ml [12].

Malignant pleural effusion

Lung cancer is the most common cause of malignant pleural effusion, especially in smokers. Pleural metastases are most common in breast cancer (25%), ovarian cancer (5%), and gastrointestinal cancer (2%) [4].

Two mechanisms of pleural effusion formation in malignant neoplasms are distinguished: direct tumor influence (pleural metastases - increased pleural permeability, obstruction of lymphatic vessels; mediastinal lymph node involvement - decreased lymphatic outflow from the pleura; thoracic duct obstruction - chylothorax; bronchial obstruction - decreased intrapleural pressure) and indirect tumor influence (hypoproteinemia, pulmonary embolism, post-radiation therapy)

Pleural effusion is often hemorrhagic. Chromosomal analysis of pleural fluid can help in the diagnosis of lymphoma, leukemia, or mesothelioma [4].

Medications that can cause primary pleural damage

- Furadonin, metronidazole
- Dantrolene
- Methysergide
- Bromocriptine
- Amiodarone
- Procarbazine, methotrexate
- Ergonovine, ergotamine
- Practolol, minoxidil, bleomycin, mitomycin
- Interleukin-2
- Propylthiouracil
- Isotretinoin

Pleural effusion in cardiopulmonary diseases (by J. L. Johnson, 2000)

• Unilateral or bilateral pleural effusions of small to moderate size are most often due to congestive heart failure. Most cases of pleural effusions in patients with heart failure are caused by left ventricular dysfunction.

• Bilateral effusions due to chronic heart failure are usually of the same size. If the effusion size is markedly asymmetry, other etiological factors should be excluded.

• The presence of pleural effusions in a patient with cor pulmonale indicates the presence of another pathology. Concomitant left ventricular dysfunction, pneumonia, pulmonary embolism, and malignancy should be excluded.

• Pericardial disease should be excluded in the differential diagnosis of isolated left-sided pleural effusions. The size of such effusions can range from small to massive, and they are often associated with cardiomegaly.

• A small, usually left-sided pleural effusion often occurs after coronary artery bypass grafting. This effusion is usually limited.

Perifocal tuberculous pleurisy

It develops with a subpleural location of the main tuberculous focus. It is characterized by a recurrent course, the formation of pleural moorings during the resorption of the exudate, positive tuberculin tests. The nature of the pleural fluid is exudate: protein more than 5 g/l; 50% of all leukocytes-lymphocytes; mesothelial cells less than 5%; glucose and pH are reduced. The detection of more than 10% eosinophils excludes the diagnosis of tuberculous effusion. For the purpose of diagnosis, mycobacteria are detected in sputum and pleural fluid [7].

Diagnostics

1. Chest X-ray (Fig. 18). Detects pleural effusion when its volume is 300 ml or more. The advantages are the diagnosis of the main bronchopulmonary pathology (pneumonia, tuberculosis, lung cancer).



Fig. 18. Right-sided pleural effusion.[16]

2. Pleural puncture with pleural fluid examination.

3. Pleural ultrasound (Fig. 19). The method allows to detect even a small amount of fluid in the pleural cavity (10-15 ml). It is also used for the diagnosis of pleural effusions and is a control method during thoracocentesis [7].

[16] Case courtesy of Vivek Pai, Radiopaedia.org, rID: 27112



Fig. 19. Right-sided pleural effusion. [17]

3. Computed tomography of the chest cavity (Fig. 20). With the help of this examination method, it is also possible to detect other etiological factors of pleural effusion (PE, lung cancer, pleural mesothelioma [4].



Fig. 20 Massive right-sided pleural effusion. [18]

4. Lung ventilation perfusion scan (calculation of the ventilation-perfusion ratio ($\dot{V}/\dot{Q}$)). It`s recommended for suspected PE.

5. Bronchoscopy is indicated for suspected endobronchial cancer based on one or more of the following criteria: presence of lung infiltrate or tumor on plain chest X-ray or CT, hemoptysis, massive pleural effusion, mediastinal shift toward the effusion [4].

[17] https://err.ersjournals.com/content/29/156/190136.figures-only
[18] https://www.thoracic.org/professionals/clinical-resources/quick-hits/pleural-effusion-confusion.php

6. Percutaneous pleural biopsy. In the presence of an undiagnosed exudative effusion with suspicion of tuberculosis or malignancy, closed-needle pleural biopsy is recommended for histological examination of the obtained material. By combining histological examination (sensitivity 80%) and culture for sterility (sensitivity 56%) of the pleural biopsy specimen, the diagnosis of tuberculosis can be confirmed in more than 90% of patients. However, this diagnosis is indicated by a high level of adenosine deaminase in the pleural fluid, such most patients do not need a confirmatory biopsy [7].

8. Video-assisted thoracoscopy (especially informative for the diagnosis of malignant neoplasms) .



Fig. 21 Thoracoscopy in a patient with lung adenocarcinoma [19]

[19] https://thorax.bmj.com/content/78/Suppl_3/s43.abstract



Fig. 22. Algorithm for the evaluation of patients with pleural effusion[20]

Treatment

1. Conservative treatment.
2. Therapeutic thoracentesis.

[20] https://www.aafp.org/pubs/afp/issues/2006/0401/p1211/jcr:content/root/aafp-article-primary-content-container/aafp_article_main_par/aafp_figure2.enlarge.html

3. Pleural drainage through the intercostal space and intrapleural injection of a sclerosing agent (pleurodesis).

4. Thoracoscopy with pleurodesis using talc.

5. Long-term drainage using a permanent tunnel catheter in the pleural cavity.

Symptomatic relief of dyspnea is achieved with thoracentesis and drainage of the pleural cavity with effusion. Treatment of the pathology that provokes the development of pleural effusion, for example, heart failure, often leads to its disappearance [7].

Infectious pleural effusion. In patients with massive effusion, the introduction of tissue plasminogen activator (TPA) in combination with DNase is used: TPA 10 mg twice a day + 5 mg DNase twice a day for 3 days or 5 mg TPA twice a day + 5 mg DNase twice a day [12]. Pleural cavity lavage with saline solution is also performed.

When a pleural infection is diagnosed, high doses of antibiotics are prescribed: aminopenicillins, including protected ones (amoxiclav); cephalosporins I (cefazolin), II (cefuroxime, ceftriaxone), IV (cefepime) generations; aminoglycosides (tobramycin, amikacin); macrolides (clarithromycin, spiramycin, azithromycin), often in combination with metronidazole. Antibiotics are administered both intravenously and into the pleural cavity.

In case of pleural empyema, the pleural cavity is drained under ultrasound control, a Seldinger drain is inserted, and continuous aspiration of the contents is performed. Antibiotic therapy is carried out using aminoglycosides, carbapenems and monobactams. After evacuation of the pus, the pleural cavity is washed with a warm furacilin solution or a 0.1-0.2% dioxidine solution. The decision to perform decortication should be individualized for each patient.

Early video-assisted thoracoscopic surgery is also effective. Empyema can rupture externally through the chest wall or into the bronchial tree, forming a bronchopleural fistula, and cause significant pleural fibrosis with restriction of lung mobility [12].

Malignant pleural effusion. First-line therapy involves pleurodesis through the introduction of a talc suspension or solution, or the placement of a permanent pleural catheter (Fig. 23) with lavage using a saline or heparin solution.



Fig. 23. Indwelling pleural catheter[21]

Surgical treatment includes decortication of the lung. Intrapleural fibrinolytics may be effective in patients with severe dyspnea [7].

Prognosis

Pleurisy does not determine the prognosis of the underlying disease. The prognosis depends on effective treatment of the disease that caused pleurisy.

Test tasks for self-assessment

1. When examining the fluid obtained by pleural puncture, the following was found: protein < 10%, Rivalta reaction was negative, leukocytes - 3-5 in the field of view, erythrocytes - 2-3 in the field of view. Evaluate the nature of the fluid.

A. Exudate

B. Transudate

C. Purulent contents

D. Chylous fluid

E. Hemorrhagic fluid

[21] https://thorax.bmj.com/content/78/Suppl_3/s43.abstract

2. The patient complains of pain in the right half of the chest, which is aggravated by deep breathing and coughing. He fell ill after hypothermia. On percussion over the lungs there is a pulmonary sound, on auscultation there is a pleural friction rub. Indicate the most likely diagnosis.

A. Bronchitis

B. Right-sided pneumonia

C. Right-sided exudative pleurisy

D. Right-sided dry pleurisy

E. Bronchiectasis

3. A patient with coronary artery disease, and congestive heart failure complaints of shortness of breath. In the lower parts of both sides, percussion reveals dullness, and auscultation reveals no breathing. What is the most likely diagnosis?

A. Pneumonia

B. Hydrothorax

C. Lung cancer

D. Pneumosclerosis

E. Dry pleurisy

4. The patient complains of shortness of breath, fever up to 37°C, dry cough. On the radiograph there is a homogeneous shadow in the lower right part. What diagnostic and therapeutic measures should be prescribed?

A. Pleural puncture

B. Physiotherapy

C. Surgical treatment

D. Inhalation therapy

E. Positional drainage

5. A patient was suspected pleural effusion. What is the most informative method of diagnosis?

A. Complete blood count

B. Chest X-ray

C. Bronchography

D. Bronchoscopy

E. Sputum analysis

6. A patient is diagnosed with right-sided exudative pleurisy. What changes on the radiograph correspond to the established diagnosis?

A. Increased transparency of the lung tissue

B. Homogeneous opacification with a clear upper border

C. Inhomogeneous opacification with blurred contours

D. Decreased transparency of the lung tissue

E. Homogeneous opacification without clear contours

7. On the third day of hospitalization for pneumonia of the lower lobe of the right lung, the patient's shortness of breath significantly increased. Respiratory rate - 24/min. On percussion in the lower parts of the right, dullness, breathing is not heard. Blood pressure - 100/60 mm Hg. What complication can be thought of in this case?

A. Dry pleurisy

B. Septic shock

C. Lung abscess

D. Right-sided exudative pleurisy

E. Right-sided empyema

8. The chest X-ray shows a homogeneous darkening in the right half of the chest with a clear upper border that runs diagonally from the chest to the mediastinum from top to bottom. What is this characteristic of?

A. Lung abscess

B. Lung cancer

C. Bronchiectasis

D. Pneumonia

E. Exudative pleurisy

9. The patient complains of a dry cough, an increase in body temperature to 37.50 C, chest pain on the right at deep breath. Percussion over the lungs reveals lung sound, while auscultation shows crackles on both inspiration and expiration below the right scapular angle, which intensify when pressure is applied to the chest with the stethoscope. Your diagnosis is:

A. Pneumonia

B. Bronchitis

C. Exudative pleurisy

D. Dry pleurisy

E. Pneumothorax

10. The patient underwent a study of the fluid obtained from the pleural cavity: protein >30 g/l, Rivalta reaction is positive, leukocytes - 10 - 15 in the field of view. Assess the nature of the fluid.

A. Transudate

B. Exudate

C. Chylous fluid

D. Pus

E. Blood

Standard answers: 1 - B, 2 - D, 3 - B, 4 - A, 5 - B, 6 - B, 7 - D, 8 - E, 9 - D, 10 - B

INFECTIOUS DESTRUCTIVE LUNG DISEASES

Relevance of the topic. Infectious destructive lung diseases (IDLD) of the bronchopulmonary system are a significant medical and social issue, as they often lead to disability among the working-age population. These diseases are characterized by a severe course and frequently pose a life-threatening risk to patients.

Recently, the incidence of acute infectious-destructive lung diseases, such as abscess and gangrene, has decreased by 30% due to the use of modern diagnostic and treatment methods [18].

The prevalence of bronchiectasis (BE) has significantly increased worldwide over the past 20 years, which is attributed to improved diagnostic techniques. Post-infectious BE (e.g., following a severe respiratory viral infection or pneumonia) is the most common type. Other causes include autoimmune conditions, COPD, asthma, tuberculosis, fungal infections, and genetic disorders. According to clinical studies, the prevalence of bronchiectasis in COPD patients averages 54.3%, while in asthma patients, it is 42%. However, in nearly 40% of cases, the cause of BE remains unknown [6].

Infectious-destructive diseases of the bronchopulmonary system are a group of respiratory diseases that include lung abscess, lung gangrene, and bronchiectasis.

A **lung abscess** is a condition characterized by purulent, putrid, or necrotic liquefaction of lung tissue due to infection, resulting in the formation of one or more cavitary lesions, often surrounded by inflammatory perifocal infiltration. According to classification, lung abscesses are divided into acute and chronic forms. The transition from acute to chronic abscess occurs in 10–15% of cases. A chronic abscess can only be diagnosed after 4–6 weeks from the onset of the acute process [21].

Primary abscesses (60%) develop due to existing parenchymal lung conditions, often associated with aspiration of oral material, poor oral hygiene, dental diseases, alcoholism, drug addiction, or in patients with impaired consciousness. Secondary lung abscesses occur in the presence of mechanical bronchial obstruction (foreign body, neoplasm), hematogenous infection spread (e.g., septic endocarditis), thoracic surgery, and other conditions [18].

Lung gangrene is a purulent-putrid necrosis of a significant portion of lung tissue, accompanied by ichorous liquefaction and sloughing, with a tendency to spread. Lung gangrene is a severe pathological process with a poor prognosis. The disease develops in the presence of mixed microbial flora, including obligatory anaerobic microorganisms, particularly in individuals with severe immune dysfunction [15].

The terms "*necrotizing pneumonia*" or "*lung gangrene*" are also used to describe pneumonia that is complicated by necrosis and numerous small abscesses.

Bronchiectasis is a chronic inflammatory disease characterized by the development of purulent endobronchitis in irreversibly altered (dilated and deformed) and usually functionally impaired bronchi, primarily in the lower lung regions [5, 6].

The deterioration in quality of life associated with bronchiectasis, as measured by the St. George's Respiratory Questionnaire (SGRQ), is equivalent to that seen in severe COPD, idiopathic pulmonary fibrosis, and other respiratory diseases that lead to disability.

Bronchiectasis has a diverse etiology and can be either idiopathic or secondary to various pathological conditions, with prior respiratory infection being considered the most common contributing factor. When diagnosing bronchiectasis, it is essential to first identify the underlying cause, if possible. Additionally, screening for bronchiectasis should be conducted in patients with allergic bronchopulmonary aspergillosis, immunodeficiencies, cystic fibrosis, and tuberculosis [5].

Etiology and pathogenesis of infectious-destructive lung diseases

The etiology of IDLD is highly diverse. The pathogenesis primarily involves the negative interplay of the following factors:

- Acute inflammatory process in the pulmonary parenchyma;
- Bronchial obstruction;
- Microcirculatory disturbances;
- Tissue necrosis formation in the lungs.

There are no specific etiological factors for IDLD. For instance, the development of a lung abscess is primarily driven by a diverse coccal flora, mainly staphylococci and streptococci. It has been proven that staphylococcal pneumonia is most often responsible

for abscess formation in the affected lung area [11]. A significant role in the development of IDLD is played by the association of fusiform bacteria (Fusobacterium) and spirochetes (fusospirochetal symbiosis). In patients with alcohol abuse, Klebsiella pneumoniae is frequently the causative agent of infection [21].

Pathways of infection entry into the bronchopulmonary system

The following pathways of infectious agent entry into the bronchopulmonary system are distinguished:

- Bronchogenic
- Lymphogenic
- Hematogenic
- Direct spread of the pathological process from affected organs (e.g., abscess perforation with the formation of pleural empyema)
- Infection due to mechanical lung injury

The most common pathway of lung tissue infection is bronchogenic, which leads to inflammation of the pulmonary parenchyma and small bronchi. Bronchial obstruction occurs due to blockage, spasm, and edema, resulting in lung atelectasis. The progression of tissue infiltration and pulmonary edema compresses blood vessels and capillaries, disrupting microcirculation and potentially leading to thrombosis [15]. Hematogenic and lymphogenic spread of pathogenic microflora from an obstructed bronchus, upper respiratory tract, or oral cavity into a necrotic area results in purulent decay. If the immune system functions effectively, the virulence of microorganisms is low, bronchial drainage is adequate, and therapy is appropriate, the inflammatory infiltration resorbs, and the abscess cavity heals. However, if the pathogen is highly virulent and immune reactivity is reduced, the purulent-necrotic process progresses beyond the primary focus, leading to gangrene.

Risk factors for infectious destructive lung diseases

- Smoking
- COPD
- Bronchial asthma
- Diabetes mellitus

- Influenza and other acute respiratory viral infections
- Chronic alcoholism

Considering these factors, IDLD are often secondary rather than primary. They arise as complications of pneumonia, surgical interventions, hematogenous infection spread to the lungs, purulent-inflammatory processes in adjacent organs, lung trauma, or aspiration of foreign bodies into the bronchi and lungs. Additionally, IDLD may develop as complications of chronic pulmonary diseases such as syphilis, malignant lung tumors, and echinococcal lung cysts. The most common underlying conditions leading to IDLD include pneumonia (including aspiration pneumonia), influenza, and septic lung emboli [15].

Lung abscesses are classified based on their development mechanism into:

- Bronchopulmonary abscesses (including aspiration abscesses);
- Lymphogenic pleural abscesses;
- Hematogenous-embolic abscesses;
- Post-traumatic abscesses.

Chronic bronchopulmonary diseases serve as a background for lung abscess formation, including: COPD (especially in smokers), bronchiectasis and bronchial asthma. Lung abscesses are most commonly a complication of pneumonia, particularly in immunocompromised patients, such as HIV-infected patients, drug users, alcoholics, patients with hypovitaminosis, diabetes mellitus, influenza, or hematologic disorders [11]. Lung abscesses are usually polymicrobial infections, developing due to an aerobic-anaerobic association of microorganisms.

The pathological process in lung abscess formation follows these stages:

1. Infiltration stage
2. Necrosis and cavity formation stage
3. Abscess drainage stage
4. Healing stage

Mostly lung abscesses occur in posterior segment of right upper lobe or apical segment of either lower lobes, the anatomical disposition of these segmental bronchi accepting the passage of aspirated liquid in supine position most readily.

The primary difference in the pathogenesis of lung gangrene compared to an abscess is the absence of clear boundaries in the pathological process. Gangrene typically develops in the setting of severe immunodeficiency [15].

Causes of bronchiectasis

- Idiopathic
- Post-infectious
- Immunodeficiency conditions
- Allergic bronchopulmonary aspergillosis
- Ciliary dysfunction
- Rheumatoid arthritis
- Gastroesophageal reflux disease /Aspiration
- Ulcerative colitis
- Cystic fibrosis
- Panbronchiolitis
- Mycobacterial infection
- Congenital causes

Bronchiectasis primarily develops due to immune system dysregulation, as it is frequently observed in patients with immunodeficiency and autoimmune conditions such as rheumatoid arthritis and Crohn's disease.

Although the exact trigger of BE pathogenesis remains unclear, most researchers support the "vicious cycle hypothesis" proposed by P.J. Cole. This hypothesis suggests that chronic respiratory infections, most commonly caused by Haemophilus influenzae and Pseudomonas aeruginosa (less frequently Moraxella catarrhalis, Staphylococcus aureus, and Enterobacteriaceae), stimulate and sustain lung inflammation. Persistent detection of these microorganisms in sputum or bronchoalveolar lavage is associated with increased frequency of exacerbations, worsened quality of life and higher mortality rates [5, 6]. This is especially true for P. aeruginosa infections.

The inflammation in bronchiectasis is predominantly neutrophilic and is strongly linked to persistent bacterial infections. Excessive neutrophilic inflammation leads to increased exacerbation rates, rapid lung function declines due to elastin degradation in the airways.

Mucociliary clearance is impaired due to structural bronchiectasis, airway dehydration, and excessive mucus volume and viscosity. Bronchiectasis-related structural alterations include bronchial dilation, bronchial wall thickening, mucus plugging, small airway disease and emphysema.

Over 50% of patients with BE have obstructive respiratory failure, but restrictive and mixed patterns are also common. Some patients maintain normal lung function. Dyspnea is one of the strongest predictors of mortality in bronchiectasis. It results from airflow obstruction, impaired gas exchange, and comorbid conditions [5].

Types of bronchiectasis by shape

Bronchiectasis can be classified based on the shape of bronchial dilation into:

- Cylindrical
- Saccular (cystic)
- Fusiform (spindle-shaped)
- Mixed

Common causes of bronchiectasis (BTS, 2019)

1) COPD – associated with increased sputum production, more frequent and severe exacerbations, poorer lung function, higher plasma inflammatory markers, and more frequent colonization by potentially pathogenic microorganisms, especially Pseudomonas aeruginosa.

2) Alpha-1 antitrypsin deficiency – particularly in individuals with the PiZZ phenotype.

3) Asthma – especially poorly controlled asthma.

4) HIV or HTLV-1 infection.

5) Rheumatoid arthritis – bronchiectasis may develop even before arthritis symptoms appear.

6) Other connective tissue diseases, including Sjogren's syndrome, Marfan syndrome, ankylosing spondylitis, systemic lupus erythematosus)

7) Inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis.

8) Infectious diseases, including measles, pertussis, tuberculosis, pneumonia - particularly if symptoms appear soon after infection.

Classification of Infectious destructive lung Diseases according to ICD-10:

- ✓ J85 Lung and mediastinal abscess
- ✓ J85.0 Lung gangrene and necrosis
- ✓ J85.1 Lung abscess with pneumonia
- ✓ J85.2 Lung abscess without pneumonia

Currently, there is no unified expanded classification of IDLD that fully considers pathogenetic and clinical aspects. A widely used classification by Boyko V.V. and Florykyan A.K. (2007) includes:

1. Based on Pathogenesis:
   - Post-pneumonic
   - Aspiration-obstructive
   - Hematogenous-embolic
   - Traumatic
   - Lymphogenic
2. Based on process character:
   - Purulent abscess
   - Gangrenous abscess
   - Extensive gangrene
   - Pyopneumothorax
3. Based on localization:
   - Lung segment
   - Lung lobe
   - Entire lung
4. Based on disease spread:
   - Single abscesses
   - Multiple abscesses
   - Bilateral abscesses
5. Based on severity:
   - Mild
   - Moderate

- Severe

6. Based on presence of complications:

- Uncomplicated
- Complicated:
  - Pulmonary hemorrhage
  - Pleural empyema (localized, total)
- Pyopneumothorax (localized, total, tensioned)
- Sepsis (septicemia).

Examples of diagnosis formulation:

1. Post-pneumonic abscess of the lower lobe of the right lung, severe course. Pulmonary hemorrhage.

2. Aspiration abscess of the upper lobe of the left lung. Acute severe respiratory failure.

3. COPD, group B, moderate exacerbation. Bronchiectasis of the middle lobe of the left lung. Moderate acute respiratory failure.

Clinical presentation of infectious-destructive lung diseases

Clinical presentation of lung abscess

According to clinical classification, lung abscesses are divided into acute and chronic. In the course of acute lung abscesses, two distinct periods are identified, which differ significantly in clinical manifestations and laboratory findings:

1. First period (infiltrative-necrotic phase) – from the formation of the abscess until its rupture into the draining bronchus.

2. Second period (drainage of the abscess) – rupture of the abscess into the draining bronchus [15].

Symptoms in the first period

Severe condition of the patient with pronounced intoxication syndrome: fever (≥39°C) with chills, increased sweating, dyspnea, weakness, adynamia. In immunocompromised patients (e.g., chronic alcoholism, diabetes mellitus), symptoms may be less pronounced. A “silent” abscess may occur with primary anaerobic microflora, leading to a poor prognosis [18].

If the abscess is subpleural, chest pain occurs, worsening with deep inspiration. If *basal segments are affected and the recurrent nerve is involved, the patient may experience irradiating back pain – known as the phrenic nerve symptom (Frénicus symptom).

Dyspnea is a common symptom caused by exclusion of lung parenchyma from gas exchange, reduced ventilation due to pain syndrome.

Cough can be mild and superficial or more pronounced. It intensifies in the second stage of the disease when the abscess ruptures into the bronchus. In the drainage stage, cough becomes intense with significant sputum production, leading to symptomatic relief. In some cases, streaks of blood may appear in the sputum.

Perforation of the abscess into a bronchial wall leads to expectoration of large volumes of purulent, foul-smelling sputum, sometimes with necrotic lung tissue, indicating gangrenous transformation [15].

Physical examination in lung abscess

Percussion findings:

- Dullness over the affected lung area (due to consolidation and fluid accumulation);
- Tympanic sound over a large abscess cavity.

Auscultation Findings:

- Weakened breath sounds over the involved area;
- Medium and fine crackles in the affected lung region;
- Amphoric breathing (hollow, metallic sound) in the presence of a large abscess cavity.

In the acute stage of inflammation, there are significant losses of electrolytes and protein, which causes fluid and volume imbalances due to insufficient compensation. As a result, weight loss and hypoproteinemic edema of the lower limbs may develop in severe cases.

Chronic abscess mainly develops against the background of an unfavorable prolonged course of an acute abscess.

Forms of chronic abscess

- Solitary fibrous-walled abscess with a surrounding pneumonic infiltration zone
- Localized pneumosclerosis with multiple abscesses of varying sizes
- Localized pyosclerosis (seen as alternating areas of opacities and lucencies on X-ray)
- Bronchiectasis, which may be widespread or localized

Clinical symptoms of chronic abscess usually more persistent and resistant to treatment. Weight loss, anemia, and hypertrophic pulmonary osteoarthropathy may occur in severe cases. Signs of chronic intoxication, potentially leading to cardiac, hepatic, and renal insufficiency. Physical findings are often normal in mild cases. Occasionally, moist and dry rales are heard over affected areas [21].

Clinical presentation of lung gangrene

Key clinical features:

- Severe intoxication syndrome (fever, chills, extreme weakness)
- Arterial hypotension (low blood pressure due to sepsis and systemic inflammatory response)
- Cough with foul-smelling sputum (often dirty-gray in color, sometimes exceeding 1 liter per day)

The general condition of a patient is usually severe. It is characterized by hectic fever, progressive weight loss, chills, loss of appetite, chest pain on the affected side [15]. During physical examination over the percussion of the affected area reveals a dull sound and tenderness (Kiesling's symptom). Against the background of rapid disintegration of necrotic tissue, the following is observed expanding dullness with areas of tympanic resonance. Auscultation reveals vesicular, harsh, or bronchial breathing over the necrotic area. After drainage of the abscess into a bronchus - numerous moist rales. In general, pulmonary gangrene is characterized by an unfavorable prognosis. Mortality rates reaching up to 90% according to various studies [18].

Clinical presentation of bronchiectasis

Symptoms of bronchiectasis primarily appear during exacerbations associated with a purulent inflammatory process. The frequency of exacerbations varies from a few episodes per year to multiple episodes per month. During remission, patients with multiple bronchial dilations and concomitant pneumosclerosis may experience a dry or wet cough and signs of respiratory failure.

Typical symptoms of bronchiectasis

- Chronic productive cough (typically worse in the morning; sputum volume may be small)

- Dyspnea with physical exertion
- Rhinosinusitis
- General weakness
- Hemoptysis (may range from streaks to massive bleeding)
- Chest pain

In some patients (both children and adults), BE may lead to bronchial obstruction.

Complications of bronchiectasis

- Acute and chronic lung abscess
- Pleural empyema
- Pulmonary hemorrhage

Physical examination findings. Patients often exhibit indirect signs of chronic hypoxia, such as:

- clubbing of the fingers ("drumstick fingers");
- nail deformities ("watch-glass nails");
- hypertrophic osteoarthropathy (Pierre Marie-Bamberger syndrome) is commonly seen in patients with extensive bronchiectasis and active purulent endobronchitis.

During exacerbation, signs of respiratory failure are typically present. Lung percussion can reveal hyperresonant ("boxy") sound over the lungs or areas of dullness. Fine and medium bubbling rales, predominantly in the lower lung segments can be heard at auscultation.

Given that bronchiectasis can occur both as a primary disease and as a manifestation of another pathology, a multidisciplinary diagnostic approach is essential.

Indications for bronchiectasis diagnosis

The diagnosis of bronchiectasis should be suspected in patients with:

- Chronic or persistent cough (with or without sputum) for 6-8 weeks
- Persistent and/or recurrent lung crackles that cannot be explained by other causes
- Incomplete resolution of pneumonia after appropriate therapy or recurrent pneumonia in the same location
- Persistent bronchial obstruction syndrome that is resistant to therapy

- Respiratory symptoms in patients with structural or functional abnormalities of the gastrointestinal tract or upper respiratory tract
- Hemoptysis

Diagnosis of infectious destructive lung diseases

Laboratory Examination

1. **Bacteriological and mycological examination of sputum**:
   - High number of neutrophilic leukocytes
   - Cellular debris
   - Fatty acid crystals
   - Dittrich plugs
   - Numerous elastic fibers
   - Pathogenic microflora

Bacteriological studies are conducted to identify the specific infectious agent and determine its antibiotic sensitivity. This examination is mandatory for patients with BE and allows for monitoring bacterial infection. If indicated, tests for tuberculosis infection should also be performed [5].

2. **Complete blood count**:
   - leukocytosis;
   - left shift in the leukocyte formula;
   - increased erythrocyte sedimentation rate (ESR);
   - decreased hemoglobin and erythrocyte levels.

3. **Urinalysis**: proteinuria, cylindruria (toxic kidney syndrome). Reduced renal excretory function, manifested by isosthenuria and decreased diuresis.

4. **Biochemical blood tests**: markers of inflammation (C-reactive protein), assessment of kidney and liver function.

5. **Arterial blood gas** -evaluation of respiratory failure.

5. **Immunological tests**. Evaluation of serum immunoglobulin levels (total IgG, IgA, IgM, IgE) is recommended during the initial assessment of patients with bronchiectasis (BE) to differentiate from primary immunodeficiency disorders. If elevated IgE levels are

detected in BE, allergic bronchopulmonary aspergillosis should be ruled out by testing for antibodies against Aspergillus spp. in the blood.

6. **Sweat test.** A sweat chloride test is performed in patients with BE to exclude cystic fibrosis.

7. **Spirometry.** Assessment of pulmonary function (FEV1, FVC).

8. **Chest radiography.** Chest X-ray plays a key role in diagnosing lung abscesses. In the early stages of the disease, chest radiographs may reveal segmental or lobar consolidation, which becomes spherical as pus accumulates [15]. The appearance of one or more radiolucent areas against the background of homogeneous lung opacification indicates the formation of a solitary or multiple abscess. Over time, multiple small cavities may merge into larger ones, in which fluid levels become visible after the abscess ruptures into a bronchus and purulent sputum is expectorated.



Fig. 24. Left-sided lung abscess [22]

[22] Case courtesy of Abu-Rahmeh Zuhair, Radiopaedia.org, rID: 30554

Suspicious but nondiagnostic radiographic findings in most patients with BE include linear atelectasis, dilated and thickened airways (ie, tram or parallel lines, ring shadows on cross section) and irregular peripheral opacities that may represent mucopurulent plugs.

9. **Bronchoscopy with targeted biopsy**. Diagnosis of purulent endobronchitis allows to identify the source of bleeding. Analysis of a biopsy of the bronchial mucosa in BE can reveal significant changes in ciliated epithelium, reduction of the ciliated apparatus, and diffuse damage to cytomembranes.

10. **Computed Tomography**. Additional information about the number and localization of abscesses, as well as the presence of associated pleural effusion, which may be poorly visible on radiographs, can be obtained through chest CT [12].



Fig. 25. Left-sided lung abscess[23]

[23] Case courtesy of Ahmed Abdrabou, Radiopaedia.org, rID: 24443

Both conventional computed tomography and computed abscessography—transthoracic administration of water-soluble radiopaque agents into the destruction cavity—are used. The proximity of the purulent focus to the chest wall allows for its puncture under ultrasound guidance.

CT features of bronchiectasis

- ✓ Airway-to-arterial ratio ≥1.5 (internal airway lumen diameter/adjacent pulmonary artery diameter)
- ✓ Lack of tapering of bronchi (tram track appearance)
- ✓ Airway visibility within 1 cm of a costal pleural surface or touching the mediastinal pleura

11. **Thoracoscopy.** The indication for thoracoscopy is the presence of pleural empyema or pneumothorax. This procedure allows for the detection of bronchopleural fistulas and enables biopsy of the pleura or lung to clarify the etiology of the disease.

Treatment of infectious destructive lung diseases

1. **Antibiotic therapy**. A combined treatment approach is administered using two or three antibiotics simultaneously at sufficiently high doses, with periodic changes in the antibiotic groups (carbapenem, vancomycin, ciprofloxacin, ceftriaxone, clindamycin). Additionally, anticandidal therapy is prescribed (fluconazole, nystatin).

Before the identification and verification of the pathogen (from sputum, bacteriological examination of sputum and blood), empirical antibacterial therapy is administered. Subsequently, antibiotic selection depends on the sensitivity of the identified pathogens. In severe cases, intravenous antibiotic administration is recommended. To achieve maximum concentration at the site of inflammation, bronchial artery catheterization followed by regional antibiotic therapy is performed.

First-line antibiotics include amoxicillin/clavulanic acid or ampicillin/sulbactam (IV). Cefoperazone/sulbactam (IV) or benzylpenicillin + metronidazole (IV), followed by step-down therapy with oral amoxicillin + metronidazole, may also be used [5, 20].

Alternative regimens include [5,6]:

- Lincosamide + aminoglycoside or III-IV generation cephalosporin
- II-III generation fluoroquinolone + metronidazole

- IV fluoroquinolone
- Carbapenem

The duration of therapy is determined individually but typically lasts 3-4 weeks or more. Treatment should continue until resolution and complete elimination of the cavity.

2. **Routes of drug administration via the respiratory tract**:
   - through a rubber catheter inserted into the bronchus;
   - through a bronchoscope;
   - in the form of aerosols.

3**. Improvement of bronchial drainage function**:
   - enhancing sputum clearance using expectorants (acetylcysteine, carbocysteine, erdosteine, ambroxol);
   - postural drainage;
   - inhalation of alkaline solutions.

4. **Surgical treatment indications**:
   - Profuse recurrent hemorrhages
   - Pyopneumothorax
   - Pleural empyema.

Prevention of infectious destructive lung diseases involves timely and comprehensive treatment of underlying lung diseases that contribute to their development.

Principles of bronchiectasis treatment

The treatment of bronchiectasis is primarily based on preventing or suppressing acute and chronic bronchial infections, improving mucociliary clearance, and reducing the impact of structural lung damage.

- Treatment of the underlying condition causing BE (e.g., COPD, rheumatoid arthritis, or inflammatory bowel disease).
- Disease activity monitoring:
  - Annual assessment of lung function
  - Regular sputum cultures to identify colonizing microorganisms and assess antibiotic resistance.

Mucolytic therapy

The use of oral and inhaled medications that reduce sputum viscosity helps facilitate expectoration, which theoretically shortens the duration and frequency of exacerbations and reduces symptoms.

Long-term mucolytic therapy (lasting more than 3 months) is recommended for adult patients with BE who experience a low quality of life and difficulty expectorating sputum. This therapy is also considered when standard airway clearance techniques do not effectively control symptoms [5].

Mannitol is a hyperosmolar agent that is thought to hydrate airway secretions, which might improve mucus clearance. Dry powder mannitol for inhalation may be considered in patients with bronchiectasis without asthma.

Nebulized hypertonic saline (6-7%) improves mucus rheology, increases ciliary motility, and enhances cough clearance. Nebulized hypertonic saline is beneficial in patients with cystic fibrosis.

Oral mucolytics (carbocysteine) are prescribed during exacerbations to improving mucus clearance.

Antibacterial therapy

Antibacterial treatment is a key component in managing bronchiectasis, aimed at controlling acute exacerbations and preventing chronic infections. The recommended duration of antibiotic therapy for BE exacerbations is 14 days.

The initial antibiotic selection is guided by any sputum culture results obtained within the past 12 to 24 months as well as prior patient experience.

Empirical therapy (no recent sputum culture data)

- Levofloxacin, Moxifloxacin per os.

Sputum culture doesn't show Pseudomonas aeruginosa

- Amoxicillin 500 mg three times daily or
- Doxycycline 100 mg twice daily

Sputum culture with nonpseudomonal beta-lactamase-positive organism (Moraxella catarrhalis, H. influenzae)

- Amoxicillin/clavulanic acid
- Doxycycline

- II-III cephalosporin (cefotaxime, ceftriaxone)
- Fluoroquinolone (moxifloxacin, levofloxacin)
- Antipseudomonal fluoroquinolones (ciprofloxacin, levofloxacin) oral or IV.

Patients with BE demonstrating evidence of severe infection, sepsis, or impending respiratory failure should receive broad-spectrum intravenous antibiotics covering both Pseudomonas and methicillin-resistant Staphylococcus aureus (MRSA) while awaiting culture data. In hospitalized patients with MRSA in sputum samples, the initial empiric regimen should include vancomycin or linezolid 600 mg every 12 hours.

Antibiotics with antipseudomonal activity:

- Piperacillin-tazobactam
- Cephalosporins (ceftazidime, cefoperazone, cefepime)
- Monobactam (aztreonam)
- Fluoroquinolones (ciprofloxacin).

Patients with known chronic pseudomonal infection should receive dual-agent therapy (addition of a fluoroquinolone or aminoglycoside to one of the options listed above) pending culture results. The questions of single versus dual therapy and antibiotic selection is requires individual management. Aminoglycosides should never be used as single agents.

Inhalational antibiotic therapy holds a special place in the treatment of patients with BE. It is associated with a reduction in bacterial load and a decrease in inflammation within the airways. For chronic Pseudomonas aeruginosa colonization, inhaled antibiotics with high efficacy against this pathogen are recommended, such as tobramycin. For individuals who cannot tolerate tobramycin, inhaled aztreonam, colistin, or gentamicin are possible choices. For other infections, long-term oral macrolides can be considered as part of the treatment regimen. In cases where inhaled antibiotics or oral macrolides do not provide adequate or sufficient effects, combination therapy using inhaled antibacterial agents may be employed.

Surgical treatment. The goal of surgical extirpation includes removal of the most involved segments or lobes while preserving the remaining lung. Middle and lower lobe

resections are most often performed. The superior segment of the lower lobe may be involved to a lesser extent and can frequently be salvaged during lower lobe resection.

Indications for surgical treatment of bronchiectasis:

- pulmonary hemorrhage;
- recurrent infective episodes not responsive to medical therapy;
- overwhelming purulent and viscid sputum production in patients with localized bronchiectasis that is unresponsive to medical therapy;
- severe chronic respiratory failure.

One of the contemporary strategies is damage-control surgery, which aims to minimize the extent of initial intervention while preparing the patient for a delayed radical operation [5]. Damage-control tactics are used in life-threatening situations, such as massive pulmonary hemorrhage - bronchial artery embolization (performed via angiography with minimal trauma).

Lung abscess. Transthoracic abscess drainage (to relieve intoxication and stabilize the patient before surgery). Surgical treatment is reserved for carefully selected cases where medical management is insufficient, ensuring the best possible long-term outcomes.

Pulmonary rehabilitation

Pulmonary rehabilitation increases exercise capacity and can improve quality of life in individuals with bronchiectasis.

Airway clearance techniques

- Massage
- Vibration massage
- Long-term aerotherapy
- Percussion massage therapy
- Postural drainage (the positioning of a patient for better drainage of broncho-pulmonary secretions from the tracheobronchial tree)
- Inhalation of bronchodilators (β2-agonists, anticholinergics).

Test tasks for self-assessment

1. Which disease of the bronchopulmonary system does not belong to шnfectious destructive lung diseases?

A. Acute abscess

B. Gangrene

C. Fibrosing alveolitis

D. Bronchiectasis

E. Chronic abscess

2. Which of the following stages is not a stage of abscess development?

A. Infiltration stage

B. Necrosis and cavity formation stage.

C. Abscess drainage stage

D. Healing

E. Organization stage

3. According to the mechanism of development of bronchiectasis, the following are distinguished, except:

A. Retention bronchiectasis

B. Destructive bronchiectasis

C. Atelectatic bronchiectasis

D. Restrictive bronchiectasis

4. A 58-year-old man complaints on cough. He has been coughing for the past 2 months and is associated with mucopurulent and tenacious sputum production, which has progressively worsened. Past history is significant for COPD. He smokes 1 pack of cigarettes daily for the past 34 years. On physical exam, the patient has wheezes and crackles bilaterally to auscultation. A radiograph of the chest is unremarkable; however, a CT scan of the chest demonstrates stigmata of bronchial dilatation. What os the most likely diagnosis?

A. Community-acquired pneumonia

B. COPD exacerbation

C. Pulmonary edema

D. Bronchiectasis

E. Cystic fibrosis

5. What is the most common pathogen of lung abscesses?

A. Pneumococcus

B. Streptococcus

C. Staphylococcus

D. Proteus

E. Haemophilus influenzae

6. What sputum type is typical for patients with IDLD?

A. Serous

B. Chylous

C. Purulent

D. Serous-fibrinous

E. Hemorrhagic

7. Sputum examination in patients with IDLD usually shows everything, except for:

A. Detritus

B. Fatty acid crystals

C. Dittrich's plugs

D. Curschmann's spirals

E. Microbiological agents

8. What lung disease should be excluded first of all when an abscess is localized in the upper lobe of the lung?

A. Tuberculosis

B. Pneumonia

C. Pneumoconiosis

D. Lung cancer

E. Echinococcosis

9. Which complication of IDLD is not an absolute indication for surgical treatment?

A. Profuse recurrent bleeding

B. Pyopneumothorax

C. Acute empyema

D. Cor pulmonale

10. What medications can be prescribed in combination (2-3 drugs from the same group)?

A. Expectorants

B. Nonsteroidal anti-inflammatory drugs

C. Antibacterial drugs

D. Detoxification agents

E. Cardioprotective agents

Standard answers: 1 - C, 2 - E, 3 - D, 4 - D, 5 - C, 6 - C, 7 - D, 8 - A, 9 - D, 10 - C.

RESPIRATORY FAILURE

Relevance of the topic. **Respiratory failure** (RF) is a disorder of gas exchange between ambient air and arterial blood, characterized by a decrease in arterial blood PaO2 (<60 mmHg) and/or an increase in arterial blood PaCO2 (>45 mmHg) [3].

Currently, there are no comprehensive epidemiological data on acute respiratory failure (ARF). Available data pertain only to specific nosological forms. According to epidemiological studies, in developed countries, the number of patients with chronic respiratory failure requiring oxygen therapy exceeds 8–10 cases per 10,000 population [2].

During the observation period, 3–5% of patients with bronchial asthma experience 1–2 exacerbations of the disease with confirmed ARF, which, in the absence of effective therapy, may lead to a fatal outcome [3]. The proportion of community-acquired pneumonias requiring hospitalization in the intensive care unit and exhibiting signs of ARF accounts for 3–10% of all pneumonia cases.

Acute respiratory distress syndrome (ARDS) has an incidence ranging from 1.5 to 13.5 cases per 100,000 population per year, according to various sources. Among intensive care unit (ICU) patients requiring prolonged oxygen support via mechanical ventilation (MV), ARDS cases constitute 16–18% [3]. Approximately 14% of COVID-19 patients develop a severe form of the disease requiring hospitalization and oxygen therapy, while 5% require treatment in intensive care units.

Respiratory failure is a syndrome caused by the inability of the external respiratory system to maintain a normal gas composition of arterial blood. RF also occurs in cases where maintaining a normal arterial blood gas composition at an adequate level is achieved at the expense of excessive functional strain on this system [15].

Depending on the rate of development of clinical signs and disturbances in blood gas composition, RF is classified as acute or chronic.

There are two main pathophysiological types of respiratory failure:

1) Hypoxemic RF (Type 1) is characterized by hypoxia without hypercapnia, with a partial pressure of oxygen in arterial blood (PaO_2) <8 kPa (<60 mmHg). It develops in

patients with pneumonia, fat embolism of the pulmonary artery branches, and pulmonary edema due to severe ventilation-perfusion disturbances and intrapulmonary shunting [2].

2) Hypercapnic RF (Type 2) is hypoxia accompanied by an increased partial pressure of carbon dioxide in arterial blood ($PaCO_2$) >6.5 kPa (>50 mmHg). It includes two types of impairments: ventilation-perfusion imbalance and inadequate alveolar ventilation.

Acute respiratory failure is an acute dysfunction of the respiratory system that leads to inadequate oxygen supply to organs and tissues (hypoxemia) and carbon dioxide retention in the body (hypercapnia). ARF is characterized by a rapid onset of gas exchange disturbances over the course of several days, hours, or even minutes, with a tendency to progress [3]. This pathological condition requires urgent diagnosis and emergency medical intervention.

Most patients with ARF exhibit both gas exchange impairments and hypoventilation. In Type 2 ARF, a sharp increase in carbon dioxide concentration is associated with respiratory acidosis (arterial blood pH <7.35).

Main mechanisms and causes of respiratory failure

1. ***Respiratory center suppression***
   - Drug overdose (opioids), intoxication
   - Central nervous system diseases
   - Unconsciousness
   - Improper oxygen therapy in patients with chronic hypoventilation
2. ***Impaired neural signal transmission to respiratory muscles***
   - Spinal cord injury
   - Myelitis
   - Infections (tetanus, poliomyelitis, botulism)
   - Neuromuscular diseases (myasthenia, motor neuron diseases, muscular dystrophy): chronic hypoventilation with sudden exacerbations, e.g., during respiratory infections
   - Polyradiculitis
3. ***Mechanical ventilation disorders***
   - Chest trauma, diaphragmatic rupture

- Tension pneumothorax, hemothorax
- Severe kyphoscoliosis (usually chronic hypoventilation with sudden exacerbations, e.g., during respiratory infections)
- Grade III obesity (Pickwickian syndrome – a combination of obesity and hypoventilation, chronic RF with exacerbations)

4. Airway obstruction

- Foreign bodies
- Obstruction by a tumor or mucus
- Severe exacerbation of bronchial asthma or chronic obstructive pulmonary disease

5. Parenchymal lung diseases

- Severe pneumonia
- Acute respiratory distress syndrome
- Pulmonary edema
- Interstitial lung diseases

6. Insufficient pulmonary circulation

- Pulmonary embolism

7. Reduced blood oxygenation

- Severe anemia
- Carbon monoxide poisoning
- Prolonged seizures

Table 22. Differential diagnosis of acute respiratory failure

Condition	*Characteristics*
More common	
Asthma	Cough, wheeze, response to bronchodilator
COPD	Decreased air movement, prolonged expiratory phase

Cardiogenic pulmonary edema	History of cardiac disease, jugular venous distension, peripheral edema, third heart sound, enlarged heart silhouette on chest X-ray
Pneumonia	Productive cough, fever, pleuritic chest pain
Less common	
Pneumothorax	Acute onset of dyspnea, pleuritic chest pain; tall and thin body habitus
Diffuse alveolar hemorrhage	Often associated with autoimmune diseases (vasculitis) or following bone marrow transplantation; hemosiderin-laden macrophages in bronchoalveolar lavage fluid
Acute eosinophilic pneumonia	Cough, fever, pleuritic chest pain, and myalgia; greater than 15% eosinophils in bronchoalveolar lavage fluid. Usually responds rapidly to high-dose corticosteroid therapy.
Acute interstitial pneumonia, Hamman-Rich syndrome	Slower onset than ARDS (over 4-6 weeks) with progressive course. High resolution chest CT show bilateral, patchy, symmetric areas of ground glass attenuation, often accompanied by airspace consolidation, septal thickening, and traction bronchiectasis
Major pulmonary embolism	Severe hypoxemia, hypotension, requiring vasopressors, mimicking ARDS with sepsis. Higher clinical probability of PE (Geneva score). Chest

	radiograph - unilateral or no infiltrates. CT scan confirm PE

Clinical manifestations of respiratory failure

- Shortness of breath, increased respiratory rate
- Agitation, confusion, and altered consciousness
- Increased respiratory effort, use of accessory respiratory muscles
- Decreased peripheral blood oxygen saturation (SpO_2) as measured by pulse oximetry
  - A saturation level >90% is generally considered sufficient.
  - In acute cases, the target SpO_2 is 94–98%, unless the patient is prone to carbon dioxide retention (e.g., COPD).

Fig. 26. Pulse oximetry [24]

Pulse oximetry (fig. 26) is a useful method for quickly detecting hypoxemia but does not identify hypoventilation.

The chest radiograph is a simple and widely available test used to assess patients with acute hypoxic respiratory failure. In cases of established ARDS, the chest radiograph

[24] https://aemc.org.ua/info/article/40/

typically demonstrates findings of diffuse, bilateral alveolar infiltrates consistent with pulmonary edema. However, especially early in the course of the disorder, the infiltrates associated with ARDS may be variable: mild or dense, interstitial or alveolar, patchy or confluent.



Fig. 27. Chest X ray at ARDS. [25]

Radiographic criteria of cardiogenic edema

- Increased heart size
- Increased width of the vascular pedicle,
- Vascular redistribution toward upper lobes,
- Presence of septal lines, or a perihilar (bat's wing) distribution of the edema

Lack of these findings, in conjunction with patchy peripheral infiltrates that extend to the lateral lung margins, suggests ARDS.

[25] https://radiopaedia.org/articles/acute-respiratory-distress-syndrome-1

Laboratory studies at respiratory failure

- Decreased PaO_2 <60 mmHg while breathing ambient air
- Decreased pH <7.35 and increased $PaCO_2$ >45 mmHg

Blood gas analysis is used to measure arterial (or venous) oxygen (PaO_2) and carbon dioxide ($PaCO_2$) levels. pH is also an important indicator of the overall acid-base status of arterial, capillary, and venous blood. The possible cause of pH disturbances can be assessed by considering $PaCO_2$ levels and bicarbonate (HCO_3^-) concentration (excess or deficiency of bases). Metabolic acidosis is commonly observed in cases of severe circulatory disturbances or oxygen delivery impairment, such as in severe hypoxemia due to viral infections (e.g., SARS), ARDS, sepsis, or septic shock.

The severity of ARF is primarily evaluated based on arterial blood partial pressures of oxygen (PaO_2) and carbon dioxide ($PaCO_2$) [3].

Table 23. Assessment of Acute Respiratory Failure Severity

Classification	***$PaCO_2$ mm Hg***	***PaO_2 mm Hg***
Norma	36-44	80-96
Mild ARF	46-55	79-65
Moderate ARF	56-65	64-55
Severe ARF	54-45	70-85
Hypercapnic coma	up to 130	44-35

In addition to arterial blood gas measurements, several other laboratory studies may be helpful in investigating other causes of respiratory failure and evaluating additional aspects of critical illness associated with ARDS. Cardiac enzymes (creatine phosphokinase, troponins) are useful for evaluating the presence of myocardial injury in patients with suspected coronary artery disease. Another cardiac-related laboratory test that may be useful in this clinical context is plasma brain natriuretic peptide (BNP). BNP greater than 500 pg/mL indicates that CHF is likely with a highly positive predictive value. When BNP is less than 100 pg/mL you can reasonably exclude a cardiac cause for acute pulmonary edema in the patients with dyspnea.

Management of Respiratory Failure

- ✓ Oxygen therapy

- ✓ Maintaining adequate cardiac output and hemoglobin concentration
- ✓ Ensuring airway patency
- ✓ Etiotropic treatment (targeting the underlying cause, e.g., pneumonia, heart failure, airway obstruction)

Oxygen therapy is administered under SpO_2 monitoring (pulse oximetry) to ensure proper correction of oxygen deficiency while avoiding overcorrection, particularly in patients with chronic hypoventilation. Venturi mask (28–40%) or nasal cannulae are commonly used [8].

 [26]

Fig. 28. Oxygen therapy with Venturi mask

[26] https://flexicare.com/ru/product/aerosol-venturi-masks/

 [27]

Fig. 29. Oxygen therapy with nasal cannula.

The goal of treatment is to increase arterial PaO_2 to 60–75 mmHg and maintain oxygen saturation above 90%. In cases of COPD exacerbation, the target oxygen saturation (SpO_2) is 88–92%.

Mechanical ventilation (MV)

Mechanical ventilation supports and assists breathing, reduces respiratory effort, increases lung volume, reopens collapsed airways, enhances ventilation, and improves gas exchange.

Types of mechanical ventilation

- Non-invasive ventilation (without an artificial airway)
- Invasive ventilation (via intubation)

Non-Invasive Positive Pressure Ventilation (NPPV) is a respiratory support method that does not require invasive airway devices. It is used in patients with spontaneous breathing through a tightly fitted nasal or full-face mask. Since the airway remains unprotected, aspiration is possible, so the patient must be conscious with intact airway reflexes [8].

Types of NPPV

✓ Continuous Positive Airway Pressure (CPAP)

[27] https://www.verywellhealth.com/nasal-cannulas-914867

- ✓ Bilevel Positive Airway Pressure (BPAP)

CPAP maintains a constant positive pressure throughout the respiratory cycle without additional inspiratory support. BPAP is a two-level positive airway pressure caused by the patient's breathing.

BPAP provides varying levels of positive airway pressure based on the patient's respiratory cycle:

- ✓ Expiratory Positive Airway Pressure (EPAP) – Maintains airway patency and functions as a physiological equivalent of CPAP.
- ✓ Positive End-Expiratory Pressure (PEEP) – Prevents alveolar collapse by maintaining residual lung volume at the end of exhalation.
- ✓ Inspiratory Positive Airway Pressure (IPAP) – Provides additional support during inhalation, reducing respiratory effort and improving gas exchange.

Fig. 30. Non-invasive positive pressure ventilation [28]

Indications for NPPV

- Severe exacerbation of COPD ($PaCO_2$ > 45 mmHg or pH < 7.30)

[28] https://respiratory-therapy.com/disorders-diseases/critical-care/icu-ventilation/high-flow-oxygen-therapy-bipap-respiratory-failure/

- Cardiogenic pulmonary edema with progressive hypoxemia
- Obesity hypoventilation syndrome
- Patients with immunodeficiency experiencing progressive respiratory failure, where intubation poses a higher risk of infection
- Hypoxemic respiratory failure

Indications for invasive mechanical ventilation (intubation)

- Severe gas exchange impairment (ARDS)
- Severe hypoventilation (pH < 7.20) in patients actively undergoing treatment
- Airway protection (in unconscious patients)
- Patients with inadequate spontaneous breathing

Acute respiratory distress syndrome

Acute respiratory distress syndrome (ARDS) is an acute, diffuse, inflammatory form of lung injury that is associated with a variety of etiologies. Recognizing and promptly treating ARDS is critical to reduce the associated high mortality. ARDS arises as a result of acute inflammation that increases the permeability of the alveolar-capillary membrane, allowing neutrophils and other inflammatory mediators to enter the alveolar space, leading to pulmonary edema. The resulting inflammatory exudate inactivates surfactant and causes consolidation of the distal air spaces, leading to a loss of the lung's gas exchange surface area. This should be compensated by hypoxic pulmonary vasoconstriction; however, the inflammatory process also affects vascular tone regulation. As a result, deoxygenated blood traveling to the left atrium bypasses non-ventilated pulmonary acini. These two processes contribute to severe hypoxemia and lead to type 2 respiratory failure [2].

Etiology of ARDS

- Pneumonia of various etiologies
- Inhalation of irritant and toxic substances (chlorine, nitrogen oxides, phosgene, ammonia, pure oxygen leading to oxygen toxicity)
- Pulmonary embolism (fat embolism, air embolism, amniotic fluid embolism)
- Sepsis, shock (septic, anaphylactic), blood transfusions, disseminated intravascular coagulation (DIC)

- Acute hemorrhagic pancreonecrosis with the release of large amounts of lecithinase A, which destroys surfactant, leading to atelectasis and pneumonia
- Chest trauma and crush syndrome
- Systemic lupus erythematosus, Goodpasture syndrome, etc.
- Aspiration of vomit or water (near-drowning)
- Severe metabolic disorders (diabetic ketoacidosis, uremia)
- Venous fluid overload (colloids, saline solutions, plasma, plasma substitutes, lipid emulsions)
- Use of cardiopulmonary bypass
- Hypovolemic shock, massive blood transfusion

Thus, ARDS can be triggered by any condition that leads to the accumulation of bacterial toxins or endogenous biologically active substances (leukotrienes, platelet-activating factor, thromboxane, enzymes) in the bloodstream, provoking inflammatory reactions. Pathomorphologically, ARDS is indistinguishable from pneumonia. The only morphological difference between ARDS and pneumonia is the absence of infectious pathogens in the lung parenchyma [2].

Pathologic stages of ARDS

1. Early diffuse alveolar damage (during the first 7 to 10 days) is characterized by interstitial edema, acute and chronic inflammation, type II cell hyperplasia, and hyaline membrane formation.
2. Late diffuse alveolar damage (after approximately 7 to 10 days) is characterized by resolution of pulmonary edema, proliferation of type II alveolar cells, squamous metaplasia, interstitial infiltration by myofibroblasts, and early deposition of collagen. It is unknown how long this phase lasts but is probably in the realm of two to three weeks.
3. Fibrotic stage is characterized by obliteration of normal lung architecture, fibrosis, and cyst formation. The degree of fibrosis ranges from minimal to severe.

ARDS can be diagnosed once cardiogenic pulmonary edema and alternative causes of acute hypoxemic respiratory failure and bilateral infiltrates have been excluded.

Clinical Manifestations of ARDS

✓ Severe dyspnea and diffuse cyanosis

✓ Cough with frothy, pink-tinged sputum (due to erythrocyte leakage)

✓ Tachypnea and cardiac arrhythmias

✓ ***Pulmonary auscultation***: numerous moist rales of varying calibers in the lungs, pronounced crepitation—hallmarks of pulmonary edema

✓ Signs of progressive pulmonary hypertension with acute cor pulmonale syndrome in the absence of pre-existing cardiovascular pathology

✓ Multiple organ failure: kidneys (oliguria/anuria, proteinuria, cylindruria, microhematuria, increased creatinine levels), liver (jaundice, elevated levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and lactate dehydrogenase (LDH)), brain (dizziness, lethargy, and impaired consciousness).

Diagnostic approach to ARDS

- Respiratory symptoms must have begun within one week of a known clinical insult, or the patient must have new or worsening symptoms during the past week.
- Bilateral opacities must be present on a chest radiograph or CT scan or ultrasonography. The opacities must not be fully explained by pleural effusions, lobar collapse, lung collapse, or pulmonary nodules.
- The patient's respiratory failure must not be fully explained by cardiogenic edema or fluid overload.
- A moderate to severe impairment of oxygenation must be present, as defined by the ratio of arterial oxygen tension (PaO2) to fraction of inspired oxygen (FiO2).
- •Nonintubated patients – ARDS is present when the PaO2/FiO2 is ≤300 mmHg or the SpO2/FiO2 is ≤315 mmHg (if the SpO2 ≤97 percent) while on humidified high-flow oxygen delivered via nasal cannulae (HFNC) ≥30 L/minute or noninvasive ventilation CPAP ≥5 cm H2O end-expiratory pressure.

Laboratory studies

✓ Arterial hypoxemia: $PaO_2 < 50$ mmHg and hypercapnia: $PaCO_2 > 45–50$ mmHg

✓ Reduction of pH to ≤ 7.2 and other signs of respiratory acidosis

✓ PaO_2/FiO_2 ratio ≤ 300 on positive end-expiratory pressure (PEEP) or continuous positive airway pressure (CPAP) ≥ 5 cm H_2O (PaO_2 – partial pressure of oxygen in arterial blood, FiO_2 – fraction of inspired oxygen, expressed as a decimal fraction).

ECG findings in ARDS

- Right axis deviation of the heart's electrical axis
- Right atrial hypertrophy (P-pulmonale)

Imaging

Imaging findings are variable and depend upon the severity of ARDS. The initial chest radiograph typically has bilateral diffuse alveolar opacities with dependent atelectasis, although findings can be subtle. Chest CT may show widespread patchy and/or coalescent airspace opacities that are usually more apparent in the dependent lung zones [19]. The opacities can be subtle (eg, patchy ground glass), particularly in early ARDS, but can become consolidative in appearance as severity worsens.

Bedside lung ultrasound is more sensitive than chest radiograph for the detection of bilateral lung infiltrates, that more likely to lead to the diagnosis of ARDS.

Clinical stages of ARDS

Stage I (latent period)

- Lasts approximately 24 hours after exposure to the etiological factor
- Pathophysiological changes occur without clinical or radiological signs, except for mild tachypnea (respiratory rate > 20 breaths per minute)

Stage II (initial period)

- Occurs 1–2 days after exposure
- Symptoms: marked tachypnea, tachycardia, harsh breathing sounds, and scattered dry rales
- Radiographic findings: enhanced vascular markings, especially in peripheral lung regions, indicating the onset of interstitial pulmonary edema
- Arterial blood gas: mild PaO_2 reduction

Stage III (period of pronounced clinical manifestations)

- Characterized by acute respiratory failure

- Severe dyspnea, diffuse cyanosis, tachycardia, and hypotension
- Chest percussion: dullness in posterior basal lung regions
- Pulmonary auscultation: harsh breath sounds, dry rales; the appearance of moist rales and crepitation indicates alveolar pulmonary edema
- Radiographic findings: severe interstitial edema, bilateral diffuse infiltrates with irregular, cloud-like opacities
- Arterial blood gas: significant PaO_2 drop (<50 mmHg) despite oxygen therapy

Stage IV (terminal period)

- Marked progression of respiratory failure
- Severe arterial hypoxemia and hypercapnia
- Development of metabolic acidosis
- Formation of acute cor pulmonale due to worsening pulmonary hypertension

2012 BERLIN DEFINITION OF ARDS

1. Acute, meaning onset over 1 week or less - the appearance of new respiratory symptoms, or worsening of existing symptoms.

2. Origin of edema.

- Respiratory failure cannot be fully explained by heart failure or fluid overload.
- -Additional evaluation (echocardiography) is required to rule out hydrostatic pulmonary edema if no risk factors are present.

3. Severity of oxygenation impairment (determined based on arterial blood gas analysis data).

Table 24. Berlin definition of ARDS.

Level of severity	PaO2 /FiO2	PEEP
Mild	$200 < x \leq 300$	$\geq$ 5 см H2O (or CPAP)
Moderate	$100 < x \leq 200$	$\geq$ 5 см H2O
Severe	$x \leq 100$	$\geq$ 5 см H2O

Note. CPAP - continuous positive airway pressure; FIO2 - fraction of inspired oxygen; PaO2 - partial pressure of arterial oxygen; PEEP - positive end-expiratory pressure.

4. Bilateral opacities consistent with pulmonary edema must be present and may be detected on CT or chest radiograph. Infiltrates cannot be fully explained by pleural effusion, lobar or whole-lung atelectasis, pulmonary nodules.

Table 25. Kigali modification to the Berlin Definition of ARDS (in resource limited settings)

Problem	Adaptation
No arterial blood gas analyzer to assess the degree of hypoxemia	SpO2 /FiO2 ≤ 315 = ARDS
No mechanical ventilation	Don`t use PEEP or CPAP criteria
No X-ray or CT scan	Use ultrasound to detect bilateral diffuse infiltrates

Management of ARDS

1. Treatment of the underlying disease (etiological factor)
2. Ensuring adequate gas exchange in the lungs
3. Ensuring adequate cardiac function and tissue perfusion
4. Correction of anemia
5. Treatment of pulmonary edema
6. Normalization of circulating blood volume and correction of blood rheological properties
7. Correction of metabolic disorders, acid-base balance, and water-electrolyte disturbances
8. Correction of endogenous intoxication syndrome
9. Correction of coagulation abnormalities
10. Prevention and treatment of post-hypoxic complications in the gastrointestinal tract (stress ulcers, bleeding)
11. Prevention and treatment of infectious complications

Treatment of ARF. Treatment of ARF includes symptomatic and etiotropic components. In this regard, the clinician should use antibiotics for pneumonia, diuretics and vasodilators for pulmonary edema, and bronchodilators for obstructive pulmonary disease [3]. Additionally, oxygen therapy, correction of blood pressure and electrolyte

disturbances, and prevention of deep vein thrombosis may be performed. Treatment of ARF includes elimination the cause of ventilation and perfusion disorders, correction of hypoxia and acid-base disorders. At the same time, patients with type 1 ARF can be supplied with high concentrations of O2 in the inhaled air, as there is no risk of CO2 retention. Type 2 ARF is usually an indication for mechanical ventilation [20]. In case of severe pain, local or general anesthesia is performed.

Oxygen therapy. It is indicated for patients with ARDS, hypoxemia or shock. The initial volume is 5 l/min using a nasal oxygen cannula.

Table 26. Oxygen flow rate and approximate FiO2 by oxygen delivery systems

Oxygen delivery devices	Flow-rate (lpm)	Approximate Fi02
Nasal cannula	1 to 6	0.24 to 0.44
Simple face mask	5 to 8	0.4 to 0.6
Partial rebreathing mask	6 to 10	0.6 to 0.8
Non rebreathing mask	10 to 15	0.9 to 1
Venturi mask	2 to 15	0.24 to 0.6

Monitor with continuous pulse oximetry. Titrate oxygen to achieve an $SpO_2 \geq 90\%$ (target $SpO_2 > 94\%$) using the appropriate dosage (flow rate) and ventilator. In some cases, without hypercapnia, hypoxemic DN, newer high-flow oxygen therapy systems can be used.

Assessment of FiO2 at oxygen delivery

- 2–4 l/min ~ FiO2 0,28–0,36
- 5 l/min ~ FiO2 0,40
- 6–10 l/min ~ FiO2 0,44–0,60
- 10–15 l/min ~ FiO2 0,60–0,95

Intubation and invasive mechanical ventilation are indicated for most patients with ARDS and hypoxemic respiratory failure [20]. Protective lung ventilation reduces mortality in ARDS patients.



Fig 31. Oxygen therapy in a patient with ARDS[29]

[29] https://www.who.int/publications/i/item/clinical-care-of-severe-acute-respiratory-infections-tool-kit

Protective lung ventilation

- Ensuring a low respiratory volume (target: 6 mL/kg of ideal body weight or less);
- Achieving a low plateau pressure in the airways (Pplat) (target: Pplat ≤ 30 cm H_2O); and
- Using moderate positive end-expiratory pressure (PEEP) to maintain lung recruitment.

In adult and pediatric patients with moderate to severe ARDS (P/F <150), the prone position is used. For patients with COVID-19, extracorporeal membrane oxygenation (ECMO) is applied, but it should only be performed in expert centers following strict protocols for patients who do not respond to protective lung ventilation and prone positioning strategies [19].

The use of high-flow nasal cannula (HFNC) may be safe for patients with mild to moderate hypercapnia that does not worsen (mild ARDS), a normal mental state, stable hemodynamics, and no need for emergency intubation. Patients receiving oxygen therapy via HFNC should remain in a controlled environment under the supervision of experienced staff capable of performing endotracheal intubation if the patient's condition deteriorates to acute respiratory failure or does not improve after a short therapy period (approximately 1 hour) [20].

Acute respiratory failure and ARDS in COVID-19 patients

A COVID-19 patient may continue to experience respiratory distress or hypoxemia even when oxygen is delivered via a face mask with a reservoir bag (flow rate of 10-15 L/min, typically the minimum required to maintain bag inflation; FiO_2 0.60-0.95). Hypoxemic respiratory failure in ARDS is usually due to intrapulmonary ventilation-perfusion mismatch or shunting and often requires mechanical ventilation [20].

For patients with severe ARDS, lung ventilation in the prone position for more than 12 hours per day is recommended, with body position changes every 3-4 hours.

Indications for intubation and mechanical ventilation

• Refractory hypoxemia (SpO_2 <85%)

• Altered consciousness

• Psychomotor agitation

• Respiratory rate >45 breaths/min with accessory muscle use

Preoxygenation with 100% FiO_2 for five minutes should be performed using a face mask with a reservoir bag, a valve mask, high-flow nasal oxygen, or noninvasive ventilation.

ECMO is indicated for ventilated patients with refractory hypoxemia (PaO_2/FiO_2 <50 mmHg for 3 hours or PaO_2/FiO_2 <80 mmHg for >6 hours) [19].

Chronic Respiratory Failure

The pathogenesis of chronic respiratory failure (CRF), like ARF, includes two main types: hypoxemic and hypercapnic. As the condition progresses, both types of gas exchange impairment are observed.

Chronic hypoventilation develops first and worsens during sleep. Gas exchange disturbances manifest as chronic hypoxemia and are always associated with chronic lung diseases such as COPD and pulmonary fibrosis.

Depending on the mechanisms of impaired pulmonary ventilation, CRF is classified into:

Obstructive type: associated with airflow obstruction to the alveoli. This can result from both non-pulmonary causes (upper airway obstruction or deformation, laryngeal pathology, foreign objects, etc.) and pathological processes in the bronchi and lungs, including bronchial smooth muscle spasm, inflammatory infiltration or edema of the bronchial mucosa, increased secretion viscosity, bronchial deformation, and expiratory bronchial collapse.

Restrictive type: common pulmonary causes include infiltrative and inflammatory lung tissue changes, pneumosclerosis, pulmonary fibrosis, lung volume reduction due to surgery, atelectasis, or congenital hypoplasia. Non-pulmonary factors include pleural pathology, pneumothorax, musculoskeletal disorders of the chest, and diaphragm mobility reduction due to abdominal diseases or pain syndrome. Restrictive breathing disorders may also be associated with heart failure and pulmonary hypertension.

Mixed type is characterized by the simultaneous presence of both obstructive and restrictive ventilatory disorders [15].

The primary complaint of patients is dyspnea, which worsens with physical exertion. The respiratory rate exceeds 24-26 breaths per minute and is accompanied by disrupted

breathing rhythm and the involvement of accessory respiratory muscles. Cyanosis develops when one-third of hemoglobin in the blood circulates in its reduced form. In chronic respiratory failure, cyanosis is central (also called "warm cyanosis") because peripheral blood flow is not significantly slowed [15].

Signs indicating sleep-related hypoventilation

- Disturbed sleep, morning headaches, and daytime drowsiness
- Fatigue and weakness during the day
- Impaired memory and attention
- Periodic episodes of acute respiratory failure

Radiological and instrumental methods play a crucial role in diagnosing CRF, along with patient history, to identify the underlying disease.

Spirometry is a simple and informative method for diagnosing CRF.

Obstructive respiratory failure:

- Decreased FEV_1
- FEV_1/FVC ratio < 70%
- FVC and VC may remain normal

Restrictive respiratory failure

- Reduced VC, FVC, and FEV_1
- FEV_1/FVC ratio remains normal (>70%)

Oxygen saturation and carbon dioxide monitoring

- Pulse oximetry (SpO_2) to assess oxygen levels
- Transcutaneous CO_2 ($PtcCO_2$) or end-tidal CO_2 ($PETCO_2$) to measure CO_2 retention

Signs of nocturnal apnea

- Nighttime oxygen saturation <90% for at least 20% of sleep
- Lowest oxygen saturation <85%
- $PtcCO_2$ and/or $PETCO_2$ >52–60 mmHg at night

Arterial blood gas analysis

- PaO_2 < 60 mmHg and/or $PaCO_2$ > 40 mmHg
- Normal pH with elevated BE (base excess) and HCO_3^- (bicarbonate)

Over time, patients may develop signs of polycythemia and symptoms of pulmonary heart disease.

Treatment of chronic respiratory failure

The main therapeutic measures for CRF focus on restoring and maintaining bronchial drainage function, ensuring airway patency, and administering antibacterial and non-specific anti-inflammatory therapy.

Chronic hypoxemia is treated with long-term oxygen therapy at home. However, oxygen therapy alone may worsen hypoventilation.

Primary therapy – assisted ventilation (home mechanical ventilation). Assisted ventilation is primarily required during sleep/nighttime. Non-invasive ventilation (NIV) via a mask at night is often sufficient.

The goal of ventilation therapy is to:

- Prevent respiratory suppression during sleep
- Alleviate symptoms of nocturnal hypoventilation
- Improve sleep quality
- Reduce episodes of respiratory failure

Home oxygen therapy may be combined with ventilation therapy to optimize respiratory support.

Test tasks for self-assessment

1. The main directions of treatment for respiratory failure are:

A. Treatment of the underlying disease that caused respiratory failure

B. Ensuring adequate gas exchange

C. Supporting the function of external respiration

D. All of the above are correct

E. None of the above

2. The obstructive type of respiratory failure develops due to:

A. Disruption of air flow through the respiratory passages

B. Decreased ability of the lungs to collapse and expand

C. Decreased oxygen content in the inhaled air

D. Presence of anemia

E. Circulatory disorders

3. The restrictive type of respiratory failure develops due to:

A. Disruption of air flow through the respiratory passages

B. Decreased ability of the lungs to collapse and expand

C. Decreased oxygen content in the inhaled air

D. Presence of anemia

E. Circulatory disorders

4. "Cor pulmonale" is characterized by:

A. Right ventricular insufficiency

B. Left ventricular insufficiency

C. Total heart failure

D. Arrhythmia and conduction disturbances

E. None of the above

5. Clinical signs of respiratory failure include everything listed except:

A. Dyspnea

B. Tachycardia

C. Cyanosis

D. Feeling of air shortage

E. Arterial hypertension

6. A 54-year-old patient complains of shortness of breath during minor physical activity, cough with difficult to separate sputum. Objectively: diffuse cyanosis. The chest is barrel-shaped. In the lungs, vesicular respiration with prolonged exhalation, dry whistling rales. Blood pressure - 140/80 mm Hg, pulse - 92 beats per minute, rhythmic. Spirometry: FEV1/FEV2 - 65%, FEV1/FEV2 - 50%. Determine the type of respiratory failure (RF) in the patient:

A. Restrictive type of respiratory failure

B. Obstructive type of respiratory failure

C. Mixed type of RF with predominance of restriction

D. There is no respiratory failure

E. Mixed type of RF with predominance of obstruction

7. A 36-year-old patient was admitted to the hospital in an agitated state, periodically experiencing auditory hallucinations, delusions. Wounds of the face and neck. Cyanosis and acrocyanosis are expressed. Breathing is rapid, shallow, participation of auxiliary muscles in the act of breathing, respiratory rate 36 per 1 min, heart rate 130 per 1 min, blood pressure - 150/95 mm Hg.

A. Radiography of the chest

B. Examination of the ENT organs

C. Determination of PaCO2 and PaO2

D. Examination of the function of external respiration

E. Determination of central venous pressure

8. A 45-year-old patient is brought in unconscious from the street. The smell of alcohol is detected. The skin and visible mucous membranes are cyanotic. There are bruises on the neck and chest. Breathing is shallow, respiratory rate 28 in 1 minute. In the lungs - crepitations on the right in the lower parts. Cardiac activity is arrhythmic, pulse 120 per 1 min, blood pressure - 160/90 mm Hg. ECG - sinus rhythm, heart rate 120 per 1 min, ST segment depression in V3-V5 leads up to 1 mm. What is the most likely cause of respiratory failure?

A. Chest trauma

B. Acute myocardial infarction

C. Acute cerebrovascular accident

D. Pneumonia

E. Alcohol intoxication

9. A 47-year-old patient with COPD complains of shortness of breath, which appeared during the day after hypothermia, fever to 38.0°C. Objectively: moderate severity, severe cyanosis and acrocyanosis, respiratory rate 26/min, dry cough, auxiliary muscles are involved in the act of breathing. Single whistling rales and single moist rales are heard in the lungs. Heart rate 120 bpm, heart sounds are muffled, blood pressure is 140/85 mm Hg. After treatment, which included antibacterial and bronchodilators, the patient's condition improved. What are the measures to prevent the development of ARF in this patient?

A. Avoid hypothermia, vaccination against influenza, pneumococcal infections

B. Continuous use of antibiotics

C. Constant use of bronchodilators

D. Prophylactic use of glucocorticoids

E. Prophylactic use of non-steroidal anti-inflammatory drugs

10. A 67-year-old patient who suffered a myocardial infarction 2 months ago was admitted to the clinic with complaints of chest pain, shortness of breath, mostly in a horizontal position, and dry cough. Objectively: severe cyanosis and acrocyanosis, a large number of small bubbly rales are heard over the lungs on both sides. t 37.4 oC. The heart is rhythmic, heart rate - 100 per 1 min, blood pressure - 100/70 mm Hg. The boundaries of relative cardiac bluntness are widened to the left up to 1 cm. Tones at the top are muffled. The liver protrudes 5 cm from under the edge of the rib arch. What measures should be taken immediately?

A. Mechanical ventilation

B. Nitroglycerin IV

C. Furosemide, prednisolone IV

D. Spironolactone per os

E. Ceftriaxone per os

Standard answers: 1 – D, 2 – A, 3 – B, 4 – A, 5 – E, 6 – E, 7 – C, 8 – A, 9 – A, 10 – C.

RECOMMENDED LITERATURE

Basic

1. 2024 GINA Report, Global Strategy for Asthma Management and Prevention, 263 p. https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Strategy-Report-24_05_22_WMS.pdf

2. GOLD. Global strategy for prevention, diagnosis and management of COPD: 2025 Report. https://goldcopd.org/2025-gold-report/

3. ERS/ESTS statement on the management of pleural infection in adults. Eihab O. [et al.]. European Respiratory Journal Feb 2023, 61(2) 2201062; DOI: 10.1183/13993003.01062-2022

4. Harrison's Principles of Internal Medicine / J. L. Jameson, D. L. Kasper, A. S. Fauci [et al.]. - 21st eds. - McGraw-Hill Education, 2022.

5. NICE Guideline. Pneumonia in adults: diagnosis and management. 2023. 44 p. https://www.nice.org.uk/guidance/cg191/resources/pneumonia-in-adults-diagnosis-and-management-pdf-35109868127173

Additional

1. Internal medicine : textbook for English-speaking students of higher medical educational establishments / K. M. Amosova [et al.] ; ed. by.: M. A. Stanislavchuk, V. K. Sierkova. P. 2 : Pulmonology. Gastroentrology. Nephrology. Diseases of the internal organs in countries with hot climate. - Vinnytsya : Nova Knyha, 2019. - 360 p.

2. Dubin S, Patak P, Jung D. Update on Asthma Management Guidelines. Mo Med. 2024;121(5):364-367.

3. ERS statement on benign pleural effusions in adults. Sundaralingam A, Grabczak EM, Burra P, [et al.]. Eur Respir J 2024; 64.

6. Klefti G, Hill AT. The benefits of non-invasive ventilation for Community-Acquired Pneumonia: A meta-analysis. QJM 2020.

7. Lung Ultrasound Prediction Model for Acute Respiratory Distress Syndrome: A Multicenter Prospective Observational Study. Smit MR, Hagens LA, Heijnen NFL, [et al.]. Am J Respir Crit Care Med 2023; 207:1591.

8. Microbial Dysregulation of the Gut-Lung Axis in Bronchiectasis. Narayana JK, Aliberti S, Mac Aogáin M, [et al.]. Am J Respir Crit Care Med 2023; 207:908.
9. To drain or not to drain? Abscess or empyema? McDill H, Hassan M, Dack G, [et al.]. Thorax 2021; 76:313.
10. Transforming clinical research and science in bronchiectasis: EMBARC3, a European Respiratory Society Clinical Research Collaboration. Chalmers JD, Aliberti S, Altenburg J, [et al.]. Eur Respir J 2023; 61.
11. Use of Lung Ultrasound in the New Definitions of Acute Respiratory Distress Syndrome Increases the Occurrence Rate of Acute Respiratory Distress Syndrome. Plantinga C, Klompmaker P, Haaksma ME, [et al.]. Crit Care Med 2024; 52:e100.
12. A New Global Definition of Acute Respiratory Distress Syndrome. Matthay MA, Arabi Y, Arroliga AC, [et al.]. Am J Respir Crit Care Med 2024; 209:37.
13. BTS Pleural Guideline Development Group. British Thoracic Society Guideline for pleural disease. Roberts ME. [et al.]. Thorax. 2023;78 (Suppl 3):s1-s42. doi: 10.1136/thorax-2022-219784.
14. British Thoracic Society Quality Standard for Clinically Significant Bronchiectasis in Adults 2022. Hill AT [et al.]. BMJ Open Resp Res Published Online First. doi:10.1136/bmjresp-2022-001369

REFERENCES

1. 2024 GINA Report, Global Strategy for Asthma Management and Prevention, 263 p. https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Strategy-Report-24_05_22_WMS.pdf
2. A New Global Definition of Acute Respiratory Distress Syndrome. Matthay MA, Arabi Y, Arroliga AC, [et al.]. Am J Respir Crit Care Med 2024; 209:37.
3. An Update on Management of Adult Patients with Acute Respiratory Distress Syndrome: An Official American Thoracic Society Clinical Practice Guideline. Qadir N, Sahetya S, Munshi L [et al.]. Am J Respir Crit Care Med. 2024 Jan 1; 209 (1):24-36. doi: 10.1164/rccm.
4. Bibby A.C. et al. ERS/EACTS statement on the management of malignant pleural effusions. Eur Respir J. 2018; 52: 1800349. https://doi.org/10.1183/13993003.00349-2018.
5. British Thoracic Society guideline for bronchiectasis in adults. T Hill A, L Sullivan A, D Chalmers J. [et al.]. Thorax 2019; 74:1–69.
6. British Thoracic Society Quality Standard for Clinically Significant Bronchiectasis in Adults 2022. Hill AT [et al.]. BMJ Open Resp Res Published Online First. doi:10.1136/bmjresp-2022-001369
7. BTS Pleural Guideline Development Group. British Thoracic Society Guideline for pleural disease. Roberts ME. [et al.]. Thorax. 2023 Jul;78 (Suppl 3):s1-s42. doi: 10.1136/thorax-2022-219784.
8. Clinical care of severe acute respiratory infections – Tool kit. WHO. 2022. – 306 c. WHO/2019-nCoV/SARI_toolkit/2020.1.
9. Cornelius T. Clinical guideline highlights for the hospitalist: GOLD COPD update 2024. J Hosp Med. 2024 Sep;19(9):818-820. doi: 10.1002/jhm.13416.
10. Dubin S, Patak P, Jung D. Update on Asthma Management Guidelines. Mo Med. 2024 Sep-Oct;121(5):364-367.
11. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Martin-Loeches I, Torres A, Nagavci B [et al.] Intensive Care Med. 2023 Jun;49(6):615-632. doi: 10.1007/s00134-023-07033-8.

12. ERS/ESTS statement on the management of pleural infection in adults. Eihab O. [et al.]. European Respiratory Journal Feb 2023, 61 (2) 2201062; DOI: 10.1183/13993003.01062-2022

13. GOLD COPD report: 2025 update Venkatesan, Priya The Lancet Respiratory Medicine, Volume 13, Issue 1, e7 - e8.

14. GOLD. Global strategy for prevention, diagnosis and management of COPD: 2025 Report. https://goldcopd.org/2025-gold-report/

15. Harrison's Principles of Internal Medicine, 21e Eds. Jameson J.L., Kasper D.L., Fauci A.S., et al. McGraw-Hill Education, 2022, https://accessmedicine.mhmedical.com/content.aspx?bookid=3095&sectionid=259856983.

16. Kelly DN, Martin-Loeches I. Comparing current US and European guidelines for nosocomial pneumonia. Curr Opin Pulm Med. 2019 May;25(3):263-270. doi: 10.1097/MCP.0000000000000559.

17. Management of Community-Acquired Pneumonia in Adults: the 2024 Practice Guideline from The Dutch Working Party on Antibiotic Policy (SWAB) and Dutch Association of Chest Physicians. https://swab.nl/nl/exec/file/download/300.

18. Mohapatra MM, Rajaram M, Mallick A. Clinical, Radiological and Bacteriological Profile of Lung Abscess - An Observational Hospital Based Study. Open Access Maced J Med Sci. 2018 Sep 23;6(9):1642-1646. doi: 10.3889/oamjms.2018.374.

19. Non-invasive ventilatory support and high-flow nasal oxygen as first-line treatment of acute hypoxemic respiratory failure and ARDS. Grieco DL, Maggiore SM, Roca O. [et al.]. Intensive Care Med. 2021 Aug;47(8):851-866. doi: 10.1007/s00134-021-06459-2.

20. Oxygen therapy in acute hypoxemic respiratory failure: guidelines from the SRLF-SFMU consensus conference. Helms J, Catoire P, Abensur Vuillaume L, [et al.]. Ann Intensive Care. 2024 Sep 5;14(1):140. doi: 10.1186/s13613-024-01367-2

21. Wu DW, Wang SW, Chang YF, Tsai JH. Effective pharmacotherapy for lung abscess in a patient with alcoholism. Respir Med Case Rep. 2020 Apr 21;30:101061. doi: 10.1016/j.rmcr.2020.101061.